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Abstract
Small molecule drug discovery relies heavily on synthetic organic chemistry to develop
novel chemical entities that elicit desirable therapeutic effects. The development of targeted
chemical syntheses is of paramount importance to access molecules for biological evaluation and
is usually considered the bottleneck in most drug discovery campaigns. Targets for chemical
syntheses commonly draw inspiration from molecules of natural origin. Nature harbors a wealth
of chemical diversity that has established itself over millions of years through chemical and
biological evolution. Organisms have an inherent ability to protect themselves from predators and
harmful environments. In doing so, many of them evolve to produce chemical defenses in order to
survive in their environments. Unfortunately, most bioactive natural products are not present in
large abundance and require chemical syntheses for evaluation of their therapeutic potential.
Antibiotic resistance has become a major health concern that is creating a health and
financial burden on society. There is an unmet need to develop new antibiotics to combat the everevolving microbes. Drug-resistant bacteria capable of adopting biofilm morphology become
increasingly resistant to antibiotic treatment, threatening the life of the patient. A series of marine
natural products (MNPs) have recently been identified to exhibit promising activity against
methicillin resistant Stahphylococcus aureus (MRSA) biofilms. One of the most potent compounds
in the series was the MNP membranolide. The intriguing biological properties of membranolide
have led us to develop an enantioselective synthesis of the natural product and related analogs for
further evaluation against MRSA biofilms (outlined in chapter 2).

xv

Microbial infections are not limited to bacteria. Parasitic and amoebic pathogens can cause
infections as well, with the latter being underrepresented in drug discovery. The lack of research
and development in the area of amoebic infections may be partly due to the rarity of occurrence.
However, some amoebic infections have extremely high mortality rates, such as those caused by
Naegleria fowleri, presenting a dire need for new therapeutics. Phytocannabinoid natural products
have been found to exhibit anti-proliferation activity against N. fowleri and represent a class of
compounds that may aid in the efforts in combatting its infections. A novel chemical synthesis is
disclosed in chapter 3 that gives rise to tetrahydrocannabinol (THC) and cannabidiol (CBD) and
related analogs to further evaluate and understand their biological activity. Furthermore, these
compounds could be effective treatments against a myriad of other clinical indications including
but not limited to pain, inflammation, anxiety and even Alzheimer’s disease.
The cannabinoids are well-known for their unique biological and physiochemical
properties; however, they lack ideal pharmacokinetic profiles to become successful therapeutics.
Their poor absorption through traditional delivery routes can be addressed either by analog
development or different drug delivery methods. The low oral bioavailability and high lipophilicity
of the cannabinoids has prompted the development of a transdermal route for their delivery.
Throughout chapter 4, a novel transdermal delivery system for the cannabinoids is discussed
including the first use of a skin PAMPA assay to assist in the transdermal patch development for
the cannabinoids.
.

xvi

Chapter 1
The Importance of Synthetic Organic Chemistry: Molecules Matter

1.1

Introduction
All life is composed of matter and all living matter is composed of molecules. The

molecules within every living organism vary in complexity from simple amino acids to the
polymeric peptides that form proteins. At their core, the molecules of life contain the single most
important element, carbon. Chemistry is the science of matter that encompasses all elements and
is considered by many as the central science that links physics and biology. Organic chemistry, a
discipline within chemistry, is the science of carbon-based matter. Within organic chemistry there
are subdisciplines such as those that focus on understanding the physical interactions and
connectivity of organic molecules (physical organic chemistry) and the synthesis of organic
molecules by making and breaking the bonds that hold them together (synthetic organic
chemistry). All disciplines and subdisciplines of chemistry are equally important to answering
fundamental questions of our universe at the molecular level.
The ability to make and break bonds has revolutionized society in every regard. From the
development of modern medicine to the discovery of plastics and resins and the high-tech materials
that surround our everyday lives, the capability of creating new molecules has had a profound
impact on everyone. Synthetic organic chemistry is a continually advancing science that is
enabling the creation of molecules with increasing complexity through the development of new

1

synthetic methodology unfathomable at its birth centuries ago. The advancements in instrumental
analysis and computer technology have aided in the evolution of synthetic chemistry and have
enabled it to become what it is today. Molecules that are now accessible from known synthetic
methods have contributed to answering central questions in biology as well as the discovery of
new therapeutics to treat and cure disease – and this only scratches the surface.

1.2

Historical background
Synthetic chemistry stems back to the days of the alchemist in the 17th century where

Robert Boyle and Antoine de Lavoisier studied physical properties of matter and established the
differences between mixtures and pure substances and of course, the scientific method. The roots
of synthetic organic chemistry were planted by the “father” of organic chemistry, Friedrich Wöhler,
who was the first person to synthesize an organic molecule (derived from a living organism) in
1828.1 Wöhler’s serendipitous discovery of synthesizing urea (Figure 1.1) from ammonium
cyanate in the early 19th century sparked the interest of chemists throughout Europe, ushering new
synthetic discoveries. Hermann Kolbe’s synthesis of acetic acid (1845),2 Adolf von Baeyer’s
synthesis of the dye indigo (1870)3 and Emil Fischer’s synthesis of D-glucose (1893)4 are only a
few remarkable syntheses of their age that have impacted the science of synthetic organic
chemistry. One of the most noteworthy syntheses and contributions to society during the dawn of
organic chemistry is Felix Hoffmann’s synthesis of O-acetylsalicylic acid (aspirin) in 1897.5

Figure 1.1: Historically famous chemical structures synthesized in the 19th century.

2

The 19th century was full of advancements in synthetic organic chemistry that fueled the
fire for discovery into the 20th century where the synthesis of natural products and new synthetic
methods had been discovered and are still used today in modern organic chemistry. All the
impactful discoveries made in the 1900s will not be discussed here; however, a few honorable
mentions are in order. Undoubtedly the most common synthetic methods known to organic
chemists are the use of Grignard reagents discovered by Auguste Grignard (1901) (Figure 1.2), 6
the Diels-Alder cycloaddition discovered by Otto Diels and Kurt Alder (1928)7 and the Wittig
olefination discovered by Georg Wittig (1954),8 all of which have expanded the horizons of organic
synthesis. The early and mid-20th century also saw a boom in natural product synthesis that have
shaped society including but not limited to the synthesis of morphine (Figure 1.2) by Marshall
Gates (1952),9 penicillin V by John Sheehan (1957)10 and cephalosporin C by Robert Woodward
(1966).11

Figure 1.2: Examples of important synthetic methods and total syntheses in the early and mid-20th century.
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Throughout the rest of the 20th century, we have seen an explosion in the synthesis of
biologically active natural products and an increasing amount of methodology development. The
chemistry giants of the late 19th and early 20th centuries such as R. B. Woodward and H. C. Brown
had disseminated their knowledge and passed the torch onto their predecessors who would
continue to shape the field of organic chemistry throughout the rest of the 20th and into the 21st
centuries. Modern organic chemistry has been molded and reshaped by the work of E. J. Corey,
Barry Sharpless and Stuart Schreiber (as well as many others) which cannot go unnoticed in this
brief historical overview of organic chemistry.
Corey’s, Sharpless’ and Schreiber’s contributions to the science of organic chemistry and
chemical biology are some of the most profound to this day and have directly impacted research
groups all around the world. To review the synthetic methods and elegant total syntheses of
complex molecules that have been accomplished in Corey’s, Sharpless’ and Schreiber’s
laboratories would go far beyond the scope of this “brief” historical overview. Some of their
achievements are highlighted in Figure 1.3 and it is encouraged to view the following references
for further details and highlights of their work.12-27
The fundamental synthetic knowledge imparted by Corey to the field of organic chemistry
is unparalleled. From the development of new organic transformations, such as the asymmetric
reduction of ketones (Figure 1.3), to the hundreds of total syntheses accomplished by his lab,
Corey’s contribution to the field has molded it into what it is today. While Sharpless’ lab has
developed two of the most important and widely used methods to install chirality within a molecule
using oxidation chemistry, he also spearheaded the idea of bioorthogonal chemistry using “click”
reactions that have revolutionized chemical biology (Figure 1.3). Schreiber’s work in organic
synthesis has led to the discovery of important small molecules that modulate protein-protein
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interactions (FKBP/FK506), and the idea of diversity-oriented synthesis to rapidly create libraries
of complex molecules that access underrepresented chemical space for drug discovery efforts.
To finish off the high-level historical perspective of organic chemistry, it’s imperative to
discuss the effects organometallic chemistry has had on the synthesis and discovery of new
therapeutics, materials and biomedical tools. Organometallic chemistry utilizes metals, such as
palladium (Pd), copper (Cu), iron (Fe), ruthenium (Ru), lithium (Li) and others within the s, p, d,
and f blocks, to affect transformations on organic molecules.28 Advances in organometallic
chemistry have led to the discovery of catalytic systems capable of creating new C-C and Cheteroatom bonds that may have never been possible otherwise.
Some of the most impactful organometallic reactions are as follows: Suzuki-Miyaura
reaction (1985, Figure 1.4)29 – coupling of an sp2 halide to a boronic acid/ester, Buchwald-Hartwig
reaction (1995, Figure 1.4)30-31 – coupling of an sp2 halide to an amine, Mizoroki-Heck reaction
(1972)32 – coupling of an sp2 halide to an alkene. Other important organometallic cross-coupling
reactions exist such as the Stille, Ullmann, Negishi, Sonogashira, and Grubbs olefin metathesis
reactions (among others).33 The impact organometallic chemistry has had on drug discovery and
material science is astronomical. Molecules that were once inaccessible can now be realized by
using transition metal catalysis and the other advancements seen in the modern era of synthetic
organic chemistry. It appears that the sky is becoming the limit when it comes to synthetic
capabilities.

5

Figure 1.3: Highlighted methodologies and total syntheses from Corey, Sharpless, and Schreiber.
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Figure 1.4: Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions. Selected examples performed
on industrial scales for the synthesis of drug intermediates.

1.3

The importance of natural products and total synthesis
The synthesis of organic molecules started in 1828 with the synthesis of a naturally

occurring molecule known as urea (Figure 1.1), by Hermann Wöhler as mentioned in the previous
section. What proceeded from the laboratory synthesis of urea was an explosion in the chemistry
of natural products and synthetic organic chemistry that can still be seen today.34-35 The seemingly
infinite structural diversity found in nature has led to the isolation of countless natural products
with unique structures and biological activities that are the targets of many chemical syntheses. As
of 2016, greater than 65% of FDA (Food and Drug Administration) approved drugs have been
derived from or mimic natural products.36 Even natural products themselves have become
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important pharmaceutical drugs such as the chemotherapy agent paclitaxel (Taxol)37-39 and the pain
medication morphine (Figure 1.5).9

Figure 1.5: FDA approved natural products: Taxol and morphine.

One of the pitfalls of using natural products for therapeutics is the fact that organisms that
produce bioactive compounds have evolved to increase their own longevity, not that of humans. It
is common that natural products are not metabolically stable in humans and have poor
pharmacokinetic profiles.40 Natural products provide molecular scaffolds that exhibit bioactivity
where in most cases extensive synthetic modifications are required to optimize their properties for
human therapeutics. Due to the complex structures of natural products, medicinal chemists have
viewed them with low therapeutic potential since it is deemed difficult to make the necessary
modifications to change the pharmaceutical profiles. Recent advances in chemical synthesis,
chemical biology, and genetic engineering have resurrected many natural product scaffolds, giving
rise to new clinical candidates.40
At its core, natural product synthesis is the heart of molecular discovery where different
theories and discoveries can stem from the following: the evaluation of physical organic theories,
discovery of new synthetic methodology to construct three-dimensional molecular architectures,
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further exploration of the scope of known synthetic methods and enabling biology and medicine
by providing access to nature’s molecules. It is important that we, as a scientific community, do
not lose sight of what natural product chemistry and synthesis represents in the overall scheme of
chemical discovery and the advancement of science.
To provide historical context, the total synthesis efforts of quinine (Figure 1.6) led to new
synthetic methods and studies of heteroaromatic ring systems in the early 20th century.41-43 As a
result, the scientific discoveries associated with quinine have brought on the discovery of several
classes of antimalarial drugs.44 In the 1950s Sheehan’s synthesis of penicillin fostered the
discovery of carbodiimide-based reagents45 (Figure 1.6) that continue to shape peptide chemistry
and allowed for the discovery of penicillin analogs that were more potent than naturally-derived
penicillin.46
The total synthesis of prostaglandins by E. J. Corey resulted in the discovery of one of the
most powerful and general ketone asymmetric reductions, the CBS reduction (Figure 1.3).
Pioneering work by Albert Eschenmoser and R. B. Woodward in the 1960s-1970s toward the
synthesis of vitamin B12 fostered many physical organic chemistry theories and discoveries.
Eschenmoser’s corrin syntheses (Figure 1.5)47-48 and Woodward’s cobyric acid synthesis are what
laid the foundation for the discovery of the Woodward-Hoffman rules, a set of rules used to predict
aspects of stereochemical outcomes of pericyclic reactions under thermal or photochemical
control.49-50
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Figure 1.6: Selected natural products that have fueled scientific discoveries in the 20th century.

Without the discovery of natural products and the interests in their synthetic accessibility,
many fundamental questions in chemistry, biology, and medicine would be left unanswered today.
Nature provides us with complex molecular architectures having unique biological and physical
properties that continue to drive scientific discoveries. The wells of chemical diversity are still
flowing with new natural products discovered every year from which new scientific questions arise
from. Synthetic organic chemistry has come a long way since the synthesis of urea in 1828 but the
seemingly limitless chemical structures that are present today allow for the new discoveries of
tomorrow. Attempts to relay the importance of natural product synthesis to science and society has
come to a close and will be left with a quote from a giant figure in organic chemistry:
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“How many challenging and worthy synthetic targets remain to be
discovered? How many truly powerful and general new synthetic
strategies and synthetic reactions remain to be discovered? Is there
a prospect for the development of entirely new ways of planning or
executing synthesis? In my judgment the opportunities for new
developments and discoveries are so vast that today’s synthesis is
best regarded as a youngster with a brilliant future.”
– E. J. Corey51

1.4

List of references

1. Wöhler, F., Ueber künstliche Bildung des Harnstoffs. Annalen der Physik 1828, 88 (2), 253256.
2. Kolbe, H., Beiträge zur Kenntniss der gepaarten Verbindungen. Justus Liebigs Annalen der
Chemie 1845, 54 (2), 145-188.
3. Baeyer, A.; Emmerling, A., Reduction des Isatins zu Indigblau. Berichte der Deutschen
Chemischen Gesellschaft 1870, 3 (1), 514-517.
4. Fischer, E., Ueber die Glucoside der Alkohole. Berichte der Deutschen Chemischen
Gesellschaft 1893, 26 (3), 2400-2412.
5. Kuhnert, N., Hundert Jahre Aspirin® - Die Geschichte des Wohl Erfolgreichsten Medikaments
des Letzten Jahrhunderts. Pharmazie in Unserer Zeit 2000, 29 (1), 32-39.
6. Tissier; Grignard, The Organic Metal Formation of Magnesium. C. r. d. l'Acad. des Sciences
1901, 132, 835-37.
7. Diels, O.; Alder, K., Synthesen in der Hydroaromatischen Reihe. Justus Liebigs Annalen der
Chemie 1928, 460 (1), 98-122.
8.Wittig, G.; Schollkopf, U., Triphenylphosphinemethylene as an Olefin-Forming Reagent. I.
Chem. Ber. 1954, 97, 1318-30.
9. Gates, M.; Tschudi, G., The Synthesis of Morphine. Journal of the American Chemical Society
1952, 74 (4), 1109-1110.
10. Sheehan, J. C.; Henery-Logan, K. R., The Total Synthesis of Penicillin V. Journal of the
American Chemical Society 1957, 79 (5), 1262-1263.
11. Woodward, R. B.; Heusler, K.; Gosteli, J.; Naegeli, P.; Oppolzer, W.; Ramage, R.;
Ranganathan, S.; Vorbrüggen, H., The Total Synthesis of Cephalosporin C1. Journal of
the American Chemical Society 1966, 88 (4), 852-853.

11

12. Corey, E. J.; Suggs, J. W., Pyridinium chlorochromate. An Efficient Reagent for Oxidation of
Primary and Secondary Alcohols to Carbonyl Compounds. Tetrahedron Letters 1975, 16
(31), 2647-2650.
13. Corey, E. J.; Helal, C. J., Reduction of Carbonyl Compounds with Chiral Oxazaborolidine
Catalysts: A New Paradigm for Enantioselective Catalysis and a Powerful New Synthetic
Method. Angewandte Chemie International Edition 1998, 37 (15), 1986-2012.
14. Corey, E. J.; Fuchs, P. L., A Synthetic Method for Formyl→Ethynyl Conversion. Tetrahedron
Letters 1972, 13 (36), 3769-3772.
15. Corey, E. J.; Weinshenker, N. M.; Schaaf, T. K.; Huber, W., Stereo-Controlled Synthesis of
dl-Prostaglandins F2α and E2. Journal of the American Chemical Society 1969, 91 (20),
5675-5677.
16. Corey, E. J.; Kang, M. C.; Desai, M. C.; Ghosh, A. K.; Houpis, I. N., Total Synthesis of (+/-)Ginkgolide B. Journal of the American Chemical Society 1988, 110 (2), 649-651.
17. Mushti, C. S.; Kim, J.-H.; Corey, E. J., Total Synthesis of Antheliolide A. Journal of the
American Chemical Society 2006, 128 (43), 14050-14052.
18. Katsuki, T.; Sharpless, K. B., The First Practical Method for Asymmetric Epoxidation.
Journal of the American Chemical Society 1980, 102 (18), 5974-5976.
19. Jacobsen, E. N.; Marko, I.; Mungall, W. S.; Schroeder, G.; Sharpless, K. B., Asymmetric
Dihydroxylation via Ligand-Accelerated Catalysis. Journal of the American Chemical
Society 1988, 110 (6), 1968-1970.
20. Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K. S.;
Kwong, H. L.; Morikawa, K.; Wang, Z. M., The Osmium-Catalyzed Asymmetric
Dihydroxylation: a New Ligand Class and a Process Improvement. The Journal of
Organic Chemistry 1992, 57 (10), 2768-2771.
21. Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Click Chemistry: Diverse Chemical Function
from a Few Good Reactions. Angewandte Chemie International Edition 2001, 40 (11),
2004-2021.
22. Fu, Y.; Mi, L.; Sanda, M.; Silverstein, S.; Aggarwal, M.; Wang, D.; Gupta, P.; Goldman, R.;
Appella, D. H.; Chung, F.-L., A Click Chemistry Approach to Identify Protein Targets of
Cancer Chemopreventive Phenethyl Isothiocyanate. RSC Advances 2014, 4 (8), 39203923.
23. Hein, C. D.; Liu, X.-M.; Wang, D., Click Chemistry, a Powerful Tool for Pharmaceutical
Sciences. Pharmaceutical Research 2008, 25 (10), 2216-2230.
24. Schreiber, S. L., Target-Oriented and Diversity-Oriented Organic Synthesis in Drug
Discovery. Science 2000, 287 (5460), 1964-1969.
25. Burke, M. D.; Berger, E. M.; Schreiber, S. L., Generating Diverse Skeletons of Small
Molecules Combinatorially. Science 2003, 302 (5645), 613-618.
26. Nakatsuka, M.; Ragan, J. A.; Sammakia, T.; Smith, D. B.; Uehling, D. E.; Schreiber, S. L.,
Total synthesis of FK506 and an FKBP probe reagent, [C(8),C(9)-13C2]-FK506. Journal
of the American Chemical Society 1990, 112 (14), 5583-5601.
27. Jamison, T. F.; Shambayati, S.; Crowe, W. E.; Schreiber, S. L., Cobalt-Mediated Total
Synthesis of (+)-Epoxydictymene. Journal of the American Chemical Society 1994, 116
(12), 5505-5506.
28. Crabtree, R. H., The Organometallic Chemistry of the Transition Metals, 6th ed.. Wiley: 2014.
29. Suzuki, A., Organoboron Compounds in New Synthetic Reactions. In Pure and Applied
Chemistry, 1985; Vol. 57, p 1749.

12

30. Louie, J.; Hartwig, J. F., Palladium-Catalyzed Synthesis of Arylamines From Aryl Halides.
Mechanistic Studies Lead to Coupling in the Absence of Tin Reagents. Tetrahedron
Letters 1995, 36 (21), 3609-3612.
31. Guram, A. S.; Rennels, R. A.; Buchwald, S. L., A Simple Catalytic Method for the
Conversion of Aryl Bromides to Arylamines. Angewandte Chemie International Edition
in English 1995, 34 (12), 1348-1350.
32. Heck, R. F.; Nolley, J. P., Palladium-Catalyzed Vinylic Hydrogen Substitution Reactions
With Aryl, Benzyl, and Styryl Halides. The Journal of Organic Chemistry 1972, 37 (14),
2320-2322.
33. Biffis, A.; Centomo, P.; Del Zotto, A.; Zecca, M., Pd Metal Catalysts for Cross-Couplings
and Related Reactions in the 21st Century: A Critical Review. Chemical Reviews 2018,
118 (4), 2249-2295.
34. Nicolaou, K. C., The Emergence and Evolution of Organic Synthesis and Why It is Important
to Sustain It as an Advancing Art and Science for Its Own Sake. Israel Journal of
Chemistry 2018, 58 (1-2), 104-113.
35. Herzon, S. B.; Vanderwal, C. D., Introduction: Natural Product Synthesis. Chemical Reviews
2017, 117 (18), 11649-11650.
36. Newman, D. J.; Cragg, G. M., Natural Products as Sources of New Drugs from 1981 to 2014.
Journal of Natural Products 2016, 79 (3), 629-661.
37. Holton, R. A.; Somoza, C.; Kim, H. B.; Liang, F.; Biediger, R. J.; Boatman, P. D.; Shindo,
M.; Smith, C. C.; Kim, S., First Total Synthesis of Taxol. 1. Functionalization of the B
Ring. Journal of the American Chemical Society 1994, 116 (4), 1597-1598.
38. Holton, R. A.; Kim, H. B.; Somoza, C.; Liang, F.; Biediger, R. J.; Boatman, P. D.; Shindo,
M.; Smith, C. C.; Kim, S., First Total Synthesis of Taxol. 2. Completion of the C and D
Rings. Journal of the American Chemical Society 1994, 116 (4), 1599-1600.
39. Nicolaou, K. C.; Yang, Z.; Liu, J. J.; Ueno, H.; Nantermet, P. G.; Guy, R. K.; Claiborne, C. F.;
Renaud, J.; Couladouros, E. A.; Paulvannan, K.; Sorensen, E. J., Total Synthesis of Taxol.
Nature 1994, 367 (6464), 630-634.
40. Yñigez-Gutierrez, A. E.; Bachmann, B. O., Fixing the Unfixable: The Art of Optimizing
Natural Products for Human Medicine. Journal of Medicinal Chemistry 2019.
41. Woodward, R. B.; Doering, W. E., The Total Synthesis of Quinine1. Journal of the American
Chemical Society 1944, 66 (5), 849-849.
42. Woodward, R. B.; Doering, W. E., The Total Synthesis of Quinine. Journal of the American
Chemical Society 1945, 67 (5), 860-874.
43.Stork, G.; Niu, D.; Fujimoto, A.; Koft, E. R.; Balkovec, J. M.; Tata, J. R.; Dake, G. R., The
First Stereoselective Total Synthesis of Quinine. Journal of the American Chemical
Society 2001, 123 (14), 3239-3242.
44. Achan, J.; Talisuna, A. O.; Erhart, A.; Yeka, A.; Tibenderana, J. K.; Baliraine, F. N.;
Rosenthal, P. J.; D'Alessandro, U., Quinine, an Old Anti-malarial Drug in a Modern
World: Role in the Treatment of Malaria. Malaria Journal 2011, 10, 144-144.
45.Sheehan, J. C.; Hlavka, J. J., The Use of Water-Soluble and Basic Carbodiimides in Peptide
Synthesis. The Journal of Organic Chemistry 1956, 21 (4), 439-441.
46. Wright, P. M.; Seiple, I. B.; Myers, A. G., The evolving role of chemical synthesis in
antibacterial drug discovery. Angewandte Chemie International (ed. in English), 2014, 53
(34), 8840-8869.

13

47. Eschenmoser, A., Roads to Corrins. Quarterly Reviews, Chemical Society 1970, 24 (3), 366415.
48. Eschenmoser, A., Corrin Syntheses. Part I. Helvetica Chimica Acta 2015, 98 (11‐12), 14831600.
49. Woodward, R. B., The Total Synthesis of Vitamin B12. Pure and Applied Chemistry 1973,
33, 145.
50. Woodward, R. B.; Hoffmann, R., Stereochemistry of Electrocyclic Reactions. Journal of the
American Chemical Society 1965, 87 (2), 395-397.
51. Nicolaou, K. C.; Snyder, S. A., Classics in Total Synthesis II: More Targets, Strategies,
Methods. Wiley-VCH: Weinheim, Germnay, 2003.

14

Chapter 2
Enantioselective Synthesis of Marine Natural Product Membranolide and Related Analogs

2.1

Introduction to marine natural products: membranolides and related compounds
Throughout the last 50 years, marine natural products (MNPs) have contributed to and

greatly impacted the chemical diversity found within the realm of natural products (NPs). The
unique chemical structures found within marine environments are accompanied by intriguing
biological activity including anti-infective, anti-cancer, anti-inflammatory and even neurological
protectants.1-2 Marine habitats comprise nearly 75% of the earth’s surface and are some of the most
under-explored places on earth. Wells of untapped chemical diversity still exist throughout marine
environments where over 1000 new MNPs have been reported yearly throughout the last decade.3
The structural diversity found in secondary metabolites of marine organisms rivals their terrestrial
counterparts and is expected to supersede them in structural novelty and therapeutic usefulness in
the future.3-4

Figure 2.1: Selected marine natural products that have impacted drug-discovery and medicine.
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Some MNPs with extraordinary chemical structures have led to the discovery of novel
biological activities that are unprecedented elsewhere. The unique bioactivities of okadaic acid
(Figure 2.1, potent and selective phosphatase inhibitor)5 and xestospongin C (Figure 2.1, blocker
of IP3-mediated Ca2+ release)6 have provided biomedical probes that have profoundly impacted
our understanding of cellular mechanisms.7-8 In terms of drug discovery, MNPs have just broken
the surface. An increasing number of FDA approved drugs of MNP origin are beginning to make
a big wave in the drug discovery community.3
Drug discovery programs have been able to capitalize on the unique biological properties
of newly discovered MNPs, leading to new target and lead identification.9 To date, there have been
several FDA approved drugs that were either inspired by or originated from MNPs, with a few
being the direct MNP.3 Most marine drug discovery efforts are focused on anticancer therapeutics
which is reflected by FDA approvals as of 2017.3 However, as screening campaigns and research
collaborations broaden, we may see a paradigm shift in the focus of MNP drug discovery.
Since the first report of an isolated biologically active MNP (spongothymidine, Figure 2.1)
in the 1950s by Bergmann,10-12 most coastal regions that are easily accessible by humans have
been extensively plundered for their sources of NPs. Early efforts in MNP discovery focused
heavily on temperate and tropical regions due to accessibility and the expectations of high
productivity.13 It has become more common for NP chemists and ecologists to explore the farreaches of the earth, weathering extreme environments, in search of new chemical entities and a
further understanding of marine ecology. Some marine environments that are of great interest to
chemists and ecologists are too extreme for humans to access and require specialized equipment
and remote operating vehicles (ROVs) to reach the desired depths for organism collection.14-15
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Treacherous environments such as Antarctica are havens of chemical diversity that are
unprecedented elsewhere on earth.14
Among the frigid waters surrounding Antarctica is a thriving community of invertebrates
and algae that produce intriguing MNPs with profound biological activities. One of the best known
MNPs from this region is perhaps the polyketide palmerolide A (Figure 2.2), isolated from the
tunicate Synoicum adareanum by Baker and colleagues.16 Palmerolide A is described as a potent
inhibitor of melanoma (UACC-62, LC50 = 18 nM) with three-fold selectivity over other cancer cell
lines within the NCI’s 60 cell line panel.16 The markedly striking biological activity of palmerolide
A attracted the attention of the synthetic chemistry community with a desire to gain access to the
NP and its derivatives for further biological evaluation.17 Since the discovery of palmerolide A in
2006, other MNPs have been isolated and characterized from the harsh Antarctic environment that
may prove to be just as intriguing to chemists and biologists alike.

Figure 2.2: Structure of palmerolide A.

Tunicates are not the only well studied invertebrates found in Antarctic waters. The
chemodiversity of other Antarctic invertebrates, such as sea sponges, has been extensively studied
throughout the last 25 years.18 Among the Antarctic sea sponges that have been thoroughly
examined is Dendrilla membranosa, a bright yellow cactus sponge known to produce a variety of
bioactive diterpenoid MNPs (Figure 2.3).19-23 The structurally related diterpenoids found within
17

D. membranosa possess anti-infective properties against methicillin resistant Staphylococcus
aureus (MRSA) and Leishmania donovani at the sub-micromolar level.23
Interestingly, the most structurally simplistic MNP in Figure 2.3 (membranolide, 2.1), has
shown promising MRSA biofilm eradication activity. Membranolide’s unique biological activity
and lack of synthetic access to the NP and its derivatives has attracted us to the membranolide
series of MNPs. The relative simplicity of 2.1 is important from a drug discovery perspective as it
resembles a more “drug-like” structure, following Lipinski’s rule of 5.24 The other membranolides,
along with darwinolide and aplysulphurin, vary in oxidation states and stereochemistry around the
lactone/acetal region of the molecule and may be accessible from 2.1 or an advanced synthetic
intermediate.

Figure 2.3: A series of structurally related marine natural products isolated from the Antarctic sea sponge
Dendrilla membranosa.

In 2014, a series of compounds that are structural related to the membranolides was
discovered by Northcote and colleagues in New Zealand from the sea sponge Darwenilla oxeata
18

and have been named the oxeatamaides.25 The oxeatamides contain core structural features that
are similar to the membranolides, as seen in Figure 2.4. The structural similarities between 2.1
and the oxeatamides include: a trimethylcyclohexyl moiety bearing a quaternary carbon
stereocenter and an α-arylated propionic acid or ester appendage containing a second stereocenter.
The key structural difference between the oxeatamides and the membranolides is the presence of
a lactam and lactone, respectively. The relative position of the lactam carbonyl found in most of
the oxeatamides is also inconsistent to the lactone carbonyl found in 2.1. Ten different oxeatamides
have been reported, with most of them differing by the N-substituent of the lactam ring. To date,
there has yet to be a report on the biological activity of the oxeatamides; however, given the
structural similarity to the membranolides, it is expected that the oxeatamides will exhibit similar
activity.

Figure 2.4: A structural comparison of membranolide to the oxeatamides.

2.2

Introduction to MRSA and MRSA biofilms
The pathogen responsible for methicillin-resistant bacterial infections, causing a global

epidemic, is the gram-positive bacterium Staphylococcus aureus. In humans, S. aureus is found in
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20-40% of the population where it mostly resides in the nasal mucosa and is part of the human
commensal microbiota.26-27 People who are carriers of S. aureus are at a higher risk for infection,
especially once the mucosal membrane has been disrupted.26 Once infected with S. aureus, the
diagnosis is usually a staph infection which can be treated with a variety of antibiotics including
but not limited to flucloxacillin, dicloxacillin, cephalexin and clindamycin (Figure 2.5).28 If drugresistance develops, vancomycin is currently the last therapeutic option for severe MRSA
infections.29 Unfortunately, there have been strains of MRSA isolated in the U.S. that show
vancomycin-resistance (VRSA).30 The remarkable incidence of antibiotic resistance found in S.
aureus has created an unmet need for new antibiotics to combat current and future infections.

Figure 2.5: Antibacterial agents used to treat S. aureus infections.

In the 1960s, countries around the world began to observe forms of S. aureus that were
resistant to the β-lactam methicillin.31 Resistance emerged quickly after its introduction to clinical
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practice and was first observed in 1961 in England.32 Even though methicillin is no longer used
due to its toxicity, the term “MRSA” is still used to describe forms of S. aureus that are resistant
to methicillin in clinical diagnosis.33 Ever since the discovery of MRSA, there has been an
alarming increase in outbreaks that have been associated with their locations of prevalence such
as the following: healthcare-associated (HA-MRSA), community-associated (CA-MRSA) and
livestock-associated (LA-MRSA). In the United States, MRSA has been identified as the most
common cause of skin and soft tissue infections (SSTIs) and has been associated with CA-MRSA
strains (USA300 clone).34-35
The biology of S. aureus is not entirely unique in the microbiological realm; however, its
aptitude for horizontal gene transfer resulting in the transfer of antibiotic resistance can be alarming
from a health care perspective. The specific mobile genetic element that confers methicillin
antibiotic resistance, as well as resistance against other β-lactams, is the staphylococcal cassette
chromosome mec (SCCmec).36 Within SCCmec are genes that encode for the unique antibiotic
defenses of MRSA. Interestingly, MRSA is often associated with other antibiotic resistance, not
only associated with β-lactams and most likely originates from similar horizontal gene transfers.37
S. aureus has an extraordinary arsenal of virulence factors that have been associated with mobile
gene elements and are capable of transferring from clone to clone.38 With S. aureus’s ability to
transfer gene elements containing antibiotic resistant and virulent factors as well as its prevalence
in the general population, human-human transfer of MRSA strains has become more prominent.
S. aureus infections are usually initiated by bacterial transfer from one host to another either
onto an open lesion or wound. The bacterium adheres to the extracellular matrix through a variety
of surface proteins enabling S. aureus to grow and multiply on the wound surface.39 Among the
most dangerous variants of S. aureus is one that forms biofilms on foreign surfaces such as plastics
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and metals. MRSA biofilm infections in humans are commonly associated with medical devices
during surgical implantations that could lead to sepsis or pneumonia with high mortality rates.40-41
Biofilms are mostly composed of extracellular polysaccharides, proteins and DNA.42 The
morphology of a biofilm protects the bacterial colony from mechanical forces as well as hostdefenses and antibiotics – protecting the bacteria and creating a nearly untreatable problem.
Extensive research to understand biofilm formation and adhesion mechanisms of S. aureus is
ongoing. A more detailed discussion of biofilms would be beyond the scope of this dissertation.3942

Once a biofilm has formed within the body, it becomes very difficult to treat with current
therapies.43 There has been considerable progress in understanding the mechanisms that S. aureus
uses to evade a host’s immune system and to increase antibiotic resistance in the biofilm state.4346

A variety of antibiotics have been examined to treat biofilms where vancomycin has been

regarded as the current last resort treatment. Antibiotic combination therapies as well as
monotherapies of rifampin have been shown to be highly efficacious.47 Antibiotic treatment in
conjunction with surgical intervention to remove the biofilms remains the current standard of care
for biofilm treatment.
To date, there remains a lack of therapeutic options capable of fully eradicating MRSA
biofilms and the mechanistic understanding of their formation has yet to provide a promising
druggable target. If the film can be disrupted or eradicated, the bacteria within the film may be
susceptible to antibiotic treatment. Further investigation of novel compounds capable of biofilm
eradication may reveal new biological targets to aid in drug discovery efforts for the treatment of
drug-resistant biofilms.
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2.3

Research goal and rationale
Our lab has embarked on a synthetic journey to gain access to the enantiopure form of 2.1

that could give rise to other related MNPs and novel analogs. We have a vested interest in the
membranolides with regards to their bacterial biofilm eradication activity and would like to
understand their mechanism of action as well as to determine the structural requirements for the
observed biological activity. Our synthetic strategies towards 2.1 were designed with the prospect
of analog development and to access the structurally related oxeatamides for biological evaluation.
The routes taken towards 2.1 and a short structure activity relationship study of truncated 2.1
analogs for their biological activity against MRSA biofilms will be discussed herein. Our synthetic
route should allow for the development of novel analogs of 2.1 as well as chemical tools to aid in
the elucidation of 2.1’s mechanism of action against MRSA biofilms.

2.4

Synthesis of truncated membranolide analogs: Short SAR study
The biological target of 2.1 is unknown. Without structural information of the biological

target and its interactions with 2.1, it becomes difficult to perform rational drug discovery. A
common technique used to probe an active site or drug/target interface is a structure-activity
relationship (SAR). Using synthetic chemistry, it is possible to modify the structure of 2.1 in such
a way as to determine the structural requirements for its biological activity. When conducting an
SAR study, it’s imperative to make one change at a time in order to determine the specific impact
of the change made on desired bioactivity. Membranolide has two sites of interest that would be
useful for the development of analogs and biological probes. Three analogs were designed to
determine if the two sites are in fact necessary to maintain activity against MRSA biofilms.
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2.4.1 Truncated analog rationale
All three truncated analogs were designed to maintain functionality capable of forming
strong intermolecular interactions (hydrogen bond acceptors and dipole-dipole interactions). The
isobenzofuranone core and methyl ester in the northern hemisphere of 2.1 are suspected to form
critical interactions with the target through hydrogen-bond or dipole-dipole interactions (Figure
2.6) therefore, they were kept constant in all analogs. We decided to focus on two other regions of
2.1, the trimethylcyclohexyl moiety and the α-methyl stereocenter (Figure 2.7). The size and
stereochemical requirement at the two remaining positions are currently unknown. The most
logical changes would be to modify the two aliphatic regions to determine if the structural
complexity is required for bioactivity.

Figure 2.6: Possible interactions between membranolide and biological targets.

We first set out to probe the aliphatic region highlighted in blue (Figure 2.7), as well as the
α-carbon of the methyl propionate highlighted in red. It was hypothesized that the function of the
trimethylcyclohexyl group creates hydrophobic interactions that could be substituted with another
bulky aliphatic group capable of the same interactions, such as a tert-butyl (2.2). Substituting the
trimethylcyclohexyl group with a tert-butyl provides information on the chirality requirement as
well as the size constraint at the bulky aliphatic position. If the biological activity is maintained
with the truncated tert-butyl analog, further analog development would be less synthetically
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challenging by the removal of a quaternary carbon stereocenter – notoriously difficult to control
asymmetrically.48

Figure 2.7: Truncated analogs of membranolide used for a short SAR study against MRSA biofilms.

The α-position of the methyl propionate bears the second stereocenter that may or may not
be required for activity. Removal of the α-carbon could provide insight to the structural and
stereochemical requirement at the α-position (2.3, Figure 2.7). If the loss of the methyl group is
not tolerable, larger groups could be explored as well as the other stereoisomer. Finally, removal
of the aliphatic and α-substituent would determine if the biological activity is only elicited through
the electronic interactions of the methyl ester and the isobenzofuranone core (2.4, Figure 2.7). In
order to synthesize the targeted truncated analogs of 2.1, known synthetic methods were adopted
from the literature as well as new method development which may prove useful for an
enantioselective total synthesis of 2.1.
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2.4.2 Synthesis of truncated analogs
Three truncated analogs, 2.2, 2.3 and 2.4, were proposed for a short SAR study to determine
the biological requirements at the aliphatic sites of 2.1 which would guide future analog
development. Our synthetic efforts began with the most simplistic analog, 2.4. Utilizing a known
synthetic procedure,49 3-methylpthalicanhydride (2.5) was brominated under radical initiated
conditions to furnish 2.6 in moderate yields (Scheme 2.1). Benzyl bromide (2.6) was converted to
the benzylic alcohol, which was immediately used to open the anhydride under acidic conditions
to give carboxylic acid 2.7. In order to homologate 2.7 to 2.4, an Arndt-Eistert homologation was
employed.

Scheme 2.1: Synthesis of truncated membranolide analog 2.4.

Carboxylic acid 2.7 was converted to the acid chloride 2.8, which was treated with freshly
distilled diazomethane to give a diazoketone intermediate (Scheme 2.1). It was imperative to use
freshly distilled diazomethane from Diazald™ in order to achieve the synthesis of the diazoketone.
Other methods of generating diazomethane using less hazardous procedures proved to be
ineffective. Once the correct conditions were realized, the crude diazoketone was exposed to
AgOBz in methanol to facilitate the Wolff-rearrangement and to provide the first truncated analog

26

2.4. The low overall yield of the Arndt-Eistert homologation could be attributed to the use of the
crude diazoketone. Attempts to purify the diazoketone intermediate to improve the overall yield
led to hydrolysis. However, we were able to synthesize enough of the truncated analog 2.4 for
biological evaluation.
Once the first analog was successfully synthesized, we set our eyes on the tert-butyl analogs
2.2 and 2.3. We envisioned that the methodology used for synthesis of the tert-butyl analogs would
be useful for our subsequent synthetic efforts toward the synthesis of 2.1. The synthesis of tertbutyl analog 2.2 began with treating commercially available tert-butyl phenol (2.9) with diethyl
carbamoyl chloride (2.10) and sodium hydride (NaH) to give carbamate 2.11 in nearly quantitative
yields (Scheme 2.2). The carbamate of 2.11 was used to direct an ortho-lithiation with secbutyllithium (s-BuLi) which rearranged upon warming to room temperature to give the requisite
amide that was protected as benzyl ether 2.12 in 82% over two steps. The amide of 2.12 became
the new directing group to affect a second ortho-lithiation using s-BuLi. After lithiation, the
resulting aryl anion was quenched with DMF to give an aldehyde that was directly converted to
lactone 2.13.

Scheme 2.2: Synthesis of aryl triflate intermediate 2.14.
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Formation of lactone 2.13 was achieved by reduction of the aldehyde intermediate from
the second o-lithiation event with NaBH4 followed by treatment with HCl under refluxing
conditions (Scheme 2.2). The three transformations (including the second o-lithiation) were
carried out sequentially with purification after the third step to provide 2.13 in 75% over three
steps. Once the lactone was installed, benzyl deprotection to the phenol followed by triflation using
triflic anhydride gave the desired triflate 2.14. Most of the synthetic steps up to triflate 2.14 were
straight forward with few problematic steps. Unfortunately, almost all attempts to form a new CC bond using triflate 2.14 and Pd catalysis were unsuccessful.
Initial attempts at forming a desirable C-C bond with triflate 2.14 are outlined in Scheme
2.3. A variety of reaction conditions using a wide range of Pd catalysts were attempted with
desirable coupling partners that could lend themselves to the methyl propionate found in 2.1. One
of the most common Pd coupling reactions in an organic chemist’s arsenal is the Suzuki-Miyuara
reaction between a halide/pseudo halide and a boronic acid/ester.49 Our initial attempt to install the
desired methyl propionate was to use α-boronic acid 2.15, derived from methyl acrylate (2.17),
and triflate 2.14. After many attempts to synthesize 2.15 failed, we turned to another Suzuki
reaction using boronic acid 2.16 and triflate 2.14 with little to no prevail.

Scheme 2.3: Attempts to install the methyl propionate found in 2.1.
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Stille couplings between organostannanes and sp2 halides/pseudo halides are also very
useful Pd catalyzed C-C bond forming reactions.50 Stannane 2.19, accessible from 2.17, and
commercially available stannane 2.20 were used to perform Stille couplings with triflate 2.14.
Unfortunately, both Stille couplings gave poor yields and inseparable tributyl tin byproducts.
There are a few reports of Mizoroki-Heck reactions (coupling of sp2 halides with olefins
to give E-selective linear products) that provided branched coupled products between
halides/pseudo halides and olefins. In order to obtain the uncommon branched products, bidentate
ligands are required to form unique catalytic systems that undergo migratory insertion into the
internal carbon of an olefin.51-52 Once we obtained the requisite bidentate ligands for the Heck
reaction, olefins 2.17 and 2.21 were used to couple with 2.14. All attempts using different reaction
conditions and reagents failed to give the desired branched olefin. However, a new C-C bond was
formed, albeit in low yields, when methyl acrylate 2.16 was used as the coupling partner to give
the undesired cinnamate ester arising from β-addition to the acrylate (not shown).
After exhaustive attempts to use Pd cross-coupling reactions to forge a new C-C bond
between aryl triflate 2.14 and an appropriate coupling partner had failed, we started to believe that
2.14 was too sterically hindered to perform transition metal catalysis to an appreciable extent.
However, the promising results of the Mizoroki-Heck reaction with methyl acrylate 2.16 lifted our
spirits. Following a discussion with Professor Guanbin Dong, it was realized that silylketene
acetals (SKAs) could be coupled to aryl triflates using Pd catalysis to afford α-arylated products.53
Lo and behold, commercially available silyl ketene acetal 2.22 was coupled to our aryl triflate 2.14
using a Pd2(dba)3/dppf catalytic system to provide truncated analog 2.3 in excellent yields
(Scheme 2.4). Finally, the α-methyl substituent was installed via enolate alkylation with MeI to
give 2.2, the last of the three truncated analogs for the SAR study.
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Scheme 2.4: Synthesis of two truncated membranolide analogs from aryl triflate 2.14.

All three targeted truncated analogs of 2.1 have been successfully synthesized for
biological evaluation against MRSA and MRSA biofilms. The three truncated analogs of 2.1 could
provide information on the structural requirements of 2.1 that will guide our future analog
development. The synthetic methods used to access the tert-butyl analogs of 2.1 may prove
invaluable in our subsequent enantioselective total synthesis efforts. A challenging Pd crosscoupling reaction with aryl triflate 2.14 was achieved after extraneous efforts. To our knowledge,
2.14 is one of the most hindered triflates to undergo a Pd cross-coupling in high yields and would
prove essential in the total synthesis of 2.1.

2.5

Highlighted synthetic routes toward membranolide
To date, there has been one reported synthesis of racemic 2.1 by a South Korean group in

1990,54 while an enantioselective synthesis of 2.1 has never been achieved. This section will
highlight our initial synthetic routes toward 2.1 that could translate to the first enantioselective
total synthesis. We explored many approaches that ultimately led to dead ends and it would be
unbecoming to only disclose a successful route. Each approach lent itself to invaluable synthetic
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knowledge that may have otherwise eluded us. All routes and synthetic methods/designs during
our efforts to synthesize 2.1 will not be discussed here, only selected approaches. Synthetic
methodology that has been realized from the vast efforts put forth to synthesize 2.1 may be reported
in future manuscripts.

2.5.1 Tandem Mitsunobu-Claisen rearrangement
Our first approach, and perhaps one of the succint, was to utilize a tandem MitsunobuClaisen rearrangement to install the quaternary stereocenter of 2.1 (Scheme 2.5). The utility of this
approach stems from the seminal report that outlined a microwave-assisted Mitsunobu-Claisen
rearrangement of phenols (2.23) and a variety of allylic alcohols (2.24) to give ortho-substituted
phenols (2.25).55 We sought to extend this methodology to cyclic allylic alcohols and to set
quaternary stereocenters via Claisen rearrangements of the intermediate aryl allylic ethers. The
yields of the reported reactions were promising (65-95%) and would be extremely useful if
incorporated late in the synthesis of 2.1.

Scheme 2.5: A microwave assisted tandem Mitsunobu-Claisen rearrangement of phenols with allylic alcohols.
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To apply the methodology in Scheme 2.5 to our work, we envisioned that an advanced
phenol intermediate 2.26 could undergo the Mitsunobu-Claisen rearrangement with a chiral allylic
alcohol isophorol (2.27). The Mitsunobu reaction provides intermediate 2.26.1 which can undergo
a Claisen rearrangement under the thermal reaction conditions to contrive phenol 2.28. Chirality
transfer from chiral secondary allylic alcohol 2.27 to the quaternary stereocenter of phenol 2.28
would be made possible by the Claisen rearrangement transition state.
The retrosynthetic analysis (Scheme 2.6) highlights the late-stage installation of both
stereocenters found in 2.1. By making use of the Pd catalyzed coupling of sterically hindered aryl
triflates with SKAs, we envisioned that a chiral catalytic system would be able to control the αstereocenter of 2.1 if SKA 2.29 is coupled to triflate 2.30. To control the quaternary stereocenter
of 2.1, a Mitsunobu-Claisen rearrangement between (R)-2.27 and phenol intermediate 2.31 could
be utilized. During the tandem Mitsunobu-Claisen rearrangement, the initial Mitsunobu reaction
inverts the stereochemistry of 2.27 that is transferred to quaternary stereocenter found in 2.1 via
Claisen rearrangement.

Scheme 2.6: Retrosynthetic analysis of membranolide utilizing a Mitsunobu-Claisen rearrangement.
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Our retrosynthetic approach relied on our prior methodology used to synthesize the tertbutyl analogs which included a series of ortho-lithiations and the elusive Pd cross-coupling
(Scheme 2.6). Instead of starting with an ortho-substituted phenol, as in the tert-butyl analogs,
phenol 2.34 (one of the most inexpensive building blocks) could be used as the starting material
to construct the phthalide core of 2.1. The attractiveness of this route was the use of a very
inexpensive starting material and late-stage installment of both stereocenters. Since the methods
required to synthesize phthalide 2.31 had been previously optimized, we decided to explore the
Mitsunobu-Claisen rearrangement using 2.31 instead of an early stage intermediate.
The synthesis of 2.31 began with carbamoylation of 2.34 followed by ortho-lithiation and
rearrangement to provide amide 2.35 in 82% yield over two steps (Scheme 2.7). To avoid a
protection and deprotection strategy previously used to install the lactone, we attempted the ortholithiation strategy with the unprotected 2.35. Unfortunately, the formation of the requisite dianion
was unsuccessful and we were forced to use our initial protecting group strategy. Phenol 2.35 was
protected as the benzyl ether and the three-step protocol for lactone formation was carried out
uneventfully to provide lactone 2.37. Deprotection of the benzyl ether proceeded smoothly to give
the desired hydroxy phthalide 2.31 needed for the Mitsunobu-Claisen rearrangement.

Scheme 2.7: Synthesis of hydroxy phthalide intermediate 2.31.
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With 2.31 in-hand, we could attempt the critical Mitsunobu-Claisen rearrangement with an
appropriate secondary allylic alcohol. We had first purchased 2.27 from Sigma-Aldrich but to our
surprise, the alcohol was not sufficiently pure to further advance our synthesis. Luckily, we could
easily access 2.27 from a reduction of isophorone (2.38) using LiAlH4 or NaBH4 as shown in
Scheme 2.8. Large-scale reductions of 2.28 could be achieved in a reliable manner using NaBH4
in water to give 2.27 in a 92% yield and roughly 90% purity (impurities consisted of over reduced
2.27 and unreacted 2.38). With the use of Luche conditions (CeCl3), we were able to suppress the
1,4-addition side product to achieve 98% yields with >95% purity of isophorol. Even though
LiAlH4 could be used to achieve nearly quantitative yields, the use of NaBH4 in water was more
amenable to scale (>20 g) and provided straight-forward reaction and purification procedures.

Scheme 2.8: Synthesis of isophorol (2.27) from isophorone (2.38).

Now that a reliable synthesis of 2.27 had been established, we were able to study the
Mitsunobu-Claisen rearrangement between phenol 2.31 and allylic alcohol 2.27 to install the
trimethylcyclohexyl moiety of 2.1. Phenol 2.31 and 2.27 were subjected to microwave conditions
in the presence of DIAD and PPh3 in toluene to affect a tandem Mitsunobu-Claisen rearrangement
(Scheme 2.9). Initial attempts were thwarted by the lack of conversion and difficulty of
purification. Using THF as a solvent instead of toluene was thought to increase the Mitsunobu
yield, which could ultimately lead to an increased overall conversion. Changing the solvent did
not result in any appreciable change in overall conversion or yield. Drawing from our initial results,
we had believed the lactone may be labile under the harsh reaction conditions. To address the
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phenol stability, we turned toward amide intermediate 2.35 to further explore the MitsunobuClaisen rearrangement.

Scheme 2.9: Attempts to use a Mitsunobu-Claisen rearrangement to set the quaternary stereocenter in 2.1.

The same reaction conditions were employed to perform the Mitsunobu-Claisen
rearrangement with amide 2.35 and 2.27 (Scheme 2.9). To our delight, we were able to isolate a
rearranged product with the desired molecular weight, albeit in 25% yield using toluene and 56%
with THF as the solvent. The low yield was not worrisome at this stage since the reaction had yet
to be optimization for our substrate. 1H NMR analysis of the purified rearranged product appeared
to be the desired isomer with two apparent peaks in the vinyl region. The phenol proton was
assigned as a broad peak that occurred more up field than expected and appeared to be a multiplet
with an unidentifiable splitting pattern that could possibly arise from hydrogen bonding with the
orthogonal amide and amide rotamers. To verify the assignment of the phenol peak, D2O was
doped into an NMR sample of 2.41. To our surprise, what we believed to be a vinyl peak had
completely disappeared in the 1H NMR, suggesting our initial assignment was incorrect.
After careful examination of the 1H NMR of the product isolated from the MitsunobuClaisen rearrangement between 2.27 and 2.35, it was determined that the mis-assigned phenolic
proton corresponds to a benzylic proton. If the Claisen rearrangement proceeded as expected, there
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would have been a quaternary center at the benzylic position. It wasn’t clear how the isolated
product could have arisen through the proposed Claisen rearrangement mechanism until reports of
abnormal Claisen rearrangements were unearthed from the literature that date back to 1936 by
Lauer and Filbert.56 Since the first report of an abnormal Claisen rearrangement, there have been
two proposed mechanistic routes that lend themselves to an abnormal rearranged product (Scheme
2.10).57-58

Scheme 2.10: Two possible mechanisms of the abnormal Claisen rearrangement. A) Stepwise mechanism and
B) concerted mechanism.

There is sufficient evidence that supports a consecutive mechanism over a concurrent
mechanism based on kinetic and radiolabeled studies.57-60 Laurel was the first to report on the
radiolabeled study of crotyl ethers in 1961 where he provided evidence of only 15% of the
abnormal product could be observed under their optimized conditions.57 This report led to the first
proposal of a 1,5-hydrogen shift to give the abnormal product (Scheme 2.10, B). A year later,

36

Marvell, Anderson and Ong conducted preliminary kinetic studies that had shown the abnormal
Claisen product concentration increased over time and was dependent on the presence of the
normal Claisen product.60 The importance of the phenol during the reaction was established by the
absence of an abnormal product when conducting the rearrangement using an O-alkylated normal
Claisen product. Based on the data gathered in the initial kinetic studies of crotyl phenyl ethers,
the authors proposed a stepwise mechanism that required the normal Claisen product (Scheme
2.10, A).
Following the first kinetic study of the abnormal Claisen rearrangement, Laurel revisited
their radiolabeled crotyl phenyl ether system using modified reaction procedures. When the
abnormal Claisen rearrangement was conducted for prolonged periods of time, the radiolabeled
product distribution began to increase and eventually reached 50:50 after 280 hours at 220 °C.58
The increased product distribution observed by Laurel after further radiolabeling experiments
resulted in the verification of the consecutive mechanism proposed by Marvell and colleagues.
Similar product distributions were also observed independently by a research group in Zürich,59
further supporting a step-wise mechanism.
Oddly enough, we were unable to observe any of the desired Claisen rearranged product
between a 2.35 and 2.27. The observed results in our case conflict with what is known about the
abnormal Claisen rearrangement stepwise mechanism. However, the consecutive mechanism
hasn’t been unequivocally proven in the case of more elaborate systems. It may be possible that
the reaction proceeds through a different route such as the concerted 1,5-hydrogen shift mechanism
when more constrained systems are involved. There are established methods that circumvent the
formation of abnormal Claisen products. Fukuyama had discovered the use of silyl trapping agents,
such as HMDS, that trap normal Claisen products before the subsequent rearrangement to the
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abnormal product occurs. Fukuyama’s methodology has been outlined in the total synthesis of
discorhabdin.61 All attempts to use Fukuyama trapping methods failed in our hands which we
attribute to the complexity of our Claisen rearrangement.
To our knowledge, there has yet to be a report of an aromatic Claisen rearrangement of a
cyclohexene phenyl ether that sets a quaternary stereocenter. Further investigations are required to
provide mechanistic insight in order to explain out observations. The unfortunate pitfalls of a
Mitsunobu-Claisen approach to access 2.1 and the failed attempts to resurrect this route had
prompted us to reevaluate the synthesis of triflate 2.30 (Scheme 2.6). We postulated that a DielsAlder reaction would be capable of installing the phthalide core of 2.1 after a subsequent oxidation.
Our efforts to synthesize membranolide using a Diels-Alder tactic are reported in the following
section.

2.5.2 A Diels-Alder approach
After the disappointing failure from our Mitsunobu-Claisen route to 2.1, we sought to
access the uniquely substituted isobenzofuranone core of 2.1 via a Diels-Alder cycloaddition.
Installation of the methyl propionate would be accomplished as previously hypothesized using a
Pd catalyst with 2.29 and 2.30 (Scheme 2.11). The Diels-Alder disconnection in Scheme 2.11
gives rise to a SKA diene 2.44 containing the trimethylcyclohexyl moiety and furanone 2.43. We
had planned to install the trimethylcyclohexyl group with stereocontrol by an Ireland-Claisen
rearrangement of allylic ester 2.45. The stereochemical outcome of an Ireland-Claisen
rearrangement can be predicted by using six-membered chair or boat-like transition states.62

38

Scheme 2.11: Retrosynthetic analysis of 2.1 utilizing a Diels-Alder approach.

The exploration of a Diels-Alder approach to 2.1 began with the coupling of racemic 2.27
and 3-butenoic acid (2.46) under Steglich conditions to give the Ireland-Claisen precursor 2.45
(Scheme 2.12). Ester 2.45 underwent an Ireland-Claisen rearrangement uneventfully to give
carboxylic acid 2.47. During reaction optimization, NaHMDS in THF was found to be superior to
other bases and solvents to give an 80% yield. Treatment of 2.45 with NaHMDS allowed for
deprotonation under kinetic conditions followed by enolate trapping with TMS-Cl to give a SKA
intermediate that rearranged upon warming to room temperature. Traditionally, the Ireland-Claisen
rearrangement requires heating to initiate the 3,3-sigmatropic rearrangement. In our case, we
observed the rearrangement under mild conditions at room temperature. Esterification of 2.47 set
the stage to explore a Diels-Alder cycloaddition to construct the phthalide core of 2.1.
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Scheme 2.12: Synthesis of methyl ester 2.48 in attempts to perform a Diels-Alder cycloaddition.

A variety of dienophiles and reaction conditions were explored to perform a Diels-Alder
reaction using 2.48 as the diene source. We had initially suspected that deprotonation of 2.48 under
kinetic conditions would give rise to a conjugated enolate that could be O-silylated and trapped as
SKA diene 2.44. Initial attempts towards the Diels-Alder reaction relied on the formation of a
diene followed by addition of a dienophile to undergo the reaction in situ (Scheme 2.12). A variety
of strong bases were employed to affect this transformation using 2.48 and furanone 2.43 to no
prevail. More electron deficient dienophiles, such as 2.49 and 2.50 in Scheme 2.12, were also
used. Unfortunately, we were unable to identify reaction conditions that allowed for the formation
of the desirable product.
Attempts to synthesize and isolate diene 2.44 instead of in situ generation proved unfruitful.
Despite the bulkiness of 2.48 around the alpha position, we were optimistic that the deprotonation
could be achieved by using strong bases such as LDA or Li/Na/KHMDS. A variety of bases and
silyl electrophiles (TIPS-OTf, TBS-Cl, TMS-Cl) were used to trap diene 2.44; unfortunately, we
were unable to isolate a product that resembled 2.44. After all the attempts, failure to access 2.44
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was attributed to the bulky trimethylcyclohexyl substituent surrounding the α-carbon, hindering
deprotonation. A new route was devised to circumvent the crowded α-position what would allow
for deprotonation at a less hindered site, giving rise to the same elusive enolate.

Scheme 2.13: Synthesis of carboxylic acid 2.53 via DABCO mediated Ireland-Claisen rearrangement.

The new route to 2.44 began in a similar fashion. Esterification of 2.27 with (E)-2-butenoic
acid (2.51) under the same Steglich conditions provided ester 2.52. A unique variant of the IrelandClaisen rearrangement was employed instead of the traditional methods. Ester 2.52 is set-up for a
DABCO-mediated Ireland-Claisen rearrangement. DABCO undergoes a Michael addition to form
an enolate that was trapped with TMS-Cl (Scheme 2.13, 2.52.1). The elimination of DABCO by
DBU gave an inseparable mixture of carboxylic acid isomers 2.53 and 2.47.
The fact that we were able to observe 2.53 suggests that DBU could deprotonate the αposition (labeled in blue, Scheme 2.13) and eliminate DABCO to provide 2.53. However, it is
much easier to deprotonate the γ-position (labeled in red, Scheme 2.13) to eliminate DABCO
resulting in the formation of 2.47. An increasing amount of A1,3 strain for 2.53 may also disfavor
its formation even though the π-system is conjugated.
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Despite observing a mixture of isomers for the modified Ireland-Claisen rearrangement,
we were able to move the synthesis forward by esterifying the mixture of 2.53 and 2.47 to give
esters 2.54 and 2.48 (Scheme 2.14). The mixture of esters was exposed to identical conditions as
previously mentioned for the formation of 2.44. With the presence of ester 2.54, we would be able
to determine if the bulky α-position of 2.48 was hindering the deprotonation and subsequent
formation of 2.44. In every case, we were unable to observe the formation of a Diels-Alder product
and were unable to isolate a SKA. It is possible that a diene SKA is forming in situ, albeit with
trans diene geometry that is unable to participate in a Diels-Alder cycloaddition with our reaction
conditions. Attempts to isomerize the diene under thermal conditions failed – only decomposition
was observed.

Scheme 2.14: Synthesis of ester 2.54 in attempts to perform a Diels-Alder cycloaddition.

After attempts to form a desirable diene for a Diels-Alder reaction went awry, it became
clear that a traditional Diels-Alder approach was not suitable for the intended synthesis of 2.1.
Based on the electronics of this system, a cycloaddition is not the only reaction pathway that could
result in the desired product (Scheme 2.15). If enolate 2.48.1 was able to form, a 1,4-conjugate
addition to 2.43 would give rise to a second enolate (2.48.2) what could condense on the methyl
ester of 2.48.2 to give access to 2.42. Attempts to facilitate a conjugate addition onto 2.43 also
failed when attempting in situ formation of an enolate from 2.48 in the presence of copper salts.
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Scheme 2.15: Plausible route to 2.31 via 1,4-conjugate addition pathway.

A novel approach to quickly form phthalide cores in a minimal number of steps by a DielsAlder reaction (not shown here) was also employed and may be able to solve the deprotonation
issue. However, it was decided not to disclose the methodology in this dissertation due to its
preliminary stage. Thankfully, the roadblocks encountered during the previously discussed routes
had prompted us to brainstorm new synthetic designs for the synthesis of 2.1, which will be further
discussed in the following sections.

2.5.3 A Dieckmann condensation strategy
Two synthetic routes toward 2.1 unfortunately led to dead ends. However, another synthetic
endeavor toward 2.1 is worth mentioning. The retrosynthetic analysis in Scheme 2.16 outlines the
use of a Dieckmann condensation followed by an oxidative aromatization to install the aromatic
ring of 2.1. By expanding on the synthetic methods used for the truncated tert-butyl analogs of 2.1,
the lactone could be installed and as well as the methyl propionate moiety. The diester 2.57
required for a Dieckmann condensation can be traced back to ester 2.58 of isophorol that undergoes
an Ireland-Claisen rearrangement to install the quaternary carbon stereocenter.
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Scheme 2.16: Retrosynthetic analysis of membranolide utilizing a Dieckmann condensation and oxidative
aromatization.

The third approach to 2.1 began with a Baeyer-Villiger oxidation of cycloheptanone
(2.59) to lactone 2.60 followed by ring opening with KOH in the presence of benzyl bromide
(BnBr) gave benzyl ether protected carboxylic acid 2.61 (Scheme 2.17). The crude acid was
coupled to alcohol 2.27 to give ester 2.58 in a reasonable yield (73%). An Ireland-Claisen
rearrangement using previously optimized conditions was performed on ester 2.58 to provide
carboxylic acid 2.62 in yields of 50% at best. Further reaction optimization revealed that
KHMDS in toluene and TMS-Cl/Et3N as a silylating agent resulted in an increased yield (70%)
of acid 2.62 as a mixture of diastereomers (2:1, NMR). We were not interested in the
diastereoselectivity of the Ireland-Claisen rearrangement since the α-stereocenter would be
removed upon aromatization as seen in our retrosynthetic analysis.
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Scheme 2.17: Synthetic route to carboxylic acid intermediate 2.62.

The post Ireland-Claisen product 2.62 was esterified to the methyl ester 2.63 using TMSdiazomethane, and subsequently reduced and deprotected under hydrogenation conditions to
provide primary alcohol 2.64 (Scheme 2.18). A variety of oxidative conditions were used to
oxidize alcohol 2.64 to diester 2.57. We found that a Jones oxidation followed by esterification of
the crude carboxylic acid with TMS-diazomethane provided 2.57 in the greatest yield (93% over
two steps). Once optimal oxidation conditions were established to access 2.57, the Dieckmann
condensation was affected using NaHMDS at 0 °C in THF to give cyclohexanone 2.56 as a mixture
of three diastereomers in excellent yields (95%). Although the reaction proceeded smoothly under
our optimal conditions, the resulting diastereomers were inseparable, complicating NMR analysis.
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Scheme 2.18: Synthesis of phenol intermediate 2.56 from carboxylic acid 2.62.

Attempts to oxidize cyclohexanone 2.56 were far from trivial. Among the many oxidative
conditions attempted, the best result was to use excess DDQ (2,3-Dichloro-5,6-dicyano-1,4benzoquinone) in dioxane at 140 °C in a closed reaction vessel. We were able to obtain phenol
2.55 in 30% yield on milligram scales (Scheme 2.18). All attempts to increase the yields by
modification of the solvent, reaction temperature and reaction time were unsuccessful. A Pd
catalyzed aerobic oxidation63 was also attempted with little to no avail.63 Upon scale-up (3 g), the
oxidative aromatization using DDQ gave phenol 2.55 in an abysmal yield of 10% – starting
material could be recovered and recycled to increase the overall yields. With at least five
transformations left to finish our synthesis, this route was abandoned due to undesirable yields at
the 10th synthetic step.
Looking back at our Diels-Alder approach, we began to investigate various cycloadditions
such as the tetradehydro Diels-Alder (THDA) between dienes and alkynes. We were intrigued by
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the remarkable work by Hoye and colleagues with their discovery of the hexadehydro Diels-Alder
(HDDA) reaction, a thermal cycloaddition of triynes.64 The unique HDDA cycloaddition has
proven to be extremely effective with tethered triynes allowing access to uniquely substituted
phthalides. We surmised that a HDDA will provide access to an advanced phthalide intermediate
useful in the synthesis of 2.1. A quick review of the HDDA reaction will follow in the next section
to outline its utility in chemical synthesis.

2.5.4 The final approach: hexadehydro Diels-Alder cycloaddition
The HDDA reaction is formally related to other Diels-Alder variants by a [4+2]
cycloaddition of a π-system. In a HDDA cycloaddition, a conjugated diyne and an alkyne react in
a [4+2] manner to form a benzyne intermediate (Scheme 2.19). From its initial discovery in 2012,
the HDDA reaction was thought to proceed via a concerted mechanism similar to a traditional
Diels-Alder reaction.64 Further investigations have shown that the reaction proceeds through a
step-wise diradical mechanism65 that forms an aryne capable of undergoing further reactions
(Scheme 2.19).

Scheme 2.19: Concerted and step-wise mechanistic view of the HDDA reaction.64-65

Since the initial HDDA discovery, the utility of the reaction has been extensively explored
with the use of inter and intramolecular trapping of the benzyne intermediate.66-71 Two of the most
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applicable uses of the HDDA reaction with regards to our synthetic design are A) the formation of
uniquely substituted phthalides and B) the reductive benzyne trapping that delivers hydrogen
across the benzyne triple bond (Scheme 2.20).64,

66

Scheme 2.20 provides a glimpse of the

HDDA’s synthetic utility. There are several additional examples of the utility of the HDDA
reaction.68-69, 71-73

Scheme 2.20: Use of intermolecular trapping agents in the HDDA reaction to access phthalides.

It became clear that a HDDA cycloaddition could be used to access the isobenzofuranone
core of 2.1 and other structurally related NPs based on Tom Hoye’s work with reductive benzyne
traps. Our revised approach to 2.1 relies on the same Pd methodology to install the methyl
propionate while a HDDA would be used to append the phthalide core of aryl bromide 2.65
(Scheme 2.21). The requisite triyne 2.66 for a HDDA reaction was envisioned to arise from the
convergence of three smaller subunits (2.67, 2.68, 2.69), which could provide a platform for
analogs of 2.1 and the oxeatamide MNPs. Terminal alkyne 2.69, bearing the quaternary
stereocenter of the trimethylcyclohexyl substituent, could be constructed by an Ireland-Claisen
rearrangement of ester 2.71 followed by oxidative decarboxylation then alkyne homologation of
2.70.
48

Scheme 2.21: Retrosynthetic analysis of membranolide where the key step is a HDDA cycloaddition.

As a proof of concept, the HDDA methodology was applied to the synthesis of truncated
tert-butyl analog 2.3, as seen in Scheme 2.22. Commercially available tert-butyl acetylene (2.72)
was used in a Cadiot-Chodkiewicz copper coupling with 3-bromopropargyl alcohol (2.68) to
afford diynol 2.73 (Scheme 2.22). TMS-propiolic acid 2.67 was coupled to alcohol 2.73 to give
triyne ester 2.74 in a reasonable yield (74%).
A HDDA reaction was first performed with ester 2.74 as the substrate. Three solvents were
screened for their reductive potential in the HDDA including cyclooctane, hexanes and THF at
various concentrations and temperature. To our delight, we were able to identify optimal reaction
conditions to access phthalide 2.76 in 78% yield in dilute cyclooctane (0.005M) at 150 °C for 48
hours. The other solvents, hexanes and THF, gave diminished yields (35-50%). It should be noted
that it was essential to freshly distill the cyclooctane prior to use, regardless of the commercial
source, in order to maximize yields.
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Scheme 2.22: Synthesis of truncated analog 2.3 via HDDA route.

After the optimal HDDA reaction conditions had been discovered, aryl silane 2.76 was
converted to aryl bromide 2.78 via bromodesilylation with NBS (Scheme 2.22). With 2.78 in hand,
a Pd catalyzed cross-coupling reaction was executed using the same reaction conditions previously
described (Scheme 2.4, section 2.4.2) to give truncated analog 2.3. The use of an aryl bromide in
the Pd cross-coupling reaction appeared to give slightly lower yield (78%) relative to the aryl
triflate (94%). The lower yields can be attributed to the oxidative addition potential of an aryl
bromide compared to an aryl triflate.49,51
Our next objective was to develop a synthesis of the required terminal alkyne 2.69 bearing
a trimethylcyclohexyl substituent (Scheme 2.21). Before embarking on a new synthetic endeavor
to access alkyne 2.69 for the synthesis of 2.1, we attempted to push the boundaries of the HDDA.
Instead of relying on transition metal chemistry to install the methyl propionate, we envisioned
that the C-C bonds could be in place prior to the HDDA (Scheme 2.23).
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Scheme 2.23: An alternative route towards truncated analog 2.83 using a HDDA.

Alcohol 2.79 was protected as silyl ether 2.80 using TBDPS-Cl in nearly quantitative yields
(97%) (Scheme 2.23). It was thought that the protected alcohol could serve as a surrogate for the
methyl ester found in 2.1. Protected alcohol 2.80 was treated n-BuLi and CO2 (g) to provide
carboxylic acid 2.81, which was directly used in a Steglich esterification with alcohol 2.73 to give
ester 2.82. Two other protecting groups were also explored (TIPS and Bn), however, all attempts
to cyclize the O-protected triyne esters were unsuccessful.
Efforts made to decrease the number of synthetic steps in the longest linear sequence and
to avoid the use of Pd cross-couplings for the synthesis of 2.1 had failed. However, a HDDA route
could still be useful for the total synthesis of 2.1. One of the last hurdles to overcome was to access
terminal alkyne 2.69 with stereochemical control. A few different approaches have been realized
to access aldehyde 2.70 as seen in Scheme 2.24. Terminal alkynes are easily accessible from
aldehydes via the Seyferth-Gilbert reaction.74 It was hypothesized that either an Ireland-Claisen or
Johnson-Claisen rearrangement could be used to set the quaternary stereocenter and give rise to
aldehyde 2.70 from allylic alcohol 2.27.
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Scheme 2.24: Retrosynthesis of aldehyde 2.70 by three different routes.

The retrosynthetic scheme found in Scheme 2.24 outlines the use of either A) an IrelandClaisen rearrangement to set the quaternary stereocenter from chiral allylic ester 2.71 or B) a
Johnson-Claisen rearrangement with chiral 2.27 and triethyl orthoacetate. Further oxidation of the
Claisen rearranged products in Scheme 2.24 can give rise to a truncated chiral aldehyde. Both
rearrangements would require enantiomerically pure isophorol (2.27) to set the correct quaternary
stereocenter found in 2.21. Both routes were examined as viable options and their efficiencies were
compared using racemic 2.27. While working out conditions for the Claisen rearrangement routes,
a known procedure to prepare nitrile 2.85 was used to quickly advance the racemic synthesis.75
The first route to be discussed toward aldehyde 2.70 is one that utilized known chemistry
to access racemic nitrile 2.85 from isophorone (2.28) (Scheme 2.25). Most of the synthetic
methods were straight-forward; however, a few modifications were necessary for yield
optimization. Starting from unsaturated enone 2.28, a Michael addition using KCN under mildly
acidic conditions gave ketone 2.88 in reasonable yields and on large scales (88%, +20 g). The
ketone was reduced using a modification to the Wolff-Kishner reduction known as a Caglioti
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reaction.76 The Caglioti reaction was performed in two sequential steps: formation of
tosylhydrazone 2.89 followed by reduction to hydrazine using NaCNBH3. Elimination/expulsion
of N2 under basic conditions provided 2.85 in 88% yield over two steps. A traditional WolffKishner and Clemmensen reduction were also attempted, however, the Caglioti modification
proved superior.

Scheme 2.25: Synthesis of racemic aldehyde 2.70 used for method development.

En route to the requisite aldehyde, a nitrile reduction of 2.85 to aldehyde 2.70 was explored.
It was found that DIBAL sufficed as the reductant for the transformation of nitrile 2.85 to aldehyde
2.70. It was essential to perform the reaction in DCM with an acidic quench upon work-up. It was
quickly found that 2.70 was not bench-stable and underwent spontaneous oxidation/decomposition
upon standing under ambient conditions. To complicate matters even further, 2.70 is very volatile
and required delicate handling and storage. Once the appropriate reaction conditions and handling
techniques were established, 2.70 was accessible from isophorone 2.27 on gram scales and was
used to advance the synthesis. Instead of discussing the advancement of racemic 2.1, efforts to
access the enantiopure form and the enantioselective synthesis will be discussed to avoid further
repetition.
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While working out the conditions to access racemic 2.70, a route capable of imparting
chirality had been developed. As mentioned above, an Ireland-Claisen or a Johnson-Claisen
rearrangement could set the desired quaternary center from enantiopure allylic alcohol 2.27.
Unfortunately, 2.27 is not commercially available in its enantiopure form, therefore a scalable
synthesis was required (mentioned in the following section). Instead of using valuable starting
material to work out methods capable of accessing chiral 2.70, racemic 2.27 was used. Scheme
2.25 showcases both Claisen rearrangements and the advancement of their respective products to
racemic 2.70.

Scheme 2.26: Synthesis of aldehyde 2.70 from alcohol 2.27. A) Johnson-Claisen rearrangement and B)
Ireland-Claisen rearrangement.

Route A (Scheme 2.26) capitalized on the operationally simple Johnson-Claisen
rearrangement followed by a Barbier-Weiland degradation strategy to truncate ethyl ester 2.90 to
the corresponding aldehyde 2.70. All attempts to oxidize alkene 2.86 led primarily to overoxidation of 2.70 to the carboxylic acid. Conversely, route B (Scheme 2.26) relied on an Ireland-
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Claisen rearrangement of allylic ester 2.71 followed by deprotection/reduction and oxidation of αhydroxy acid 2.92 to access aldehyde 2.70. The oxidation of 2.92 was far from trivial and required
extensive reaction optimization, careful work-up and handling conditions to achieve modest yields
of 71%. Other oxidations of 2.92 were examined including NaOCl, I2, NBS and other hypervalent
iodide species, all of which were less prosperous than NaIO4.
Route B in Scheme 2.26 was chosen for the enantioselective total synthesis of 2.1 based
on overall yields. In order to utilize the Ireland-Claisen approach stereoselectively, access to the
enantiopure form of 2.27 was essential. Many asymmetric strategies exist to control the chirality
of secondary alcohols such as 2.27. However, a preparation of both stereoisomers of 2.27 with
good to excellent enantiopurity exists with help from nature.77
To date, the only known report capable of accessing alcohol 2.27 in high enantiopurity
makes use of the intrinsic chirality of enzymes. An enzymatic kinetic resolution (EKR) of racemic
2.27 can be achieved using two different enzymes to afford both enantiomers of 2.27. The enzyme,
chiral by nature, can selectively differentiate between the two enantiomers of 2.27 in an
esterification reaction (Scheme 2.27). Both ester 2.93 and unreacted alcohol 2.27 can be separated
from the reaction with enantioenrichment. We quickly decided to make use of the established EKR
after our initial attempts at asymmetrically reducing ketone 2.28 failed.

Scheme 2.27: A hypothetical enzymatic kinetic resolution of alcohol 2.27.
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Enzymatic resolutions have become increasingly popular in organic synthesis over the
years due to the improvements in enzyme production and immobilization techniques that increase
enzyme stability to organic solvents.78 Traditionally, enzymes such as lipases and peptidases have
been used to stereoselectively cleave racemic esters and amides in buffered aqueous medium.79
More recently, enzymes have been identified that can esterify racemic alcohols with
reactive esters (acyl donors) to give high enantiopure esters and unreacted alcohols as products
(similar to Scheme 2.27). The theoretical yield of an EKR is only 50% by mass but can achieve
100% ee if the enzyme can differentiate between two enantiomers perfectly. Remarkable
enzyme/transition metal dual catalytic systems have been identified that can increase the
theoretical yields to 99%.80 The ability to dynamically affect the unreacted alcohol in a redox
fashion, results in continual racemization that siphons away the reactive alcohol (Scheme 2.28),
known as enzymatic dynamic kinetic resolution (EDKR). A dynamic kinetic resolution of alcohol
2.27 could prove paramount if an enzyme system could be identified that selectively and efficiently
esterifies the desired enantiomer of 2.27.

Scheme 2.28: A hypothetical enzymatic dynamic kinetic resolution of alcohol 2.27.

Following the known reported procedure for the EKR of alcohol 2.27, we were able to use
a lipase from Candida rugosa to obtain (S)-2.27 in 20% yields and 98% ee after three resolutions
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(Scheme 2.29). The low yields and excessive amounts of time it took to obtain 2.27 with high
levels of enantiopurity led us to explore other enzymes known to have similar properties to C.
rugosa. After screening different enzymes, solvents and acyl donors, we were unable to improve
on the previously established reaction conditions for the EKR of 2.27. The lack of selectivity
observed made us abandon the idea of an EDKR. Despite the low yields observed for the EKR of
(S)-2.27, we managed to obtain enough chiral starting material to supply our synthetic efforts
toward 2.1.

Scheme 2.29: Enzymatic kinetic resolution of 2.27 using Candida rugosa.

The enantioselective synthesis of 2.1 began by coupling (S)-2.27 to benzyl-protected
glycolic acid 2.91 to give chiral ester 2.71 in high yields (Scheme 2.30). Our previously optimized
conditions the Ireland-Claisen rearrangement of 2.71 were executed to provide carboxylic acid
2.94 in excellent yields (90%), relative to other Ireland-Claisen rearrangements throughout this
manuscript. The diastereoselectivity for the Ireland-Claisen reaction of 2.94 was approximately
1:2 (1H NMR) and can be contributed to a mixture of enolate geometries formed during the
deprotonation event.
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Scheme 2.30: Synthesis of carboxylic acid intermediate 2.94 via Ireland-Claisen rearrangement. A boat-like
transition state of the Ireland-Claisen rearrangement to provide stereochemical rationale for the reaction.

Scheme 2.30 outlines the Ireland-Claisen rearrangement transition state for cyclic systems.
Cyclic allylic esters tend to adopt a boat-like transition state rather the traditional chair-like
transition state during the rearrangement.62 The different enolate geometries between 2.71.1 and
2.71.2 give rise to the two different diastereomers observed. Both transition state models in
Scheme 2.30 convey the 1,3-chirality transfer that sets the quaternary stereocenter in 2.94.
Fortunately, we were not concerned about the stereocenter at the α-carbon since it will be converted
to an sp2 carbon upon oxidation to aldehyde 2.70 (Scheme 2.31).
En route to chiral 2.70, carboxylic acid 2.94 was reduced and deprotected in one-pot to
provide α-hydroxy acid 2.92 (Scheme 2.31). Oxidative cleavage of 2.92 with NaIO4 in methanol
in the absence of light and oxygen gave chiral 2.70 in 71% yield. Over oxidation of 2.70 to the
carboxylic acid seems to be unavoidable. Thankfully, the carboxylic acid analog of 2.70 could be
isolated and recycled back to the aldehyde via a Weinreb amide followed by reduction. Aldehyde
2.71 was immediately used after purification in a Seyferth-Gilbert homologation using the
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Bestmann-Ohira reagent (2.95)81-82 to reveal terminal alkyne 2.69 in high yields. Delicate care was
required when handling alkyne 2.69 as it readily evaporates.

Scheme 2.31: Preparation of chiral HDDA precursor 2.66 from carboxylic acid 2.94.

Once enough chiral alkyne 2.69 had been obtained, we were able to further advance our
synthesis to the HDDA precursor 2.66 (Scheme 2.31). A Cadiot-Chodkiewicz copper coupling
between alkyne 2.69 and bromo alkyne 2.68 provided alcohol 2.96 in modest yields (Scheme
2.31). Another Steglich coupling between alcohol 2.96 and TMS-propiolic acid 2.67 revealed
triyne 2.66, setting the stage for the penultimate HDDA cycloaddition.
Upon reaction optimization of the HDDA reaction, aryl silane 2.97 could be obtained in up
to 72% yield (Scheme 2.32). To obtain reasonable yields in the HDDA cycloaddition, it was
imperative to freshly distill the cyclooctane as noted previously – the cyclooctane could be
recycled and re-purified by distillation. Equipped with optimized conditions for the key-step in our
synthesis, we were able exchange the aryl silane 2.97 for a more useful synthetic handle via
bromodesilylation to give aryl bromide 2.65 in high yields.
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Scheme 2.32: Use of the HDDA cycloaddition to install the core structure of 2.1.

To our delight, aryl bromide 2.65 provided a crystalline solid after purification that was
used to obtain an X-ray crystal structure of 2.65 (Figure 2.8). The absolute stereochemistry of a
molecule can be determined by using sophisticated crystallographic techniques that were first
introduced by Bijvoet and colleagues in 1951 by exploiting the physical properties of heavy atoms
(first discovered using rubidium, Rb as the heavy atom).83 Since the first report of determination
of absolute configuration by means of X-ray crystallography for small molecules, more common
heavy atoms have been used including bromine, phosphorous, sulfur and even oxygen.84 Similar
methods were used by Dr. Wojtas of the USF X-ray crystallography core and the Flack parameter
was determined to be 0.011 (Appendix-3, Table A-3.1, pg 310), which unequivocally proved the
(S) absolute configuration 2.65.

Figure 2.8: X-ray crystal structure image of aryl bromide 2.65.
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With all the cards in place, the final hand was dealt to reveal 2.1. Initial attempts to couple
aryl bromide 2.65 with SKA 2.22 (Scheme 2.33), using our previously optimized Pd crosscoupling conditions, led to low yields and an alarming amount of protodehalogenated side-product.
The increased steric crowding around the aryl bromide is most likely decreasing the rate of
oxidative addition, typically the first and the rate-limiting step of a Pd-catalytic cycle. Different
halides/pseudo halides, such as triflates and iodides, are known to undergo oxidative addition more
rapidly than aryl bromides and chlorides.85 Unfortunately, we were unable to access an aryl triflate
from 2.65, however, aryl iodide 2.98 could be synthesized using Selectfluor™ and I2 as shown in
Scheme 2.33.
Both aryl halides (2.65 and 2.98) were used to screen a variety of Pd catalysts, ligands and
coupling partners to increase yields and to access 2.1 directly from the aryl halide. It was found
that changing the base from NaOAc to TlOAc and the Pd0 source to Pd(dba)2, SKA 2.22 could be
coupled to both aryl halides in acceptable yield (Scheme 2.33). The Tl+ counter ion facilitates
oxidative addition presumably through the generation of insoluble Tl+X- salts that drive the
catalytic cycle forward.86 Our primary strategy was to install the methyl propionate of 2.1 using
SKA 2.29, as seen in all retrosynthetic analyses throughout this chapter.
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Scheme 2.33: Optimized Pd cross-coupling of aryl halides with 2.22.

The use of a chiral Pd catalytic system should in principle be able to control the
stereochemistry at the α-position of 2.1. Other research groups have explored enantioselective αarylations using SKAs and chiral ligands such as BINAP and Josiphos with great success (>90%
yield and % ee).86-87 It was first perceived that the bulky trimethylcylcohexyl group of 2.65 would
be able to impart facial selectivity to control the α-stereoceneter; based on the surprising axial
conformation the isobenzofuranone adopts as seen in the crystal strucuture (Figure 2.8). It was
unclear that stereochemical assistance of chrial ligands would be required so we proceeded with
achiral Pd catalytic systems. We were met by dissapointment when all attempts to use SKA 2.29
in α-arylations with aryl halides 2.65 and 2.98 failed to provide the desired product (Scheme 2.34).
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Scheme 2.34: Attempts to install methyl propionate of 2.1 using an α-arylation strategy.

A multitude of reaction conditions were screened; including different ligands, catalysts,
additives, solvents and temperatures to diminish the formation of cinnamate ester 2.100 and
protodehalogenated side-product 2.101 (Scheme 2.34). Unfortunately, we were unable to directly
access 2.1 using SKA 2.29 and a Pd catalyst system despite all efforts made.
Another α-arylation strategy, developed by Hartwig and colleagues using zinc-enolates,
was attempted along with a Stille coupling using methyl acrylate stannane 2.103 (Scheme 2.35).88
Surprisingly, zinc-enolates of methy propionate 2.102 and vinyl stannane 2.103 both gave
cinnamate ester 2.100. The observed product may be due to β-hydride elimantion of the zincenolate 2.102 and protodestannylation of vinyl stannane 2.03 to produce methyl acrylate in situ
that undergoes a Pd catalyzed Heck-coupling with our aryl halides. The undesirable route could
again be attributed to the sterically hindered C-Br/I bond resulting in a decreased rate of oxidative
addition; allowing transmetallation and β-hydride elimination to occur more rapidly.
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Scheme 2.35: Alternative coupling strategies to install the methyl propionate moiety of membranolide.

In order to finish the synthesis of 2.1, we decided to revist the Pd coupling of SKA 2.22 to
aryl halides 2.65 and 2.98 as seen in Scheme 2.33. The installation of methyl acetate had been
achived using SKA 2.22 and our optimized conditions to provide 2.99 in 77% yield. Alkylation of
ester 2.99 with MeI through an enolate under kinetic conditions could provide 2.1 as a mixture of
diastereomers (~1:3, by 1H NMR) (Scheme 2.36). It wasn’t entirely surprising to observe facial
selectivity for the enolate alkylation due to the observed conformation in the crystal structure,
assuming a similar conformation in solution phase.

Scheme 2.36: Stereochemical rationale for the alkylation of 2.99 to 2.1.
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The stereochemical outcome of the alkylation that we observed can be rationalized using
the conformational analysis shown in Scheme 2.36. The axial placement of the isobenzofuranone
gives facial preference to the less sterically hindered backside of the enolate where the electrophile
(MeI) can approach. Due to the rotational barrier of the isobenzofuranone moiety (containing the
enolate) and the ability for the cyclohexane to ring-flip (placing the isobenzofuranone in an
equitorial position) a leakage of selectivity can be rationalized.
Observing a 1:3 diastereoselectivty for the alkylation of 2.99 to 2.1 was a blessing in
disguise. The preference for the unatural diastereomer of 2.1 is far from ideal. However, the facial
selectivity can be exploited by epimerizing the undesirable diastereomer 2.104 to 2.1. An
epimerization strategy of 2.104 is not an elegant approach and further improvements using other
synthetic strategies, such as epimerization catalysts or enzymatic resolutions, may increase the
overall selectivity of the final steps toward 2.1.

2.6

Further analogs of membranolide
Using our HDDA strategy to synthesize 2.1, we began to explore the modularity of the

route to further probe the western hemisphere of 2.1. A variety of terminal alkynes can be used to
incorporate different moieties to further investigate the bulky hydrophobic region of the molecule.
We envisioned that a phenyl substituent could replace the trimethylcyclohexyl moiety on 2.1.
Incorporating a phenyl group at the western hemisphere of 2.1 would give access to several new
analogs as well as a handle for chemical tool development (Figure 2.9). The planar phenyl
substituent decreases the structural complexity of 2.1 and provides further information on the
stereochemical requirement of the quaternary stereocenter. Even though a HDDA route may not
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be necessary to synthesize the target analogs of 2.1, it would outline the practicality of our synthetic
approach.

Figure 2.9: Potential phenyl analogs of membranolide.

The first and the most logical starting point for phenyl analogs of 2.1 was to determine if
phenyl acetylene 2.105 could be advanced through our synthetic route. Scheme 2.37 outlines a
straightforward approach to the phenyl analog in five synthetic steps. Phenylacetylene (2.105)
could be coupled to bromo alkyne 2.68 followed by esterification with carboxylic acid 2.67 to give
triyne 2.107 (Scheme 2.37). A HDDA cycloaddition could be performed in either cyclooctane or
hexanes to provide aryl silane 2.108 in modest yields. Bromodesilylation of 2.108 with NBS
afforded aryl bromide 2.109 that could be coupled to SKA 2.22 to give the des-methyl phenyl
analog 2.110 of membranolide.
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Scheme 2.37: Synthesis of a phenyl analog of membranolide.

The ability of phenyl analogs and some of their intermediates, to eradicate MRSA biofilms
are currently being evaluated in collaboration with Professor Les Shaw’s laboratory. Preliminary
results have suggested that the phenyl moiety can maintain the biological activity of 2.1. Further
substitution around the phenyl ring may provide increased bioactivity as well as a handle for
chemical tool development.

2.7

Conclusion and future direction
The total synthesis efforts towards 2.1 have resulted in a unique synthetic approach that

can provide novel structurally related compounds including other membranolides, oxeatamides
and their analogs. It should be apparent that many roadblocks were encountered and conquered
during the synthetic studies to access 2.1. Most, but not all, synthetic approaches to 2.1 were
reported in this chapter. Of all the routes taken toward 2.1, a route utilizing a HDDA cycloaddition
to construct the uniquely substituted phthalide core has granted us access to the MNP.
The lack of stereochemical control while setting the α-stereocenter via enolate alkylation
followed by an undesirable epimerization step can be further optimized for future syntheses.
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Among the possible strategies to improve stereochemical control are enzymatic epimerization and
the use of organocatalytic or organometallic epimerization catalysts. Other strategies could involve
a more elaborate triyne that undergoes the HDDA reaction to provide a masked propionate (similar
to a previously mentioned strategy in Scheme 2.23).
Unanswered questions regarding the structural requirements for 2.1 to elicit bioactivity
against MRSA biofilms are beginning to be realized. Based on the biological evaluation conducted
with our collaborators in Dr. Les Shaw’s laboratory, it appears that a bulky group on the western
hemisphere of 2.1 is required for observable bioactivity but is not exclusively limited to the
trimethylcyclohexyl found in 2.1. The stereochemical requirement at the quaternary stereocenter
in 2.1 appears to be minimal based on the activities of tert-butyl truncated analogs 2.2 and 2.3
along with phenyl analog 2.110. Also, the α-stereocenter found in the northern hemisphere of 2.1
seems to be of little importance with respect to bioactivity against MRSA biofilms. Further
structure-activity relationship studies using des-methyl 2.1 (2.99) could reveal the full
stereochemical requirements for 2.1’s bioactivity.
The phenyl analogs of 2.1 hold great promise for the development potent biofilm
eradicators and chemical tool molecules that will aid in understanding the mechanism of action for
this compound class. By removing some of the structural complexity of the initial hit (2.1) with
des-methyl phenyl analogs of 2.1, a more streamlined approach to analog development can be
possible. The developed synthetic methodology reported herein can be used to incorporate
fluorescent or pull-down probes to guide further chemical biology studies. As of now, the
biochemical target for 2.1 and its analogs are unknown. With the developed synthetic methodology
towards 2.1 and related analogs along with collaborative biological evaluations with Professor Les
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Shaw’s laboratory, potential druggable targets for MRSA biofilms may be revealed in future
studies.
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2.9

Chapter 2: Experimental procedures

In a 100 mL round-bottomed flask equipped with a stir bar was added 2.5 (2.51 g, 15.4 mmol) in
CCl4 (20 mL). NBS (5.76 g, 32.4 mmol) and benzoyl peroxide (0.187 g, 0.771 mmol) were added
and the reaction was heated to 80 °C (reflux) for 6 hours. The reaction mixture was cooled to room
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temperature and filtered through a cintered glass funnel. The filtrate was concentrated under
reduced pressure to give a crude solid that was dissolved in ether and decolorized with activated
charcoal. The resulting solution was evaporated and recrystallized using hexanes/Et2O to give 2.61
(3.11 g, 12.9 mmol, 83% yield) as a white solid that was used in the next step without further
purification or characterization.

In a 100 mL round-bottomed flask equipped with a stir bar was added 2.6 (2.1 g, 8.3 mmol) in
ethanol (4.2 mL) at room temperature. A solution of 2 M aqueous NaOH (20.1 mL, 40.2 mmol)
was added and heated to 80 °C for 30 min. The solution was cooled and acidified with
concentrated HCl then heated to 80 °C for 1 h. The resulting reaction mixture was cooled to
room temperature and refrigerated overnight to give a crystalline product that was recrystallized
using hot methanol to give 2.72 (1.31 g, 7.35 mmol, 89% yield) as beige needles. 1H NMR (500
MHz, DMSO-d6) δ 13.46 (s, 1 H), 7.77 - 7.85 (m, 2 H), 7.71 (d, J=7.15 Hz, 1 H), 5.44 (s, 2 H)
ppm. 13C NMR (126 MHz, DMSO-d6,): δ 169.2, 167.4, 148.7, 134.6, 132.9, 128.5, 125.3, 122.0,
70.1 ppm. HRMS m/z: [M + H]+ Calcd for C9H8O4 179.0339; found 179.0337.

In a 50 mL round-bottomed flask equipped with a stir bar was added 2.7 (0.615 g, 3.45 mmol) in
toluene (25 mL) to give a yellow suspension. SOCl2 (0.302 mL, 4.14 mmol) was added and the
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reaction vessel was equipped with a Dean-Stark trap then heated to 110 °C (reflux) for 15 h. A
precipitate formed that was filtered and recrystallized from toluene/hexanes to give 2.82 (0.566 g,
2.88 mmol, 83% yield) as a light brown solid that was used without further purification or
characterization.

In a 100 mL round-bottomed flask equipped with a stir bar was added 2.8 (851 mg, 4.32 mmol) in
THF (20 mL) at 0 °C. A cold ethereal solution of diazomethane in excess (generated by Diazald
distillation) was added and warmed to room temperature where it stirred for 15 hours. The solvent
was removed under reduced pressure and the crude was dissolved in MeOH (6 mL). A solution of
BzOAg (0.337 g, 1.47 mmol) and Et3N (4.65 mL, 33.4 mmol) was added dropwise to the reaction
mixture. Gas evolution was evident during addition of the BzOAg/Et3N solution. The reaction
stirred at room temperature for 15 hours. The reaction was diluted with 10 mL of MeOH and
activated charcoal was added then heated to 75 °C for one hour. The mixture was cooled, filtered
and washed with Et2O. The filtrate was concentrated under reduced pressure and the crude was
purified by column chromatography (4:1, Hex/EtOAc) to give 2.42 (0.102 g, 0.495 mmol, 34%
yield) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 7.64 (t, J=7.6 Hz, 1 H) 7.42 (d, J=7.6
Hz, 1 H) 7.38 (d, J=7.5 Hz, 1 H) 5.30 (s, 2 H) 4.19 (s, 2 H) 3.73 (s, 3 H) ppm.

13

C NMR (126

MHz, CDCl3): δ 171.2, 170.7, 147.2, 134.9, 134.0, 130.9, 123.8, 121.1, 69.0, 52.2, 35.7 ppm.
HRMS m/z: [M + Na]+ Calcd for C11H10O4Na 229.0471; found 229.0466.
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In a 500 mL round-bottomed flask equipped with a stir bar was added NaH (3.20 g, 80 mmol, 60%
wt) in anhydrous THF (166 mL) at 0 °C. A solution of 2.9 (10.2 mL, 66.6 mmol) in anhydrous
THF (100 mL) was added dropwise and stirred at 0 °C for 1 hour. Diethylcarbamoyl chloride 2.10
(10.2 mL, 80.1 mmol) was added dropwise while at 0 °C then heated to 60 °C where it stirred for
12 hours. The reaction was quenched with satd. aqueous NH4Cl (50 mL) and water (150 mL). The
aqueous phase was extracted with EtOAc (3 x 350 mL), combined organic layers were washed
with brine (2 x 75 mL), dried over Na2SO4, filtered and concentrated to give a crude oil. Further
purification by silica gel column chromatography using hexanes/EtOAc (4:1) provided 2.11 (14.5
g, 65.5 mmol, 98% yield) as a beige oil. 1H NMR (500 MHz, CDCl3) δ 7.37 (dd, J=7.89, 1.65 Hz,
1 H), 7.22 (td, J=7.61, 1.65 Hz, 1 H), 7.11 - 7.16 (m, 1 H), 7.01 (dd, J=7.95, 1.34 Hz, 1 H), 3.53
(q, J=7.11 Hz, 2 H), 3.43 (q, J=7.09 Hz, 2 H), 1.38 (s, 9 H), 1.29 (t, J=7.09 Hz, 3 H), 1.22 (t,
J=7.09 Hz, 3 H), ppm. 13C NMR (126 MHz, CDCl3): δ 154.3, 150.1, 141.1, 126.9, 126.8, 124.9,
124.2, 42.0, 41.6, 34.5, 30.2, 14.3, 13.4 ppm. HRMS m/z: [M + H]+ Calcd for C15H24NO2
250.1802; found 250.1809.

In a 1 L round-bottomed flask equipped with a stir bar was added TMEDA (7.26 mL, 48.1 mmol)
in anhydrous THF (400 mL) at -78 °C. s-BuLi (34.4 mL, 48.1 mmol, 1.4 M in hexanes) was added

77

dropwise to the cold solution and stirred for 10 min. A solution 2.11 (10.1 g, 40.2 mmol) in
anhydrous THF (40 mL) was added dropwise and stirred at -78 °C for 1 hour before warming to
room temperature where it stirred for 15 hours. At which time the reaction was quenched with satd.
aqueous NH4Cl (150 mL) and water (200 mL). The mixture was partitioned in a separatory funnel
with Et2O (200 mL) and the aqueous layer was extracted with Et2O (3 x 250 mL). The combined
organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated to
give a crude yellow oil. Further purification by silica gel column chromatography using
hexanes/EtOAc (4:1) gave 2.11.1 (8.51 g, 34.1 mmol, 85% yield) as a clear colorless oil. 1H NMR
(400 MHz, CDCl3): δ 9.73 (br s, 1H), 7.30 (d, J = 6.6 Hz, 1H), 7.09 (d, J = 7.7 Hz, 1H), 6.74 (t, J
= 7.7 Hz, 1H), 3.49 (q, J = 7.1 Hz, 4H), 1.39 (s, 9H), 1.25 (t, J = 7.1 Hz, 6H) ppm. 13C NMR (101
MHz, CDCl3): δ 172.5, 157.6, 138.4, 129.2, 125.1, 118.1, 117.5, 42.2, 34.9, 29.4, 13.4 ppm. HRMS
m/z: [M + H]+ Calcd for C15H24NO2 250.1802; found 250.1811.

In a 500 mL round-bottomed flask equipped with a stir bar was added NaH (2.09 g, 52.1 mmol,
60% wt) in anhydrous THF (100 mL) at 0 °C. A solution of 2.11.1 (10.1 g, 40.2 mmol) in anhydrous
THF (100 mL) was added slowly to the sodium hydride solution. Once hydrogen gas evolution
ceased, a small spatula tip of tetrabutylammonium iodide (TBAI, catalytic amount) was added to
the reaction mixture. The reaction mixture was stirred for 5 min at 0 °C then warmed to room
temperature where it stirred for an additional 30 min. BnBr (5.72 mL, 48.1 mmol) was added
dropwise then the reaction was heated to 80 °C for 6 hours. The reaction was cooled to room
temperature and quenched with MeOH (50 mL). The solvents were removed under reduced
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pressure then taken up in EtOAc (150 mL) and water (300 mL). The aqueous layer was extracted
with EtOAc (3 x 250 mL), dried over Na2SO4, filtered and concentrated to give a crude oil. Further
purification by silica gel column chromatography using (hexanes/EtOAc, 4:1) gave 2.12 (13.3 g,
39.2 mmol, 98% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.30-7.41 (m, 5H), 7.247.29 (m, 1H), 7.11-7.15 (m, 1H), 7.03-7.09 (m, 1H), 5.26 (d, J = 11.9 Hz, 1H), 4.92 (d, J = 11.9
Hz, 1H), 3.51-3.63 (m, 1H), 3.29-3.38 (m, 1H), 3.18-3.29 (m, 1H), 2.99-3.11 (m, 1H), 1.37 (s, 9H),
1.04 (t, J = 7.1 Hz, 3H), 0.95 (t, J = 7.1 Hz, 3H) ppm.

13

C NMR (101 MHz, CDCl3): δ 169.9,

153.8, 143.1, 137.7, 131.9, 128.2, 127.7, 127.4, 126.8, 126.7, 123.8, 75.5, 43.0, 39.2, 35.1, 30.6,
13.7, 12.6 ppm. HRMS m/z: [M + H]+ Calcd for C22H30NO2 340.2271; found 340.2287.

In a flame-dried 250 mL double-necked round-bottomed flask equipped with a stir bar was added
TMEDA (2.06 mL, 13.7 mmol) in anhydrous THF (40 mL) at -78 °C. Once cooled, s-BuLi (9.81
mL, 13.7 mmol, 1.4 M in hexanes) was added and allowed to complex with TMEDA for 15 min
at -78 °C. A solution of 2.12 (2.21 g, 6.51 mmol) in anhydrous THF (30 mL) was added dropwise
to reaction mixture and stirred for 1 hour. After 1 hour had elapsed, anhydrous DMF (1.52 mL,
19.6 mmol) was added dropwise to the reaction mixture and stirred for one hour at -78 °C before
warming to room temperature where it stirred for an additional hour. The reaction was quenched
with satd. aqueous NH4Cl (35 mL) and water (25 mL) then diluted with EtOAc (50 mL). The
aqueous phase was extracted with EtOAc (3 x 50 mL), combined organic layers were washed with
brine (100 mL), dried over Na2SO4, filtered and concentrated to give a crude orange oil that could
be used without further purification. Further purification can be achieved by silica gel column
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chromatography using hexanes/EtOAc (4:1) to give 2.12.1 (2.21 g, 6.01 mmol, 92% yield). 1H
NMR (400 MHz, CDCl3): δ 9.96 (s, 1H), 7.66 (d, J = 8.2 Hz, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.267.41 (m, 5H), 5.45 (d, J = 11.7 Hz, 1H), 4.95 (d, J = 11.7 Hz, 1H), 3.34-3.62 (m, 2H), 2.95-3.18
(m, 2H), 1.40 (s, 9H), 1.12 (t, J = 7.2 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H) ppm.

*The crude reaction mixture of a previous formylation step was used. Percent yield was determined
based on a 7.02 mmol scale of the previous reaction.
In a 250 round-bottomed flask equipped with a stir bar was added 2.12.1 (2.58 g, 7.02 mmol,
crude) in EtOH (70 mL) at room temperature. NaBH4 (0.292 g, 7.72 mmol) was added and the
reaction stirred at room temperature for 15 hours. The reaction mixture was acidified using 6 N
aqueous HCl (3.5 mL) and refluxed at 110 °C for 6 hours. Once complete (TLC) the reaction
mixture was diluted with water (40 mL) and partitioned in a separatory funnel with DCM (50 mL).
The aqueous layer was extracted with DCM (3 x 30 mL), combined organic layers were washed
with brine (3 x 30 mL), dried over Na2SO4, filtered and concentrated to give a crude orange oil.
The crude oil was adsorbed to silica gel and further purified by silica gel column chromatography
using hexanes/EtOAc (4:1) to provide 2.13 (1.58 g, 5.33 mmol, 76% yield). 1H NMR (400 MHz,
CDCl3) δ 7.66 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.1 Hz, 2H), 7.42 – 7.36 (m, 2H), 7.33 (d, J = 7.2
Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 5.35 (s, 2H), 5.22 (s, 2H), 1.39 (s, 9H) ppm. 13C NMR (101
MHz, CDCl3) δ 169.1, 157.8, 147.1, 143.4, 137.0, 134.0, 128.4, 128.3, 128.0, 117.9, 116.2, 76.7,
68.4, 35.4, 30.6 ppm.
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In a 100 mL round-bottomed flask equipped with a stir bar was added 2.13 (1.58 g, 5.33 mmol) in
MeOH (25 mL). The flask was vacuum purged with argon three times before Pd/C (0.284 g, 0.267
mmol, 0.1 eq, 10 wt%) was added. The atmosphere of the flask was evacuated and replaced with
H2 gas via balloon and stirred for 15 hours at room temperature under an atmosphere of H2 gas.
Once complete (TLC) the atmosphere of the flask was replaced with argon and the reaction mixture
was filtered through a bed of Celite. The filtrate was concentrated to give a crude oil that was
purified by silica gel column chromatography using hexanes/EtOAc (4:1) to give 2.13.1 (0.988 g,
4.79 mmol, 90% yield) as a clear colorless oil that solidified upon standing. 1H NMR (400 MHz,
CDCl3) δ 8.43 (s, 1H), 7.54 (d, J = 7.8 Hz, 1H), 6.87 (d, J = 7.8 Hz, 1H), 5.26 (d, J = 1.2 Hz, 2H),
1.42 (s, 9H) ppm. HRMS m/z: [M + Na]+ Calcd for C12H14O3Na 229.0835; found 229.0825.

In a 50 mL round-bottomed flask equipped with a stir bar was added pyridine (3.52 mL, 43.1
mmol) in DCM (30 mL) at 0 °C. Triflic anhydride (Tf2O) (1.976 mL, 11.70 mmol) was added
dropwise and the reaction continued to stir for an additional 5 minutes at 0 °C. A solution 2.13.1
(2.01 g, 9.75 mmol) in DCM (10 mL) was added slowly over 10 minutes. The reaction continued
to stir at 0 °C for 30 min until complete (TLC). The reaction was quenched with 1 N aqueous HCl
(25 mL) and diluted with DCM (25 mL). The organic layer was further washed with 1 N aqueous
HCl (2x 10mL), satd. aqueous NaHCO3 (35 mL) and brine (20 mL), then dried over Na2SO4,
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filtered and concentrated to give a crude oil. Further purification by silica gel column
chromatography using hexanes/EtOAc (3:1) gave 2.14 (2.88 g, 8.51 mmol, 87% yield) as a yellow
solid. 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 8.2 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 5.25 (s,
2H), 1.50 (s, 9H) ppm. HRMS m/z: [M + H]+ Calcd for C13H14F3O5S 339.0509; found 339.0499.

In a 15mL reaction vial equipped with a stir bar was added NaOAc (410 mg, 5.01 mmol), Pd2(dba)3
(92.3 mg, 0.104 mmol) and dppf (122 mg, 0.221 mmol) in anhydrous THF (3 mL). The mixture
stirred for 5 minutes at room temperature before a solution of 2.14 (254 mg, 0.751 mmol) and 2.22
(0.502 mL, 2.31 mmol) in anhydrous THF (7 mL) was added. The reaction vial was sealed with a
Teflon screw cap and the reaction mixture was heated to 80 °C where it stirred for 15 hours. Once
complete (TLC) the mixture was diluted with Et2O (20 mL) and filtered through a pad of Celite
while rinsing with Et2O. The filtrate was concentrated to give a crude dark red oil that was further
purified by silica gel column chromatography using hexanes/EtOAc (4:1) to give 2.3 (185 mg,
0.705 mmol, 94% yield) as a pale white solid. 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J=8.2 Hz, 1
H) 7.34 (d, J=8.2 Hz, 1 H) 5.23 (s, 2 H) 4.49 (s, 2 H) 3.74 (s, 3 H) 1.45 (s, 9 H) ppm. 13C NMR
(126 MHz, CDCl3) δ 171.5, 171.3, 149.7, 144.9, 134.0, 132.3, 125.7, 120.6, 68.1, 52.1, 35.8, 34.9,
31.7 ppm. HRMS m/z: [M + Na]+ Calcd for C15H18O4Na 285.1097; found 285.1101.

A flame dried 10 mL round-bottomed flask equipped with a stir bar was added 2.3 (0.181 g, 0.686
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mmol) in anhydrous THF (4 mL) at -78 °C. Once cool, NaHMDS (0.823 mL, 0.823 mmol, 1 M in
THF) was added dropwise via syringe and the solution stirred at -78 °C for 30 min. MeI (0.056
mL, 0.89 mmol) was then added via syringe and the reaction was allowed to warm to room
temperature where it stirred for 1 hour. The reaction was quenched with 1 N HCl (5 mL) and
extracted with Et2O (3 x 15 mL), dried over Na2SO4, filtered and concentrated to give a crude oil.
Further purification by silica gel column chromatography using hexanes/EtOAc (3:1) gave 2.2
(0.145 g, 0.525 mmol, 76% yield) as a light-yellow oil. 1H NMR (500 MHz, CDCl3): δ 7.77 (d, J
= 8.2 Hz, 1H), 7.31 (br d, J = 8.2 Hz, 1H), 5.23 (s, 2H), 4.60 (q, J = 6.9 Hz, 1H), 3.71 (s, 3H), 1.67
(d, J = 7.0 Hz, 3H), 1.49 (s, 9H) ppm. 13C NMR (126 MHz, CDCl3): δ 173.6, 170.7, 148.5, 146.1,
142.0, 132.6, 124.3, 120.1, 68.4, 52.1, 40.6, 36.0, 32.1, 18.0 ppm. HRMS m/z: [M + Na]+ Calcd
for C16H20O4Na 299.1254; found 299.1265.

In a 1 L round-bottom flask equipped with a stir bar was added NaH (5.15 g, 129 mmol, 60% wt)
in anhydrous THF (300 mL) at 0 °C. A solution of 2.34 (10.1 g, 107 mmol) in THF (125 mL) and
added dropwise and stirred at 0 °C for 1 h. At which time diethylcarbamoyl chloride 2.10 (16.3
mL, 129 mmol) was added dropwise to the cold reaction mixture then the reaction was heated to
60 °C where it stirred for 12 h. The reaction was quenched with aq. NH4Cl (250 mL) and water
(150 mL) then extracted with EtOAc (3 x 350 mL). The combined organic layers were dried over
Na2SO4, filtered and concentrated to give a crude oil. Further purification by silica gel column
chromatography using hexanes/EtOAc (9:1) gave 2.333 (20.1 g, 104 mmol, 97% yield) as an amber
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oil. 1H NMR (500 MHz, CDCl3): δ 7.36 (t, J = 8.1 Hz, 2H), 7.19 (t, J = 7.2 Hz, 1H), 7.13 (d, J =
7.6 Hz, 2H), 3.35-3.51 (m, 4H), 1.17-1.32 (m, 6H) ppm. 13C NMR (126 MHz, CDCl3): δ 154.3,
151.5, 129.2, 125.0, 121.8, 42.2, 41.9, 14.2, 13.4 ppm.

In a flame dried 1 L round-bottomed flask equipped with a stir bar was added TMEDA (14.2 mL,
94.1 mmol) in anhydrous THF (450 mL) at -78 °C. s-BuLi (67.0 mL, 94 mmol, 1.4 M) was added
dropwise and the reaction continued to stir at -78 °C for 15 min. A solution of 2.33 (15.1 g, 78
mmol) in anhydrous THF (250 mL) was added dropwise to the reaction mixture. The reaction
continued to stir for an additional 1.5 hours at -78 °C before warming to room temperature where
it stirred for 15 hours. The reaction was quenched with satd. aqueous NH4Cl (200 mL) and water
(150 mL). The aqueous layer was extracted with EtOAc (3 x 200 mL), dried over Na2SO4, filtered
and concentrated to give a crude oil. Further purification by silica gel column chromatography
using hexanes/EtOAc (9:1) gave 2.354 (12.4 g, 64.2 mmol, 82% yield) as a yellow oil. 1H NMR
(400 MHz, CDCl3): δ 9.69 (br s, 1H), 7.17-7.35 (m, 2H), 6.95 (br d, J = 8.2 Hz, 1H), 6.81 (br t, J
= 7.4 Hz, 1H), 3.49 (br d, J = 7.1 Hz, 4H), 1.24 (br t, J = 7.1 Hz, 6H) ppm. 13C NMR (101 MHz,
CDCl3): δ 171.3, 158.5, 132.1, 127.2, 118.4, 118.3, 117.9, 42.1, 13.4 ppm.

In a 500 mL round-bottomed flask equipped with a stir bar was added NaH (2.61 g, 65.3 mmol,
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60% wt) in anhydrous THF (150 mL) at 0 °C. A solution of 2.35 (11.4 g, 59.0 mmol) in anhydrous
THF (100 mL) was added dropwise and allowed to stir at 0 °C for 30 min. A spatula tip of
tetrabutylammonium iodide (TBAI) was added along with BnBr (7.75 mL, 65.3 mmol). The
reaction was warmed to room temperature where it stirred for an additional 15 hours. The reaction
was quenched with water (250 mL) and the aqueous layer was extracted with EtOAc (4 x 150 mL),
dried over Na2SO4, filtered and concentrated to give a crude oil. Further purification by silica gel
column chromatography using hexanes/EtOAc (4:1) gave 2.36 (14.8 g, 52.2 mmol, 88% yield) as
a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.20-7.41 (m, 7H), 6.89-7.08 (m, 2H), 4.95-5.19 (m,
2H), 2.99-3.88 (m, 4H), 0.95-1.18 (m, 6H) ppm.

13

C NMR (101 MHz, CDCl3): δ 168.6, 154.2,

136.8, 129.9, 128.4, 127.8, 127.6, 127.5, 127.0, 121.2, 112.5, 70.2, 42.7, 38.8, 14.0, 12.7 ppm.

In a flame dried triple-necked round-bottomed flask equipped with a stir bar was added TMEDA
(6.93 mL, 46.3 mmol) and s-BuLi (33.1 mL, 46.3 mmol, 1.4 M in hexanes) in anhydrous THF (75
mL) at -78 °C. The solution stirred for 15 minutes before a solution of 2.36 (10.1 g, 35.6 mmol) in
anhydrous THF (75 mL) and was added dropwise to the reaction mixture where it stirred for 1
hour. After one hour had elapsed, DMF (3.31 mL, 42.8 mmol) was added dropwise to the reaction
mixture and stirred for 10 minutes before warming to room temperature where it stirred overnight.
The reaction was quenched with satd. aqueous NH4Cl (150 mL) and water (150 mL). The aqueous
layer was extracted with EtOAc (3 x 200 mL), dried over Na2SO4, filtered and concentrated to
give a crude yellow oil that could be used in the next step without further purification.
In a 200 mL round-bottomed flask was added crude 2.36.1 (6.11 g, 19.6 mmol) in EtOH (150 mL)
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at room temperature. NaBH4 (0.741 g, 19.6 mmol) was added and the reaction stirred at room
temperature for 15 hours. At which time the reaction was acidified to a pH of 2 using conc. HCl
then heated to 100 °C for 6 hours. Once complete (TLC) the reaction was diluted with water (150
mL) and extracted with DCM (3 x 150 mL), washed with brine (100 mL), dried over Na2SO4,
filtered and concentrated to give a crude oil. Further purification by silica gel column
chromatography using hexanes/EtOAc (6:1) gave 2.375 (3.95 g, 16.4 mmol, 84% yield) as a lightyellow oil. 1H NMR (400 MHz, CDCl3): δ 7.44-7.55 (m, 3H), 7.26-7.39 (m, 3H), 6.97 (d, J = 7.8
Hz, 1H), 6.90 (d, J = 8.6 Hz, 1H), 5.32 (s, 2H), 5.22 (s, 2H) ppm.

In a 50 mL round-bottomed flask equipped with a stir bar was added 2.37 (1.24 g, 5.16 mmol) and
Pd/C (0.275 g, 0.258 mmol, 10% wt) in EtOH (25 mL) at room temperature. The flask was
vacuumed purged with argon three times then replaced with an atmosphere of H2 gas via balloon.
The reaction stirred at room temperature under an atmosphere of H2 for 15 hours. Once complete
(TLC) the reaction mixture was filtered through a pad of Celite, washed with EtOAc and the
solvents were removed under reduced pressure to give a crude oil. The oil was adsorbed onto silica
gel and further purified by silica gel column chromatography using hexanes/EtOAc (4:1) to give
2.316 (0.721 g, 4.80 mmol, 93% yield) as a white solid. 1H NMR (500 MHz, CDCl3): δ 7.77 (s,
1H), 7.58 (t, J = 7.9 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 5.35 (s, 2H) ppm.
13

C NMR (126 MHz, CDCl3): δ 172.6, 156.6, 146.7, 137.0, 115.3, 113.4, 110.9, 70.7 ppm.
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In a 1 L round bottom flask equipped with a stir bar was added Et2O (500 mL) and lithium
aluminum hydride (3.41 g, 90.1 mmol) at 0 °C. Once cooled, 2.28 (54.2 mL, 362 mmol) in Et2O
(250 mL) was added and the reaction mixture was stirred for 12 hours at room temperature. The
reaction was then quenched slowly with water (250 mL). The biphasic mixture was partitioned in
a separatory funnel and the organic layer was washed with satd. aqueous Na2CO3 (400 mL x 2)
then brine (300 mL). The aqueous layer was extracted with Et2O (200 mL x 2), washed with sat.
aqueous Na2CO3 (100 mL x 2) and brine (100 mL). The organic layers were combined and dried
over Na2SO4, filtered then concentrated under reduced pressure to give 2.277 (49.5 g, 353 mmol,
98% yield) as a clear colorless oil. The product was sufficiently pure by GC-MS and NMR and
could be used without further purification.
Alternative method
In a 2 L round-bottomed flask equipped with a stir bar was added NaBH4 (9.06 g, 241 mmol) in
water (725 mL) at room temperature. 2.38 (32.6 mL, 218 mmol) was added slowly while
vigorously stirring where the reaction continued to stir at room temperature for 48 hours. At which
time the reaction mixture was extracted with DCM (4 x 250 mL), dried over Na2SO4, filtered and
concentrated to give 2.277 (30.1 g, 206 mmol, 95% yield) that was 96% pure by GC-MS. The
product was used without further purification. 1H NMR (500 MHz, CDCl3) δ 5.41 (br s, 1 H), 4.16
- 4.29 (m, 1 H), 1.84 (br d, J=17.24 Hz, 1 H), 1.75 (ddd, J=12.44, 5.99, 0.95 Hz, 1 H), 1.67 (s, 3
H), 1.60 (br d, J=17.30 Hz, 1 H), 1.48 (br s, 1 H), 1.22 (dd, J=12.35, 9.11 Hz, 1 H), 0.98 (s, 3 H),
0.87 (s, 3 H) ppm. 13C NMR (126 MHz, CDCl3) δ 136.0, 123.6, 66.8, 45.2, 44.1, 31.2, 31.0, 26.2,
23.5 ppm.
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In a 30 mL microwave vial equipped with a stir bar was added triphenylphosphine (0.899 g, 3.43
mmol), 2.35 (0.531 g, 2.74 mmol) and 2.27 (1.654 mL, 10.29 mmol) in THF (8 mL) at 0 °C. DIAD
(0.575 mL, 2.92 mmol) was added dropwise to the cold solution and continued to stir at 0 °C for
30 minutes before warming to room temperature and stirring for 15 hours. The reaction was then
heated in a microwave (300 W, 250 °C) for 1 hour. The solvent was removed under reduced
pressure and the crude oil was adsorbed onto silica gel and purified by silica gel column
chromatography using hexanes/EtOAc (9:1) gave 2.41 (0.606 g, 1.92 mmol, 56% yield) as an
orange oil. 1H NMR (500 MHz, CDCl3): δ 9.69 (s, 1H), 7.20 (dd, J = 7.6, 1.5 Hz, 1H), 7.11 (dd, J
= 7.7, 1.6 Hz, 1H), 6.80 (t, J = 7.6 Hz, 1H), 5.38 (br s, 1H), 3.81-3.93 (m, 1H), 3.43-3.59 (m, 4H),
1.94 (br d, J = 17.1 Hz, 1H), 1.77 (br d, J = 5.6 Hz, 1H), 1.74 (s, 3H), 1.66 (br d, J = 17.2 Hz, 1H),
1.27 (t, J = 7.1 Hz, 6H), 1.17 (t, J = 12.1 Hz, 1H), 1.02 (s, 3H), 0.98 (s, 3H) ppm. 13C NMR (126
MHz, CDCl3): δ 171.9, 155.8, 135.4, 134.5, 130.8, 124.8, 122.9, 118.3, 118.1, 44.1, 43.4, 42.1,
33.7, 31.8, 30.5, 25.2, 24.1, 13.4 ppm.

In a 1 L round-bottomed flask equipped with a stir bar was added 2.27 (10.68 mL, 62.9 mmol) and
but-3-enoic acid (2.46) (6.19 mL, 69.2 mmol) in DCM (400 ml) at 0 °C. DCC (14.28 g, 69.2 mmol)
and DMAP (0.768 g, 6.29 mmol) were then added and the reaction stirred at 0 °C for 30 minutes.
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The reaction mixture was warmed to room temperature and stirred for 15 hours until complete
(TLC). The solution was vacuum filtered while rinsing with DCM (100 mL) then the filtrate was
washed with 1 N HCl (100 mL) and NaHCO3 (100 mL). The organic layer was dried over Na2SO4,
filtered and concentrated to give a crude oily solid. Further purification by silica gel column
chromatography using hexanes/EtOAc (40:1) gave 2.45 (12.1 g, 58.1 mmol, 92% yield) as a clear
colorless oil. 1H NMR (500 MHz, CDCl3): δ 5.86-5.99 (m, 1H), 5.38 (br s, 1H), 5.31-5.36 (m, 1H),
5.15-5.18 (m, 1H), 5.14 (t, J = 1.2 Hz, 1H), 3.07 (dt, J = 7.0, 1.3 Hz, 2H), 1.86 (d, J = 17.7 Hz,
1H), 1.74 (dd, J = 13.0, 6.0 Hz, 1H), 1.65-1.68 (m, 1H), 1.69 (s, 3H), 1.39 (dd, J = 12.9, 7.9 Hz,
1H), 0.99 (s, 3H), 0.93 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 171.3, 138.5, 130.5, 119.0,
118.3, 70.3, 44.0, 40.6, 39.6, 30.6, 30.3, 27.0, 23.7 ppm. HRMS m/z: [M + Na]+ Calcd for
C13H20O2Na 231.1356; found 231.1357.

In a 500 mL triple-necked round-bottomed flask equipped with a stir bar was added NaHMDS
(14.4 mL, 21.6 mmol, 1.5 M in THF) in anhydrous THF (100 mL) at -78 °C. A solution of 2.45
(3.01 g, 14.4 mmol) in anhydrous THF (100 mL) was added dropwise and stirred for 15 min at 78 °C. TMS-Cl (2.82 mL, 21.6 mmol) was then added dropwise and the reaction stirred at -78 °C
for an additional 10 minutes before warming to room temperature where it stirred for 20 h. The
reaction was quenched with satd. aqueous NH4Cl (100 mL) and water (100 mL). The aqueous
layer was extracted with EtOAc (3 x 75 mL), combined organic layers were washed with brine (75
mL), dried over Na2SO4, filtered and concentrated to give a crude oil. Further purification by silica
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gel column chromatography using hexanes/EtOAc (9:1-4:1) gave 2.47 (2.41 g, 11.5 mmol, 80%
yield) as a clear colorless oil (mixture of diastereomers 1:1.5). 1H NMR (500 MHz, CDCl3): δ
10.92 (br s, 1H), 5.87 (dt, J = 17.1, 9.8 Hz, 1H), 5.65-5.71 (m, 1H), 5.38-5.63 (m, 1H), 5.19-5.25
(m, 1H), 5.09-5.17 (m, 1H), 2.79-2.98 (m, 1H), 1.76-1.83 (m, 1H), 1.67-1.76 (m, 2H), 1.61, 1.29
(d, J = 14.2 Hz, 1H, diastereomers), 1.13-1.17 (m, 3H), 0.95-0.98 (m, 6H) ppm. 13C NMR (126
MHz, CDCl3): δ 178.6, 133.0, 131.6, 125.8, 119.1, 60.7, 45.0, 38.4, 38.3, 32.2, 29.9, 28.8, 25.6
ppm. HRMS m/z: [M + H]+ Calcd for C13H21O2 209.1536; found 209.1534.

In a 250 mL round-bottomed flask equipped with a stir bar was added 2.47 (2.02 g, 9.70 mmol)
and K2CO3 (4.02 g, 29.1 mmol) in THF (100 mL) at 0 °C. MeI (1.819 mL, 29.1 mmol) was
added and the reaction mixture stirred at 0 °C for 10 minutes then heated to 50 °C while stirring
for 15 hours. Once complete (TLC), the reaction was quenched with water (100 mL) and the
aqueous layer was extracted with EtOAc (3 x 50 mL), combined organic layers were washed
with brine (2 x 30 mL), dried over Na2SO4, filtered and concentrated to give a crude oil. Further
purification by silica gel column chromatography using hexanes/EtOAc (10:1) gave 2.48 (2.01 g,
9.04 mmol, 93% yield) as a light yellow oil. 1H NMR (500 MHz, CDCl3): δ 5.82-5.94 (m, 1H),
5.61-5.69 (m, 1H), 5.31-5.60 (m, 1H), 5.14-5.21 (m, 1H), 5.03-5.12 (m, 1H), 3.62-3.69 (m, 3H),
2.79-2.98 (m, 1H), 1.80 (d J = 13.8 Hz, 1H), 1.60 (d, J = 14.2 Hz, 1H, diastereomers), 1.71-1.77
(m, 1H), 1.63-1.70 (m, 1H), 1.13-1.18 (m, 1H), 1.11 (d, J = 10.8 Hz, 3H), 0.93-1.00 (m, 6H)
ppm. 13C NMR (126 MHz, CDCl3): δ 173.2, 133.6, 132.3, 125.5, 118.9, 61.3, 51.3, 44.4, 38.4,
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38.3, 32.3, 29.9, 28.0, 25.6 ppm. HRMS m/z: [M + H]+ Calcd for C14H23O2 223.1693; found
223.1695.

In a 500 mL round-bottomed flask equipped with a stir bar was added (E)-but-2-enoic acid 2.51
(5.02 g, 58.1 mmol) in DCM (387 mL) at 0 °C. DCC (13.2 g, 63.9 mmol) and DMAP (0.710 g,
5.81 mmol) were added along with 2.27 (9.47 mL, 63.9 mmol). The reaction continued stirring at
0 °C for 30 min was warmed to room temperature where it stirred for 15 hours. Once complete
(TLC), the reaction was vacuum filtered and rinsed with DCM (100 mL) and the filtrate was
washed with 1N aqueous HCl (150 mL) and neutralized with satd. aqueous NaHCO3 (2 x 150 mL)
then washed with brine (100 mL). The organic layer was dried over Na2SO4, filtered and
concentrated to give an oily solid. The crude material was adsorbed to silica gel and purified by
silica gel column chromatography using hexanes/EtOAc (20:1) to give 2.52 (6.81 g, 32.6 mmol,
56% yield) as a clear colorless oil. 1H NMR (500 MHz, CDCl3): δ 6.90-7.13 (m, 1H), 5.79-5.88
(m, 1H), 5.41 (br s, 2H), 1.92 (dd, J = 6.9, 1.1 Hz, 1H), 1.87-1.90 (m, 1H), 1.86 (d, J = 6.8 Hz,
3H), 1.74-1.80 (m, 1H), 1.69 (s, 3H), 1.42 (dd, J = 12.7, 7.9 Hz, 1H), 1.00 (s, 3H), 0.95 (s, 3H)
ppm.

13

C NMR (126 MHz, CDCl3): δ 166.2, 144.0, 138.1, 123.2, 119.3, 69.6, 44.0, 40.7, 30.5,

30.3, 27.0, 23.6, 17.8 ppm. HRMS m/z: [M + Na]+ Calcd for C13H20O2Na 231.1356; found
231.1359.
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In a 50 mL round-bottomed flask equipped with a stir bar was added 2.52 (1.05 g, 4.81 mmol) in
ACN (12 mL) at room temperature under and argon atmosphere. DBU (1.45 mL, 9.60 mmol),
DABCO (0.108 g, 0.960 mmol) and TMS-Cl (1.84 mL, 14.4 mmol) were added. The reaction
mixture was heated to 95 °C (reflux) and stirred for 16 hours. The reaction mixture was cooled to
room temperature and the solvent was evaporated under reduced pressure. The residue was
suspended in Et2O (30 mL) and 13 mL of 3 N aqueous HCl was added and stirred for 5 minutes.
The aqueous layer was extracted with Et2O (3 x 30 mL). The combined organic layers were washed
with brine (20 mL), dried over MgSO4, filtered and concentrated to give a crude yellow oil. The
crude oil was adsorbed onto silica gel and purified by silica gel column chromatography using
hexanes/EtOAc (4:1) to give 2.53 (0.623 g, 2.98 mmol, 62% yield of a mixture of isomers) as a
clear colorless oil. 1H NMR (500 MHz, CDCl3): δ 10.60-12.70 (m, 1H), 5.82-5.88 (m, 1H), 5.73
(dt, J = 10.2, 3.8 Hz, 1H), 5.53 (br d, J = 10.1 Hz, 1H), 1.98 (d, J = 14.0 Hz, 1H), 1.80 (d, J = 7.1
Hz, 3H), 1.66-1.75 (m, 1H), 1.39 (d, J = 14.0 Hz, 1H), 1.25-1.36 (m, 1H), 1.23 (s, 3H), 0.87-0.96
(m, 6H) ppm. 13C NMR was not interpretable due to the presence of isomer 2.47. HRMS m/z: [M
+ H]+ Calcd for C13H21O2 209.1536; found 209.1528. *The isolated product elutes with an
isomerized product identical to carboxylic acid 2.47 above.

In a 100 mL round-bottomed flask was added 2.53 (0.581 g, 2.78 mmol) in ACN (19 mL). K2CO3
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(1.15 g, 8.35 mmol) was added and stirred for 5 minutes before the addition of MeI (0.522 mL,
8.35 mmol). The reaction mixture was then heated to 60 °C for 10 hours. The solution was cooled
to room temperature and quenched with sat. aqueous NH4Cl (25 mL) and water (10 mL). The
aqueous layer was extracted with Et2O (3 x 35 mL) and the combined organic layers were washed
with brine (3 x 25 mL), dried over MgSO4, filtered and concentrated to give a crude pale yellow
oil that was purified by column chromatography (9:1, Hex/EtOAc) to give 2.54 (0.531 g, 2.39
mmol, 86% yield of isomers) as a light-yellow oil. 1H NMR (500 MHz, CDCl3): δ 5.82-5.92 (m,
1H), 5.68-5.72 (m, 1H), 5.49 (br d, J = 10.1 Hz, 1H), 3.75 (s, 3H), 1.89 (d, J = 13.9 Hz, 1H), 1.80
(d, J = 13.6 Hz, 1H), 1.73 (br s, 1H), 1.66 (d, J = 7.0 Hz, 3H), 1.33 (d, J = 13.9 Hz, 1H), 1.16 (s,
3H), 0.92 (s, 3H), 0.88 (s, 3H) ppm. 13CNMR was not interpretable due to the presence of isomer
2.48. HRMS m/z: [M + H]+ Calcd for C14H23O2 223.1693; found 223.1695. *The isolated product
eluted with an isomerized product identical to ester 2.48 above.

In a 1 L round-bottomed flask equipped with a stir bar was added mCPBA (44.1 g, 179 mmol) in
DCM (300 mL) at 0 °C. Cycloheptanone (2.59, 10.5 mL, 89.1 mmol) was added dropwise to the
cold stirring solution. The reaction mixture stirred for an additional 5 minutes at 0 °C before
warming to room temperature where it stirred for 7 days. At which time the mixture was then
filtered, washed with satd. aqueous NaHCO3 (2 x 150 mL) and satd. aqueous Na2S2O3 (150 mL)
then dried over Na2SO4. The mixture was filtered and concentrated to give crude 2.608 (11.3 g,
88.3 mmol, 99% yield) as a light-yellow oil that was used in the next steps without further
purification. 1H NMR (400 MHz, CDCl3): δ 4.32 (t, J = 5.7 Hz, 2H), 2.52 (t, J = 6.4 Hz, 2H),
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1.73-1.95 (m, 4H), 1.48-1.65 (m, 4H) ppm. 13C NMR (126 MHz, CDCl3): δ 176.7, 67.9, 31.2,
30.9, 28.3, 25.8, 23.9 ppm.

In a 1 L round-bottomed flask equipped with a stir bar was added crude 2.60 (10.1 g, 78.8 mmol)
and BnBr (32.5 mL, 273 mmol) in toluene (440 mL). Crushed KOH (19.7 g, 351 mmol) was
added and the reaction mixture was heated to 145 °C (refluxing) where it stirred for 24 hours.
The solution was cooled to room temperature and diluted with Et2O (200 mL) and water (250
mL). The layers were partitioned in a separatory funnel and the aqueous layer was extracted with
Et2O (3 x 150 mL). The combined organic layers were concentrated to approximately 200 mL of
solvent (toluene) while the aqueous solution was saved. Additional KOH (11.9 g, 212 mmol) was
added to the concentrated organic layer and heated to reflux for an additional 15 h. Water (250
mL) was added to the reaction mixture and the aqueous layer was extracted with Et2O (3 x 150
mL). The two aqueous layers from the work-ups were combined and acidified with 6 N H2SO4 to
a pH of 2, extracted with Et2O (3 x 250 mL), dried over Na2SO4, filtered and concentrated to
give 2.619 (17.9 g, 76.1 mmol, 96% yield) as a clear colorless oil. The crude oil was sufficiently
pure enough for further use. 1H NMR (500 MHz, CDCl3): δ 10.51 (br s, 1H), 7.94-8.17 (m, 2H),
7.39-7.65 (m, 2H), 7.23-7.31 (m, 1H), 4.51 (s, 2H), 3.42-3.53 (m, 2H), 2.32-2.44 (m, 2H), 1.581.71 (m, 4H), 1.27-1.45 (m, 4H) ppm. 13C NMR (126 MHz, CDCl3): δ 180.3, 138.5, 130.2,
128.4, 127.7, 72.8, 70.2, 34.1, 29.5, 28.9, 25.8, 24.6 ppm.
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In a 250 mL round-bottomed flask equipped with a stir bar was added 2.27 (7.03 mL, 42.7 mmol)
in DCM (300 mL) at 0 °C. 2.61 (11.2 g, 42.7 mmol) was added along with DCC (11.4 g, 55.5
mmol) and DMAP (0.521 g, 4.27 mmol). The reaction stirred at 0 °C for 30 min before warming
to room temperature where it stirred for an additional 15 hours. The reaction mixture was filtered,
and the resulting organic layer was washed with 1 N aqueous HCl (75 mL), satd. aqueous NaHCO3
(100 mL) and brine (100 mL). The organic layer was then dried over MgSO4, filtered and
concentrated to give a crude oily solid. The crude was adsorbed onto silica gel and purified by
silica gel column chromatography using hexanes/EtOAc (15:1) to give 2.58 (11.1 g, 31.1 mmol,
73% yield) as a clear colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.24-7.37 (m, 5H), 5.36 (br s,
1H), 5.30-5.35 (m, 1H), 4.49 (s, 2H), 3.46 (t, J = 6.6 Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H), 1.86 (br d,
J = 17.5 Hz, 1H), 1.74 (dd, J = 12.9, 6.1 Hz, 1H), 1.69 (s, 3H), 1.55-1.67 (m, 5H), 1.28-1.43 (m,
5H), 0.99 (s, 3H), 0.93-0.94 (m, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 173.6, 138.6, 138.3,
128.3, 127.6, 127.5, 119.3, 72.9, 70.3, 69.8, 44.0, 40.7, 34.7, 30.6, 30.4, 29.6, 29.0, 26.9, 25.9,
25.0, 23.7 ppm. HRMS m/z: [M + Na]+ Calcd for C23H34O3Na 381.2400; found 381.2403.
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In a flame-dried 500 mL triple-neck round-bottomed flask equipped with a stir bar was added 2.58
(12.5 g, 34.9 mmol) in toluene (356 mL) at -78 °C. Potassium bis(trimethylsilyl)amide (101 mL,
69.7 mmol, ⁓0.7 M) was added dropwise to the cold stirring solution over 25 minutes. The reaction
stirred at -78 °C for 1.5 hours before a solution of TMS-Cl (22.9 mL, 174 mmol) and Et3N (21.9
mL, 157 mmol) in toluene (30 mL) was added dropwise. The reaction continued to stir at -78 °C
for 10 minutes before warming to room temperature then heated to 120 °C where the reaction
stirred for 15 hours. The reaction was cooled to room temperature and quenched with satd. aqueous
NH4Cl (175 mL) then slowly acidified to pH 3 with 1 N aqueous HCl. The aqueous layer was
extracted with Et2O (4 x 200 mL), the combined organic layers dried over Na2SO4, filtered and
concentrated to give a crude yellow oil. Further purification by silica gel column chromatography
using hexanes/EtOAc (9:1-4:1) gave 2.62 (8.71 g, 24.3 mmol, 70% yield) as a light yellow oil. 1H
NMR (500 MHz, CDCl3): δ 9.36-12.30 (m, 1H), 7.15-7.41 (m, 5H), 5.61-5.73 (m, 1H), 5.22-5.61
(m, 1H), 4.49 (s, 2H), 3.45 (t, J = 6.6 Hz, 2H), 2.13-2.19 (m, 2H), 1.62-1.80 (m, 4H), 1.31 (s, 6H),
1.17-1.24 (m, 1H), 1.11-1.16 (m, 3H), 0.97 (d, J = 4.4 Hz, 6H) ppm. 13C NMR (126 MHz, CDCl3):
δ 180.8, 138.6, 133.4, 132.3, 128.3, 127.6, 125.7, 72.9, 70.3, 57.1, 44.3, 38.3, 37.9, 32.6, 29.9,
29.6, 28.0, 28.2, 27.4, 26.1, 25.8 ppm. *approximately 2:1 ratio of diastereomers (relative
stereochemistry wasn’t assigned). HRMS m/z: [M + H]+ Calcd for C23H35O3 359.2581; found
359.2573.
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In a 250 mL round-bottomed flask equipped with a stir bar was added 2.62 (2.93 g, 8.17 mmol) in
a mixture of toluene and MeOH (81 mL, 3:1) at 0 °C. TMS-diazomethane (4.71 mL, 9.41 mmol,
0.5 M in hexanes) was added dropwise to the cold stirring solution. The resulting mixture was
warmed to room temperature and stirred for 1.5 hours until the reaction was complete (TLC). Once
complete, the solvents were evaporated under reduced pressure to give a light yellow crude oil.
The crude oil was further purified by silica gel column chromatography using hexanes/EtOAc
(9:1) to give 2.63 (2.94 g, 7.89 mmol, 97% yield) as a clear colorless oil. 1H NMR (500 MHz,
CDCl3) δ 7.24-7.40 (m, 5H), 5.59-5.69 (m, 1H), 5.19-5.57 (m, 1H), 4.46-4.52 (m, 2H), 3.60-3.67
(m, 3H), 3.45 (td, J = 6.6, 1.2 Hz, 2H), 2.16 (dd, J = 11.8, 1.2 Hz, 1H), 1.55-1.79 (m, 6H), 1.291.49 (m, 3H), 1.12-1.28 (m, 3H), 1.07-1.10 (m, 3H), 0.94-0.99 ppm (m, 6H) ppm. 13C NMR (126
MHz, CDCl3): δ 175.7, 138.6, 133.2, 128.3, 127.6, 127.5, 125.3, 72.9, 70.3, 57.4, 57.1, 50.9, 44.5,
38.3, 37.7, 32.6, 29.8, 28.3, 27.8, 27.1, 26.2, 25.8 ppm. HRMS m/z: [M + H]+ Calcd for C24H37O3
373.2737; found 373.2742.

In a 250 mL round-bottomed flask equipped with a stir bar was added Pd/C (1.03 g, 0.966 mmol,
10 wt%) and 2.63 (7.22 g, 19.3 mmol) in MeOH (150 mL). The reaction vessel was vacuumpurged three times with argon then purged with H2 gas from a balloon. The reaction stirred under
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an atmosphere of H2 for 15 hours at room temperature. Once complete (TLC), the reaction mixture
was flushed with argon and filtered through a pad of Celite while rinsing with MeOH (150 mL).
The solvent was removed under reduced pressure to give a clear colorless oil that was sufficiently
pure for further use. If desired, further purification by silica gel column chromatography using a
gradient of hexanes/EtOAc (4:1-2:1) could be achieved to provide 2.64 (5.11 g, 17.9 mmol, 93%
yield) as a clear colorless oil. 1H NMR (500 MHz, CDCl3): δ 3.59-3.63 (m, 3H), 3.57 (t, J = 6.6
Hz, 2H), 2.03-2.19 (m, 1H), 1.87-1.99 (m, 1H), 1.39-1.64 (m, 7H), 1.24-1.36 (m, 4H), 1.01-1.20
(m, 5H), 0.97-1.01 (m, 3H), 0.92 (s, 3H), 0.83-0.88 (m, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ
176.0, 62.7, 59.2, 50.8, 49.0, 39.3, 36.6, 36.1, 34.5, 32.5, 30.7, 28.5, 28.1, 26.6, 25.7, 21.7, 18.8
ppm. HRMS m/z: [M + H]+ Calcd for C17H33O3 285.2424; found 285.2433.

In a 250 mL round-bottomed flask equipped with a stir bar was added conc. H2SO4 (37.5 mL, 56.3
mmol) and CrO3 (2.34 g, 23.4 mmol) then cooled to 0 °C to give a bright orange solution. A
solution of 2.64 (1.81 g, 6.36 mmol) in acetone (15 mL) was added dropwise to the cold stirring
solution. The reaction mixture stirred at 0 °C for 1 hour before warming to room temperature where
it stirred for an additional 1.5 hours. At which time the reaction was quenched with tartaric acid
(2.31 g, 153 mmol) and the solution turned deep blue in color while stirring for 15 minutes. The
reaction mixture was diluted with DCM (40 mL) and transferred to a separatory funnel where the
aqueous layer was further extracted with DCM (4 x 50 mL). The combined organic layers were
washed with brine (2 x 50 mL), dried over Na2SO4, filtered and concentrated to give 2.64.1 (1.82
g, 6.10 mmol, 96% yield) as a clear slightly blue oil that was used without further purification. 1H
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NMR (400 MHz, CDCl3): δ 9.88-11.64 (m, 1H), 3.59-3.63 (m, 3H), 2.21-2.38 (m, 2H), 2.02-2.20
(m, 1H), 1.53-1.71 (m, 3H), 1.39-1.51 (m, 3H), 1.28 (br s, 2H), 1.02-1.24 (m, 6H), 0.96-1.00 (m,
3H), 0.91 (s, 3H), 0.84-0.87 (m, 3H) ppm.

13

C NMR (101 MHz, CDCl3): δ 179.7, 175.8, 57.8,

50.9, 49.3, 39.2, 36.5, 36.1, 34.0, 33.9, 30.8, 28.8, 27.9, 26.3, 24.6, 21.6, 18.8 ppm.

In a 250 mL round-bottomed flask equipped with a stir bar was added crude 2.64.1 (1.82 g, 6.10
mmol) in a mixture of toluene and MeOH (61 mL, 3.66:1) at 0 °C. Once cool, TMS-diazomethane
(3.21 mL, 6.41 mmol, 0.5 M in hexanes) was added dropwise and the solution stirred for 30
minutes at 0 °C before warming to room temperature where it stirred for an additional 1 hour.
Once complete (TLC), the resulting yellow solution was concentrated under reduced pressure to
give a light yellow oil that was purified by silica gel column chromatography using hexanes/EtOAc
(9:1) to give 2.57 (1.85 g, 5.92 mmol, 97% yield) as a clear colorless oil. 1H NMR (500 MHz,
CDCl3): δ 3.65 (s, 3H), 3.62 (s, 3H), 2.21-2.34 (m, 2H), 2.04-2.19 (m, 1H), 1.57-1.68 (m, 3H),
1.45-1.56 (m, 3H), 1.23-1.37 (m, 3H), 1.10-1.22 (m, 3H), 1.02-1.09 (m, 2H), 0.98-1.02 (m, 3H),
0.94 (s, 3H), 0.86-0.89 (m, 3H) ppm.

13

C NMR (126 MHz, CDCl3): δ 175.7, 174.0, 58.1, 51.4,

50.8, 49.1, 39.3, 36.6, 36.2, 34.0, 33.9, 30.8, 28.8, 28.0, 26.4, 24.9, 21.6, 18.9 ppm. HRMS m/z:
[M + H]+ Calcd for C18H33O4 313.2373; found 313.2375.

99

In a 50 mL round-bottomed flask equipped with a stir bar was added 2.57 (0.605 g, 1.94 mmol)
and 0.35 g of 4Å molecular sieves in anhydrous toluene (20 mL) at 0 °C. Once the solution was
cool, KHMDS (8.13 mL, 4.07 mmol, 0.5 M in toluene) was added dropwise where it stirred for 1
hour at 0 °C before warming to room temperature. The reaction stirred at room temperature for an
additional 1 hour before quenching with satd. aqueous NH4Cl (25 mL). The biphasic mixture was
partitioned in a separatory funnel and the aqueous layer was extracted with EtOAc (3 x 35 mL),
washed with brine, dried over Na2SO4, filtered then concentrated to a crude yellow oil. The crude
oil was further purified by silica gel column chromatography using hexanes/EtOAc (9:1) to
provide 2.56 (0.515 g, 1.84 mmol, 95% yield) as a clear colorless oil. 1H NMR (500 MHz, CDCl3):
δ 3.70-3.76 (m, 3H), 3.27-3.40 (m, 1H), 2.35-2.48 (m, 1H), 2.13-2.34 (m, 3H), 1.91-2.13 (m, 2H),
1.69-1.87 (m, 3H), 1.47-1.57 (m, 3H), 1.25-1.34 (m, 3H), 1.05-1.11 (m, 3H), 0.91-0.98 (m, 6H)
ppm. *Due to the complex mixture of diastereomers and enol tautomers, the 13C NMR was unable
to be completely interpreted. The spectrum is shown in the appendix. HRMS m/z: [M + H]+ Calcd
for C17H28O3 281.2111; found 281.2109.

In a 100 mL reaction vial equipped with a stir bar was added 2.56 (3.12 g, 11.1 mmol) in dioxane
(73 mL). DDQ (7.53 g, 33.2 mmol) was added and the vial was sealed with a Teflon screw cap
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then heated to 140 °C where the reaction stirred for 72 hours. The reaction was cooled to room
temperature and filtered through a plug of silica gel while rinsing with hexanes/EtOAc (4:1, 150
mL). The resulting filtrate was concentrated and adsorbed onto silica gel then purified by silica gel
column chromatography using a gradient of hexanes/EtOAc (1:0 to 6:1) to give 2.55 (0.32 g, 1.2
mmol, 10% yield) as a white solid. 1H NMR (500 MHz, CDCl3): δ 11.54 (s, 1H), 7.72 (dd, J = 7.9,
1.6 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 6.81 (t, J = 7.8 Hz, 1H), 3.93 (s, 3H), 2.84 (br d, J = 13.8
Hz, 1H), 2.24 (br d, J = 13.5 Hz, 1H), 1.64-1.75 (m, 1H), 1.58 (dt, J = 13.7, 4.2 Hz, 1H), 1.32 (br
dd, J = 13.4, 2.5 Hz, 2H), 1.29 (s, 3H), 1.19-1.25 (m, 2H), 0.88 (s, 3H), 0.41 (s, 3H) ppm.

13

C

NMR (126 MHz, CDCl3): δ 171.6, 161.4, 136.5, 133.4, 127.5, 118.3, 112.2, 52.2, 47.6, 39.9, 38.7,
38.2, 33.4, 31.3, 30.5, 25.8, 19.7 ppm. HRMS m/z: [M + H]+ Calcd for C17H25O3 277.1798.; found
277.1805.

In a 250 mL round-bottomed flask equipped with a stir bar was added prop-2-yn-1-ol 2.68-1 (4.11
g, 73.3 mmol) in degassed acetone (146 mL) at -78 °C. NBS (15.6 g, 88.1 mmol) and AgNO3 (1.24
g, 7.31 mmol) were added and the reaction mixture was gradually warmed to room temperature.
After 1 hour of stirring at room temperature, the reaction was complete (TLC) and the solvent was
evaporated under reduced pressure. The crude oil was adsorbed onto silica gel and purified by
silica gel column chromatography using a gradient of hexanes/EtOAc (20:1-5:1) to give 2.68 (9.58
g, 71.0 mmol, 97% yield) as a light yellow oil. 1H NMR (CDCl3, 400 MHz): δ 4.27 (s, 2 H), 1.86
(s, 1 H) ppm. 13C NMR (CDCl3, 101 MHz): δ 78.2, 51.8, 45.8 ppm.
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In a 25 mL round-bottomed flask equipped with a stir bar was added CuCl (44.1 mg, 0.445 mmol)
in aqueous 30% n-BuNH2 (23 mL) to give a blue solution. A small spatula tip of NH2OH∙HCl was
added and the solution turned clear and colorless. The reaction solution was cooled to 0 °C and
3,3-dimethylbut-1-yne (2.72, 2.74 mL, 22.2 mmol) was added while stirring vigorously to give a
yellow precipitate. 2.68 (1.05 mL, 14.8 mmol) was then added and the reaction mixture stirred at
0 °C for 10 minutes before warming to room temperature. NH2OH∙HCl (small increments) was
added during the reaction whenever the solution started turning blue or green in color. Once
complete (TLC) the reaction mixture was extracted with ether (3 x 30 mL), washed with brine (30
mL), dried over Na2SO4, filtered and concentrated to give a golden oil. The crude oil was further
purified by silica gel column chromatography using hexanes/EtOAc (4:1) to give 2.73 (1.62 g,
11.8 mmol, 79% yield) as a light-yellow oil. 1H NMR (400 MHz, CDCl3): δ 4.29 (s, 2H), 1.67 (s,
1H), 1.22 (s, 9H) ppm.

13

C NMR (101 MHz, CDCl3): δ 89.3, 74.7, 70.7, 63.0, 51.5, 30.4, 28.0

ppm.

In a 250 mL round-bottomed flask equipped with a stir bar was added ethynyltrimethylsilane (2.671, 5.81 mL, 40.7 mmol) in anhydrous THF (100 mL) at -78 °C. n-BuLi (25.5 mL, 40.7 mmol, 1.6
M in hexanes) was added dropwise and the cold solution stirred for 30 min at -78 °C. The cooling
bath was removed, and the CO2 was bubbled through the solution for 30 min. The reaction mixture
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continued to stir for 30 min at room temperature then Et2O (80 mL) was added along with water
(90 mL) and 1 N HCl (45 mL). The layers were separated, and the aqueous layer was extracted
with Et2O (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered and
concentrated to give a thick yellow oil. Further purification by silica gel column chromatography
using hexanes/EtOAc (2:1) provided 2.6710 (4.2 g, 29 mmol, 71% yield) as a thick opaque oil. 1H
NMR (400 MHz, CDCl3): δ 9.54 (br s, 1H), 0.24 (s, 9H) ppm.

In a 250 mL round-bottomed flask equipped with a stir bar was added DCC (2.73 g, 13.2 mmol),
DMAP (0.135 g, 1.101 mmol) and 6,6-dimethylhepta-2,4-diyn-1-ol (2.73, 1.5 g, 11 mmol) in DCM
(60 mL) at 0 °C. In a separate flask was 2.67 (1.88 g, 13.2 mmol) in DCM (25 mL) which was
added dropwise via addition funnel over 20 minutes. The reaction mixture continued to stir for 30
minutes at 0 °C. The reaction was deemed complete (TLC) and the reaction mixture was filtered
through a fritted vacuum funnel. The filtrate was concentrated under reduced pressure to give a
crude oil that was purified by silica gel column chromatography using hexanes/EtOAc (20:1) to
give 2.74 (2.12 g, 8.14 mmol, 74% yield) as a clear colorless oil. 1H NMR (400 MHz, CDCl3): δ
4.78 (s, 2H), 1.22 (s, 9H), 0.23 ppm (s, 9H) ppm.

13

C NMR (126 MHz, CDCl3): δ 152.0, 95.7,

93.6, 90.0, 72.3, 69.2, 62.9, 53.8, 30.3, 28.0, -1.0 ppm. HRMS m/z: [M + Na]+ Calcd for
C15H20O2SiNa 283.1125; found 283.1130.
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In a 100 mL reaction vial equipped with a stir bar was added 2.74 (0.125 g, 0.384 mmol) in
cyclooctane (75 mL). The reaction vial was purged with argon and a Teflon screw cap was used to
seal the reaction vessel. The reaction mixture was heated for 48 hours at 150 °C. The reaction was
cooled to room temperature and the mixture was filtered through a pad of silica gel using hexanes
(100 mL) as the eluent to remove cyclooctane from the reaction mixture. The rest of the reaction
mixture was eluted with EtOAc (50 mL) and further purified by column chromatography using
hexanes/EtOAc (7:1) to give 2.76 (0.0791 g, 0.301 mmol, 78% yield) as a yellow oil. 1H NMR
(500 MHz, CDCl3): δ 7.75 (d, J = 8.2 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 5.21 (s, 2H), 1.46 (s, 9H),
0.53 (s, 9H) ppm. 13C NMR (126 MHz, CDCl3): δ 171.7, 159.2, 144.3, 142.7, 132.0, 131.0, 121.4,
68.3, 37.4, 33.5, 5.3 ppm. HRMS m/z: [M + H]+ Calcd for C15H23O2Si 263.1462; found 263.1464.

In a 20 mL scintillation vial equipped with a stir bar was added 2.76 (0.075 g, 0.23 mmol) in ACN
(3.7 mL). NBS (0.041 g, 0.23 mmol) was added to the stirring solution, the vial was purged with
argon and capped. The reaction mixture stirred at room temperature for 15 hours. The solvent was
removed under vacuum and the resulting crude solid was adsorbed to silica gel and purified by
silica gel column chromatography using hexanes/EtOAc (4:1) to give 2.78 (0.051 g, 0.19 mmol,
81% yield) as a white solid. 1H NMR (500 MHz, CDCl3): δ 7.76 (d, J = 8.1 Hz, 1H), 7.35 (d, J =
8.1 Hz, 1H), 5.17 (s, 2H), 1.58 (s, 9H) ppm. 13C NMR (126 MHz, CDCl3): δ 168.8, 150.0, 146.5,
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133.7, 125.5, 121.7, 120.5, 66.6, 37.5, 29.9 ppm. HRMS m/z: [M + H]+ Calcd for C12H14O2Br
269.0172; found 269.0179.

In a 15 mL reaction vial equipped with a stir bar was added NaOAc (0.0212 g, 0.244 mmol),
Pd2(dba)3 (4.53 mg, 4.94 µmol) and dppf (5.77 mg, 10.4 µmol) in anhydrous and degassed THF
(0.5 mL). The vessel was purged with argon then capped. The mixture stirred at room temperature
for 5 minutes before a mixture of 2.22 (0.021 g, 0.024 mL, 0.11 mmol) and 2.78 (0.011 g, 0.037
mmol) in THF (1 mL). The reaction vessel was purged with argon, capped and heated to 80 °C.
Once complete (TLC), the reaction was cooled to room temperature and filtered through a pad of
Celite. The resulting filtrate was concentrated under vacuum and further purified by silica gel
column chromatography using hexanes/EtOAc (6:1) to give 2.3 (0.0076 g, 0.028 mmol, 78% yield)
as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J=8.19 Hz, 1 H), 7.34 (d, J=8.19
Hz, 1 H), 5.23 (s, 2 H), 4.49 (s, 2 H), 3.74 (s, 3 H), 1.45 (s, 9 H) ppm. 13C NMR (126 MHz, CDCl3)
δ 171.5, 171.3, 149.7, 144.9, 134.0, 132.3, 125.7, 120.6, 68.1, 52.4, 35.8, 34.9, 31.7 ppm. HRMS
m/z: [M + Na]+ Calcd for C15H18O4Na 285.1097; found 285.1107.

In a 250 mL round-bottomed flask equipped with a stir bar was added imidazole (1.61 g, 23.6
mmol) and but-3-yn-1-ol (2.79,1.62 mL, 21.4 mmol) in DCM (120 mL) at room temperature. A
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solution of TBDPS-Cl (5.77 mL, 22.47 mmol) in DCM (10 mL) was added dropwise and the
reaction continued to stir at room temperature under an atmosphere of argon for 15 hours. At
which time the reaction mixture was washed with satd. aqueous NH4Cl (50 mL x 2), dried over
Na2SO4, filtered and concentrated to give 2.8011 (6.44 g, 20.8 mmol, 97% yield) as a clear
colorless oil that was used without further purification. 1H NMR (400 MHz, CDCl3): δ 7.71 (br
d, J = 6.0 Hz, 4H), 7.34-7.49 (m, 6H), 3.74-3.87 (m, 2H), 2.41-2.54 (m, 2H), 1.95 (br d, J = 2.4
Hz, 1H), 1.09 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3): δ 135.6, 133.6, 129.7, 127.7, 81.5,
69.4, 62.3, 26.8, 22.6, 19.2 ppm.

In a 100 mL round-bottomed flask equipped with a stir bar was added 2.80 (1.52 g, 4.93 mmol) in
anhydrous THF (25 mL) at -78 °C. Once cool, s-BuLi (3.52 mL, 4.93 mmol, 1.4 M) was added
and the reaction continued to stir at -78 °C for 30 minutes before warming to 0 °C where it stirred
for an additional 15 minutes. At which time the solution was cooled to -78 °C and CO2 (g) was
bubbled through the solution for 30 minutes at -78 °C. The CO2 line was removed, and the reaction
warmed to room temperature where it stirred for an additional 1 hour at room temperature. The
reaction was quenched with satd. aqueous NH4Cl (25 mL) and water (20 mL) and the aqueous
layer was extracted with Et2O (3 x 50 mL). The combined organic layers were dried with Na2SO4,
filtered and concentrated to give a crude oil that was purified on a plug of silica gel using
hexanes/EtOAc (9:1, 150 mL) and flushed with EtOAc (200 mL). The EtOAc fraction was
concentrated to give 2.8112 (1.22 g, 3.46 mmol, 70% yield) as a clear colorless oil that was used in
the next step without further characterization.
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In a 20 mL scintillation vial equipped with a stir bar was added 2.81 (0.16 g, 0.45 mmol) in DCM
(2.75 mL) at 0 °C. DCC (0.094 g, 0.45 mmol) and DMAP (5.5 mg, 0.045 mmol) were added along
with a solution of 2.73 (0.056 g, 0.41 mmol) in DCM (2 mL). The reaction mixture continued to
stir at 0 °C for 30 minutes before warming to room temperature where it stirred for 15 hours. The
reaction mixture was vacuum filtered and rinsed with DCM (15 mL). The filtrate was washed with
1 N aqueous HCl (20 mL), NaHCO3 (20 mL) and brine (20 mL) then dried over Na2SO4. The
filtrate was concentrated to give an oily suspension that was further purified by silica gel column
chromatography using hexanes/EtOAc (10:1) to give 2.82 (0.18 g, 0.38 mmol, 93% yield) as a
clear colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.67 (dd, J = 7.9, 1.4 Hz, 4H), 7.36-7.48 (m,
6H), 4.79 (s, 2H), 3.81 (t, J = 6.7 Hz, 2H), 2.58 (t, J = 6.8 Hz, 2H), 1.24 (s, 9H), 1.06 (s, 9H) ppm.
13

C NMR (126 MHz, CDCl3): δ 152.6, 135.5, 133.2, 129.8, 127.8, 89.8, 88.2, 73.2, 72.2, 69.4,

62.9, 61.1, 53.6, 30.3, 28.0, 26.7, 22.9, 19.2 ppm.

In a 1 L round-bottomed flask equipped with a stir bar was added 2.28 (20.2 g, 21.9 mL, 146
mmol) in DMF (730 mL). NH4Cl (11.7 g, 219 mmol) and KCN (19.1 g, 293 mmol) were added
along with water (97 mL). The reaction mixture was heated to 90 °C and stirred for 12 hours. The
reaction was cooled to room temperature and was diluted with 2:1 hexanes/EtOAc (400 mL) along
with water (400 mL). The aqueous layer was extracted with 2:1 hexanes/EtOAc (3 x 350 mL) and
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then Et2O (3 x 250 mL). The combined organic layers were washed with brine (3 x 350 mL) and
dried over Na2SO4, filtered and concentrated to give an amber oil. Further purification by silica
gel column chromatography using a gradient of 9:1 Hex/EtOAc to 2:1 hexanes/EtOAc provided
2.8813 (21.3 g, 129 mmol, 88% yield) as a white solid. 1H NMR (500 MHz, CDCl3): δ 2.70 (dt, J
= 14.6, 1.9 Hz, 1H), 2.25-2.30 (m, 1H), 2.17-2.24 (m, 2H), 2.08 (dt, J = 14.4, 1.9 Hz, 1H), 1.64 (d,
J = 14.4 Hz, 1H), 1.52 (s, 3H), 1.21 (s, 3H), 1.10 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ
206.3, 123.7, 53.4, 50.0, 48.0, 35.5, 34.0, 32.7, 29.7, 26.9 ppm.

In a 1 L round-bottomed flask equipped with a stir bar was added 2.88 (12.1 g, 58.6 mmol) in
EtOH (710 mL). 4-Methylbenzenesulfonohydrazide (12.00 g, 64.4 mmol) was added and the
reaction mixture was heated to 100 °C (reflux) for 5 hours. The reaction was cooled to room
temperature and was kept for 18 hours. The resulting solid was filtered and rinsed with cold EtOH
and dried to give 2.89 (17.5 g, 52.5 mmol, 90% yield) as a white powder which was used without
further purification. 1H NMR (400 MHz, DMSO-d6): δ 10.29-10.51 (m, 1H), 7.67 (d, J = 8.2 Hz,
2H), 7.32 (d, J = 8.1 Hz, 2H), 2.65 (br d, J = 13.7 Hz, 1H), 2.38 (br d, J = 13.7 Hz, 1H), 2.32 (s,
3H), 2.12 (d, J = 13.7 Hz, 1H), 1.73 (br d, J = 14.0 Hz, 1H), 1.61 (d, J = 13.7 Hz, 1H), 1.43 (d, J
= 14.1 Hz, 1H), 1.29 (s, 3H), 0.92 (s, 3H), 0.87 (s, 3H) ppm.
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In a 1 L triple-necked round-bottomed flask equipped with a stir bar was added 2.89 (18.1 g, 54.3
mmol) in MeOH (270 mL) under an argon atmosphere to give a white suspension. NaCNBH3 (108
mL, 108 mmol, 1 M in THF) was added dropwise via addition funnel over 15 minutes and the
solution became clear. The reaction mixture was then cooled to -20 °C using an unsaturated dry
ice bath. Once cool, AcCl (4.26 g, 3.86 mL, 54.3 mmol) was added dropwise via syringe. The
reaction mixture continued to stir for an additional hour at -20 °C. NaOAc (44.3 g, 540 mmol) was
added along with additional MeOH (270 mL). The reaction mixture was then heated to reflux for
3 hours at 95 °C. The reaction mixture was then cooled to room temperature and the solvent was
evaporated under reduced pressure. The crude material was dissolved in water (150 mL) and Et2O
(200 mL). The aqueous layer was extracted with Et2O (3 x 200 mL) and the combined organic
layers were washed with brine (150 mL), dried over MgSO4, filtered and concentrated to give a
light-yellow oil that was purified by silica gel column chromatography using hexanes/EtOAc
(10:1) to give 2.85 (7.78 g, 51.4 mmol, 95% yield) as a clear colorless oil. 1H NMR (400 MHz,
CDCl3) δ 1.98 (br d, J = 13.4 Hz, 1H), 1.67-1.83 (m, 2H), 1.54-1.65 (m, 1H), 1.45 (br d, J = 13.0
Hz, 1H), 1.31 (s, 3H), 1.15 (s, 3H), 0.99-1.13 (m, 3H), 0.89 (s, 3H) ppm. 13C NMR (101 MHz,
CDCl3): δ 125.8, 48.9, 38.3, 37.7, 33.9, 31.8, 31.0, 29.5, 25.2, 20.0 ppm.
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In 250 mL round-bottomed flask equipped with a stir bar was added 2.85 (3.21 g, 21.2 mmol) in
anhydrous DCM (53 mL). The reaction vessel was evacuated and purged with argon then cooled
to 0 °C. DIBAL-H (26.7 mL, 26.7 mmol, 1 M in hexanes) was added slowly via addition funnel
while at 0 °C. The reaction mixture was warmed to room temperature where it stirred for 12 hours.
The reaction mixture was cooled to 0 °C, quenched with 1 N aqueous HCl (50 mL) and diluted
with an additional 30 mL of DCM. This solution was stirred at room temperature for an additional
24 hours at room temperature. An additional portion of 1 N aqueous HCl (50 mL) was added and
the biphasic mixture was separated in a separatory funnel. The aqueous layer was extracted with
DCM (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over
MgSO4, filtered and concentrated to give a yellow oil. Further purification by silica gel column
chromatography using hexanes/EtO2 (20:1) gave 2.79 (3.01 g, 19.5 mmol, 92% yield) as a clear
colorless oil. 1H NMR (500 MHz, CDCl3): δ 9.46 (s, 1H), 2.00-2.09 (m, 1H), 1.73-1.81 (m, 1H),
1.41-1.50 (m, 2H), 1.27-1.35 (m, 1H), 1.14 (d, J = 14.1 Hz, 1H), 1.04-1.11 (m, 1H), 0.95-1.03 (m,
1H), 0.92 (s, 3H), 0.91 (s, 3H), 0.75 (s, 3H) ppm.

13

C NMR (126 MHz, CDCl3): δ 206.4, 47.3,

46.3, 38.5, 33.1, 31.5, 30.9, 26.0, 24.9, 19.2 ppm. HRMS m/z: [M + H]+ Calcd for C11H21O3
155.1430; found 155.1431.
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In a 100 mL round-bottomed flask equipped with a stir bar was added 2.27 (5.29 mL, 35.7 mmol)
in triethyl orthoacetate (TEOA) (65.7 mL, 357 mmol) and 5 drops of propionic acid at room
temperature. The reaction vessel was equipped with a distillation head and an elbow to a receiving
flask. The reaction mixture was heated to 170 °C and for 48 hours. The reaction was cooled to
room temperature and diluted with EtOAc (100 mL) and 1 N aqueous HCl (200 mL). The aqueous
layer was extracted with EtOAc (3 x 50 mL) and the combined organic layers were washed with
satd. aqueous NaHCO3 (100 mL), dried over Na2SO4, filtered and concentrated to give a crude oil.
Further purification by silica gel column chromatography using hexanes/EtOAc (12:1) gave 2.907
(5.81 g, 27.6 mmol, 77% yield) as a clear colorless oil. 1H NMR (400 MHz, CDCl3): δ 5.51-5.62
(m, 1H), 5.42-5.49 (m, 1H), 4.08 (q, J = 7.1 Hz, 2H), 2.24 (s, 2H), 1.69-1.75 (m, 2H), 1.61 (d, J =
13.9 Hz, 1H), 1.31 (d, J = 14.0 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H), 1.09 (s, 3H), 0.94 (s, 3H), 0.93
(s, 3H) ppm.

In a 100 mL round-bottomed flask equipped with a stir bar was added 2.90 (3.11 g, 14.3 mmol)
and Pd/C (0.759 g, 0.713 mmol, 10% wt) in EtOH (50 mL) at room temperature. The flask was
vacuum-purged three times with argon then purged with H2 gas via balloon. The reaction stirred
under an atmosphere of H2 for 15 hours at room temperature. The progress of the reaction was
monitored by GCMS. The reaction mixture was filtered through a pad of Celite and washed with
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Et2O (150 mL). The filtrate was concentrated to give a light-yellow oil that was purified by silica
gel column chromatography using hexanes/Et2O (20:1) to give 2.90.1 (2.51 g, 11.8 mmol, 83%
yield) as a clear colorless oil that was determined to be 95% pure by GCMS. 1H NMR (400 MHz,
CDCl3): δ 4.09 (q, J = 7.1 Hz, 2H), 2.20 (d, J = 3.6 Hz, 2H), 1.44-1.58 (m, 2H), 1.28 (s, 3H), 1.161.25 (m, 6H), 1.03 (s, 3H), 0.91 (s, 3H), 0.89 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 172.3,
59.8, 50.3, 48.2, 39.3, 38.1, 33.8, 32.0, 30.7, 30.4, 27.2, 19.0, 14.3 ppm.

In a 500 mL round-bottomed flask equipped with a stir bar was added 2.27 (35.6 mL, 233 mmol)
and vinyl acetate (117 mL, 127 mmol) in hexanes (233 mL). Lipase from Candida rugosa (7 g,
20% wt) was added and the reaction mixture stirred at room temperature under argon for 72 hours.
The reaction mixture was filtered through a pad of Celite and concentrated under reduced pressure.
Further purification by silica gel column chromatography using hexanes/acetone (9:1) gave (S)2.27 (17.5 g, 125 mmol, 53.5% yield) with >50% ee. The % ee was increased by subjecting
enantio-enriched (S)-2.27 to the same reaction and purification procedures. Round one = 3 days,
round 2 = 10 days, round 3 = 3-5days. After a third round of resolution (S)-2.277 (9.21 g, 65.6
mmol, 28% overall yield) was obtained as a clear colorless oil with >98% ee. Enantiopurity was
determined by GCMS using a chiral column (120-Alphadex-chiral) r.t. minor = 25 min, r.t. major
= 25.4 min. 1H NMR (500 MHz, CDCl3) δ 5.38-5.45 (m, 1 H), 4.19-4.26 (m, 1 H), 1.84 (br d,
J=17.24 Hz, 1 H), 1.75 (br dd, J=5.96, 12.44 Hz, 1 H), 1.67 (s, 3 H), 1.60 (br d, J=17.30 Hz, 1 H),
1.46 (br s, 1 H), 1.22 (dd, J=9.11, 12.35 Hz, 1 H), 0.99 (s, 3 H), 0.88 (s, 3 H) ppm. 13C NMR (126
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MHz, CDCl3) δ 136.0, 123.6, 66.8, 45.2, 44.1, 31.2, 31.0, 26.2, 23.5 ppm. *Three rounds of
resolution are required for large scales (>10 g) to obtain ≥98% ee ranging from 15-28% overall
yields.

In a 1 L round bottom flask was NaH (21.4 g, 534 mmol, 60 wt%) in THF (534 mL) at 0 °C.
Benzyl alcohol (28.8 mL, 277 mmol) was added dropwise to the cold solution. Once hydrogen gas
formation ceased, a solution of 2-bromoacetic acid (2.91-1, 19.3 g, 139 mmol) in THF (66.7 mL)
was added dropwise. The resulting reaction mixture was heated to reflux for 15 hours at 85 °C.
The reaction was cooled to room temperature and carefully quenched with water (250 mL) then
transferred to a sepratory funnel. Satd. aqueous NaHCO3 (250 mL) was added and the aqueous
layer was washed with Et2O (200 mL x 2). The aqueous layer was acidified using conc. HCl to pH
< 4. The acidic aqueous layer was extracted with Et2O (250 mL x 3) and combined separately from
the first organic wash. The second combined organic layer was dried over Na2SO4, filtered and
concentrated to give 2.9114 (21.5 g, 129 mmol, 93% yield) as a light yellow oil and was used
without further purification. 1H NMR (400 MHz, CDCl3) δ 7.27-7.43 (m, 5 H), 4.65 (s, 2 H), 4.064.18 (m, 2 H) ppm.

In a 1 L round bottom flask equipped with a stir bar was added 2.91 (10.2 g, 61.2 mmol) in DCM
(371 mL). The solution was cooled to 0 °C and (S)-2.27 (7.81 g, 55.6 mmol) was added along with
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DCC (12.6 g, 61.2 mmol) and DMAP (0.680 g, 5.56 mmol). The reaction mixture continued to stir
at 0 °C for 1 hour before warming to room temperature where it stirred for 12 hours at room
temperature. At which time the reaction mixture was filtered through a fritted funnel and rinsed
with DCM (200 mL). The resulting filtrate was concentrated to give an oily solid. The crude oil
was further purified by silica gel column chromatography using hexanes/EtOAc (20:1) to give
2.71 (14.6 g, 50.6 mmol, 91% yield) as a clear colorless oil. [α]20D= -66.6 (c = 1, CHCl3). 1H NMR
(400 MHz, CDCl3): δ 7.27-7.38 (m, 5H), 5.40-5.47 (m, 1H), 5.38 (br s, 1H), 4.62 (s, 2H), 4.05 (s,
2H), 1.82-1.89 (m, 1H), 1.75 (dd, J = 12.9, 6.1 Hz, 1H), 1.67 (s, 3H), 1.63-1.70 (m, 1H), 1.40 (dd,
J = 12.9, 7.9 Hz, 1H), 0.97 (s, 3H), 0.92 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3): δ 170.2, 138.8,
137.2, 128.4, 128.0, 127.9, 118.8, 73.3, 70.8, 67.4, 44.0, 40.6, 30.6, 30.3, 27.0, 23.6 ppm. HRMS
m/z: [M + Na]+ Calcd for C18H24O3Na 311.1618; found 311.1612.

In a double-necked 500 mL round-bottomed flask equipped with a stir bar was added KHMDS
(22.2 mL, 11.1 mmol, 0.5 M in toluene) and anhydrous toluene (44 mL) at -78 °C. Once cooled,
2.71 (1.61 g, 5.55 mmol) in toluene (44 mL) was added dropwise and stirred at -78 °C for 1 hour.
At which time a solution of pyridine (1.57 mL, 19.4 mmol) and TMS-Cl (2.17 mL, 16.6 mmol) in
toluene (22 mL) was added dropwise to the reaction mixture. The reaction continued to stir at -78
°C for 30 minutes before warming to room temperature and stirred for 15 hours. The reaction was
quenched with satd. aqueous NH4Cl (30 mL) and 1 N aqueous HCl (40 mL). The two layers were
partitioned in a separatory funnel and the aqueous layer was extracted with EtOAc (3 x 75 mL).
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The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and
concentrated to give a yellow/orange oil. The crude oil was further purified by silica gel column
chromatography using hexanes/EtOAc (9:1-2:1) to give 2.94 (1.42 g, 4.92 mmol, 89% yield) as a
light yellow oil. *Yields began to decrease on scale-up using this method.
Alternative method
In a 1 L triple-neck round-bottomed flask equipped with a stir bar was added 2.71 (9.98 g, 34.7
mmol) in anhydrous THF (510 mL, transferred via cannula) at -78 °C. TMS-Cl (40.7 mL, 312
mmol) and pyridine (12.6 mL, 156 mmol) were added via syringe. LiHMDS (173 mL, 173 mmol,
1 M in THF/ethylbenzene) was added dropwise over 15 minutes via addition funnel to the cold
stirring solution. Once the addition was complete the reaction mixture became clear with a yellow
tint. The reaction continued to stir at -78 °C for one hour before warming to room temperature
where it stirred for an additional 15 hours. The reaction was quenched with 1N aqueous HCl (100
mL) and the solvent was removed under vacuum. The resulting residue was acidified with conc.
HCl to a pH of 2 then extracted with Et2O (3 x 300 mL), dried over Na2SO4, filtered and
concentrated to give a crude oil. The crude oil was purified by silica gel column chromatography
(9:1-2:1, Hex/EtOAc) to give 2.94 (9.12 g, 31.6 mmol, 91% yield) as a yellow oil. 1H NMR (400
MHz, CDCl3) δ 7.27-7.36 (m, 5H), 5.66-5.76 (m, 1H), 5.44-5.65 (m, 1H), 4.65 (dd, J = 11.5, 3.6
Hz, 1H), 4.44 (dd, J = 11.5, 3.0 Hz, 1H), 3.69-3.72 (m, 1H), 1.75-1.83 (m, 2H), 1.67-1.74 (m, 1H),
1.26 (br d, J = 14.1 Hz, 1H), 1.14 (s, 3H), 0.95 (s, 3H), 0.89-0.94 (m, 3H) ppm. 13C NMR (101
MHz, CDCl3) δ 174.6, 136.8, 130.4, 128.4, 128.1, 126.9, 126.5, 85.6, 73.4, 43.7, 39.6, 38.4, 31.6,
29.7, 28.7, 23.9 ppm. HRMS m/z: [M + Na]+ Calcd for C18H24O3Na 311.1618; found 311.1612.
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In a 250 mL round-bottomed flask equipped with a stir bar was added 2.94 (7.11 g, 24.6 mmol)
and Pd/C (2.62 g, 0.1 eq, 10 wt%) in MeOH (123 mL) at room temperature. The vessel was
evacuated and purged with argon three times. The round bottom was evacuated and replaced with
an atmosphere of hydrogen gas via balloon. The reaction mixture proceeded to stir for 24 hours at
room temperature. At which time the reaction was vacuum filtered through a pad of Celite and
rinsed with EtOAc (200 mL). The filtrate was concentrated under reduced pressure to give 2.92
(mixture of diastereomers that were not assigned) (4.71 g, 23.5 mmol, 95% yield) as a yellowish
solid that was used without further purification. Purification by silica gel column chromatography
using a gradient of hexanes/EtOAc (4:1-2:1) can be used if needed. 1H NMR (400 MHz, CDCl3):
δ 6.20 (br s, 2H, COOH and OH), 3.91-3.96 (m, 1H), 1.39-1.54 (m, 3H), 1.31-1.38 (m, 3H), 1.061.22 (m, 2H), 0.97-1.01 (m, 3H), 0.95-0.97 (m, 3H), 0.92-0.94 (m, 3H) ppm. 13C NMR (101 MHz,
CDCl3): δ 178.5, 78.8, 46.5, 39.2, 38.5, 33.9, 33.3, 30.6, 28.9, 20.8, 18.6 ppm. HRMS m/z: [M +
Na]+ Calcd for C11H20O3Na 223.1305; found 223.1299.

In a 100 mL round-bottomed flask equipped with a stir bar and wrapped in aluminum foil was 2.92
(2.81 g, 13.9 mmol) in degassed methanol (254 mL). Sodium periodate (2.99 g, 13.9 mmol) was
added and the reaction stirred at room temperature for 12 h. The reaction was quenched with a 1N
aqueous sodium sulfite solution (35 mL), poured into a brine solution (300 mL) and extracted with
Et2O (3 x 50 mL). The combined organic layers were washed with water (2 x 50 mL), dried over
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MgSO4, filtered and carefully concentrated to give a crude liquid containing residual solvent. The
crude liquid was purified by silica gel column chromatography using hexanes/Et2O (20:1) to give
2.70 (1.52 g, 9.85 mmol, 71% yield) as a clear colorless oil. [α]20D= +14.9 (c = 1, CHCl3). 1H NMR
(500 MHz, CDCl3) δ 9.46 (s, 1H), 2.00-2.09 (m, 1H), 1.73-1.81 (m, 1H), 1.41-1.50 (m, 2H), 1.271.35 (m, 1H), 1.14 (d, J = 14.1 Hz, 1H), 1.04-1.11 (m, 1H), 0.95-1.03 (m, 1H), 0.92 (s, 3H), 0.91
(s, 3H), 0.75 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 206.4, 47.3, 46.3, 38.5, 33.1, 31.5, 30.9,
26.0, 24.9, 19.2 ppm. HRMS m/z: [M + H]+ Calcd for C10H19O 155.1430; found 155.1431.

In a 500 mL round-bottomed flask equipped with a stir bar was added dimethyl (2oxopropyl)phosphonate (2.95-1, 6.39 mL, 46.2 mmol) in anhydrous toluene (154 mL) at 0 °C.
NaH (2.2 g, 55 mmol, 60% wt) was then added portion wise and the reaction stirred at 0 °C for 1
h. A solution of 4-acetamidobenzenesulfonyl azide (2.95-2, 10.1 g, 41.6 mmol) in anhydrous THF
(77 mL) was added dropwise to the reaction mixture and the reaction was warmed to room
temperature where it stirred for 15 hours. Hexanes (150 mL) was added and the precipitate was
filtered through a pad of Celite. The filter cake was washed with ether (150 mL x 3) and the filtrate
was concentrated under reduced pressure to give a crude oil. Further purification by silica gel
column chromatography using hexanes/EtOAc (2:1 - 1:1.5) provided 2.9515 (7.5 g, 39 mmol, 94%
yield) as a bright yellow oil. 1H NMR (400 MHz, CDCl3): δ 3.81 (s, 3H), 3.78 (s, 3H), 2.21 (s, 3H)
ppm. 13C NMR (101 MHz, CDCl3): δ 189.7, 53.5, 53.5, 27.1 ppm.
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In a 200 mL round-bottomed flask equipped with a stir bar was added 2.70 (2.02 g, 13.1 mmol) in
degassed MeOH (131 mL) at room temperature. K2CO3 (3.62 g, 26.2 mmol) and 2.95 (3.02 g, 15.7
mmol) were added and the reaction mixture stirred at room temperature for 15 h. The clear yellow
solution was quenched with 5% aqueous NaHCO3 (30 mL) and extracted with ether (4 x 50 mL),
washed with brine (30 mL), dried over Na2SO4, filtered and carefully concentrated to give 2.69
(1.81 g, 12.1 mmol, 92% yield) as a clear colorless oil. The product from the work-up was
sufficiently pure and was used without further purification. [α]20D= +7.2 (c = 1, CHCl3). 1H NMR
(400 MHz, CDCl3): δ 2.06 (s, 1H), 1.78 (br d, J = 11.3 Hz, 2H), 1.60 (br d, J = 13.5 Hz, 1H), 1.441.51 (m, 1H), 1.39 (br d, J = 13.1 Hz, 1H), 1.19 (s, 3H), 1.14 (s, 3H), 0.96-1.09 (m, 3H), 0.85 (s,
3H) ppm. 13C NMR (101 MHz, CDCl3): δ 92.6, 68.6, 50.6, 39.8, 39.2, 34.4, 32.7, 31.3, 31.0, 26.2,
20.1 ppm. HRMS m/z: [M - H]- Calcd for C11H17 149.1336; found 149.1334.

In a 25 mL round-bottomed flask equipped with a stir bar was added CuCl (9.4 mg, 0.095 mmol,
0.02 eq.) in 30% aq. n-butylamine (11 mL). The solution turned blue and the flask was stirred until
all the CuCl had dissolved. A spatula tip of NH2OH∙HCl was added, and the solution turned clear
and colorless. The mixture was cooled to 0 °C and a cold solution of 2.69 (0.711 g, 4.73 mmol) in
THF (2 mL) was added. At this point the reaction mixture turned bright yellow and precipitate
formed. After stirring vigorously for 2 minutes, 2.68 (0.766 g, 0.403 mL, 5.68 mmol) was added
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in one portion along with another small scoop of NH2OH∙HCl and the reaction continued to stir at
0 °C. When the reaction turned blue or greenish in color, a small amount of NH2OH∙HCl was
added until the reaction mixture was yellow again. The reaction was completed once the mixture
turned amber in color. The reaction mixture was poured into a separatory funnel containing
saturated aqueous NH4Cl (30 mL) and ether (25 mL). The aqueous layer was extracted with ether
(3 x 25 mL). The combined organic layers were dried over MgSO4, filtered and concentrated to
give a crude oil. Further purification by column chromatography using hexanes/EtOAc (5:1) gave
2.96 (0.712 g, 3.48 mmol, 74% yield) as a yellow oil. [α]20D= +16.0 (c = 1, CHCl3). 1H NMR (400
MHz, CDCl3): δ 4.32 (s, 2H), 1.79-1.87 (m, 1H), 1.67-1.78 (m, 1H), 1.62 (br d, J = 13.6 Hz, 1H),
1.47-1.53 (m, 1H), 1.41 (br dd, J = 13.2, 1.5 Hz, 1H), 1.21 (s, 3H), 1.13 (s, 3H), 0.97-1.11 (m, 4H),
0.87 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3): δ 89.0, 74.3, 71.0, 65.0, 51.6, 50.6, 39.6, 39.0,
34.2, 32.0, 31.9, 31.2, 26.0, 20.3 ppm. HRMS m/z: [M + K]+ Calcd for C14H20OK 243.1146; found
243.1151.

In a 100 mL round bottom flask was added 2.67 (0.398 mL, 3.08 mmol) in DCM (25.6 mL) at 0
°C. DCC (0.551 g, 2.67 mmol) and DMAP (0.0131 g, 0.103 mmol) were added and the reaction
mixture stirred at 0 °C for 30 minutes. The reaction mixture was filtered through a fritted funnel
and rinsed with DCM (15 mL). The filtrate was concentrated under reduced pressure to give an
oily solid that was further purified by silica gel column chromatography using hexanes/EtOAc
(25:1) to give 2.66 (0.512 g, 1.56 mmol, 76% yield) as a clear light yellow oil. [α]20D = +44.9 (c =
0.91, CHCl3). 1H NMR (400 MHz, CDCl3): δ 4.80 (s, 2H), 1.81 (br d, J = 13.0 Hz, 1H), 1.65-1.77
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(m, 1H), 1.61 (br d, J = 13.5 Hz, 1H), 1.46-1.54 (m, 1H), 1.40 (br d, J = 13.1 Hz, 1H), 1.19 (s,
3H), 1.11 (s, 3H), 0.98-1.09 (m, 3H), 0.86 (s, 3H), 0.24 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3):
δ 152.0, 95.7, 93.6, 89.7, 72.6, 68.7, 64.8, 53.9, 50.6, 39.5, 39.0, 34.1, 32.0, 31.9, 31.2, 26.0, 20.2,
-1.0 ppm. HRMS m/z: [M + H]+ Calcd for C20H29O2Si 329.1931; found 329.1928.

In a 250 mL round-bottomed screw topped flask was added 2.66 (0.198 g, 0.603 mmol) in freshly
distilled cyclooctane (121 mL, 0.005M). The reaction mixture was purged with argon and capped
tightly then heated to 180 °C for 72 hours. At which time the reaction was cooled to room
temperature and filtered through a pad of silica gel while eluting with hexanes to remove
cyclooctane. EtOAc was used to elute the remainder of the reaction mixture that was concentrated
and purified by silica gel column chromatography using hexanes/EtOAc (20:1) to give 2.97 (0.145
g, 0.439 mmol, 73% yield) as a yellow oil. [α]20D= +16 (c = 1, CHCl3). 1H NMR (400 MHz,
CDCl3): δ 7.72 (d, J = 8.2 Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 5.22 (s, 2H), 2.32 (br d, J = 7.2 Hz,
1H), 2.24 (br d, J = 13.9 Hz, 1H), 1.45-1.55 (m, 4H), 1.40 (s, 3H), 1.15-1.25 (m, 2H), 0.88 (s, 3H),
0.53 (s, 9H), 0.12 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3): δ 171.8, 157.3, 144.2, 143.1, 132.1,
131.1, 121.2, 68.3, 53.9, 40.3, 40.0, 39.5, 35.3, 33.2, 31.6, 27.4, 19.7, 5.8 ppm. HRMS m/z: [M +
H]+ Calcd for C20H31O2Si 331.2088; found 331.2093.
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In 20 mL scintillation vial equipped with a stir bar and wrapped in aluminum foil was added 2.97
(0.0512 g, 0.154 mmol) in ACN (2.2 mL) at room temperature. NBS (0.055 g, 0.31 mmol) was
added to the stirring solution and the vial was purged with argon and then capped. The reaction
mixture stirred at room temperature for 24 hours. Once complete (TLC), the solvent was removed
under vacuum and the resulting crude solid was purified by silica gel column chromatography
(Hex/EtOAc, 6:1) to give 2.65 (0.048 g, 0.14 mmol, 91% yield) as a white solid. [α]20D= +23 (c =
1, CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 8.2 Hz, 1H), 5.18
(s, 2H), 3.28 (br d, J = 14.3 Hz, 1H), 2.31-2.42 (m, 1H), 1.67 (br dd, J = 9.3, 4.4 Hz, 2H), 1.46 (s,
3H), 1.18-1.36 (m, 4H), 0.90 (s, 3H), 0.36 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3): δ 168.9,
148.6, 146.3, 134.5, 125.7, 121.9, 120.6, 66.5, 47.0, 40.8, 40.3, 39.5, 33.1, 31.4, 30.3, 25.8, 19.8
ppm. HRMS m/z: [M + H]+ Calcd for C17H22O2Br 337.0798; found 337.0803.

In 20 mL scintillation vial equipped with a stir bar was added 2.97 (0.015 g, 0.045 mmol) was in
ACN (0.5 mL) at room temperature. Selectfluor™ (0.032 g, 0.091 mmol) and I2 (0.012 g, 0.045
mmol) was added, the vial was capped and stirred at room temperature for 2 hours. Once complete
(TLC) the solvent was removed under vacuum and the crude oil was purified by silica gel column
chromatography using hexanes/EtOAc (8:1) to give 2.98 (0.015 g, 0.039 mmol, 86% yield) as a
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yellow oil. [α]20D= +21 (c = 1, CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 8.2 Hz, 1H),
7.38 (d, J = 8.2 Hz, 1H), 5.11 (s, 2H), 3.53 (br d, J = 14.5 Hz, 1H), 2.38 (br d, J = 15.1 Hz, 1H),
1.62-1.72 (m, 2H), 1.52 (s, 3H), 1.22-1.32 (m, 4H), 0.90 (s, 3H), 0.33 (s, 3H) ppm. 13C NMR (101
MHz, CDCl3): δ 169.9, 151.0, 146.0, 133.8, 128.4, 121.4, 94.2, 65.7, 46.6, 41.4, 40.8, 39.7, 32.9,
31.5, 30.5, 26.0, 19.9 ppm. HRMS m/z: [M + Na]+ Calcd for C17H22O2INa 407.0478; found
407.0478.

In a 10 mL culture tube equipped with a stir bar was added Pd(dba)2 (2.53 mg, 4.41 µmol), dppf
(4.89 mg, 8.82 µmol) and thallium (I) acetate (0.029 g, 0.11 mmol) in anhydrous and degassed
THF (0.25 mL). The mixture stirred at room temperature for 5 minutes at room temperature. A
solution of 2.65 (0.019 g, 0.055 mmol) and 2.22 (0.032 g, 0.166 mmol) in anhydrous and degassed
THF (0.25 mL) was quickly added to the reaction mixture, purged with argon, securely capped
and heated to 80 °C for 15 hours. At which time the reaction was cooled to room temperature,
diluted with Et2O (20 mL) and filtered through a pad of Celite. The filtrate was concentrated to
give a dark oil that was purified by silica gel column chromatography using hexanes/EtOAc (6:1)
to give 2.99 (0.014 g, 0.042 mmol, 77% yield) as a pale yellow oil that solidified upon standing.
1

H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.2 Hz, 1H), 5.20 (s, 2H), 4.47 (br d, J = 7.1 Hz, 2H),

3.70 (s, 3H), 2.23 (br d, J = 14.0 Hz, 1H), 2.01 (br d, J = 13.8 Hz, 1H), 1.61-1.82 (m, 2H), 1.48 (br
d, J = 13.8 Hz, 2H), 1.30 (s, 3H), 1.26 (br d, J = 7.5 Hz, 3H), 0.88 (s, 3H), 0.38 (s, 3H) ppm. 13C
NMR (101 MHz, CDCl3): δ 171.3, 171.2, 148.9, 144.6, 134.1, 132.7, 126.0, 120.5, 68.1, 52.0,
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50.9, 40.1, 39.2, 35.2, 32.4, 31.9, 31.5, 29.7, 27.6, 19.8 ppm. [α]20D= +2.3 (c = 1, CHCl3). HRMS
m/z: [M + Na]+ Calcd for C20H26O4Na 353.1723; found 353.1721.

In a 10 mL round-bottomed flask equipped with a stir bar was added 2.99 (0.012 g, 0.036 mmol)
in anhydrous THF (0.4 mL) at -78 °C. NaHMDS (0.054 mL, 0.044 mmol, 0.8 M) was added
dropwise and then stirred for 1 hour at -78 °C. MeI (2.95 µL, 0.047 mmol) was added and the
reaction continued stirring for 1 hour at -78 °C before warming to room temperature and stirred
for 2 hours. The reaction was quenched with satd. aqueous NH4Cl (5 mL) and water (3 mL). The
aqueous phase was extracted with Et2O (4 x 10 mL), dried over MgSO4, filtered and
concentrated to give a crude oil that was further purified by silica gel column chromatography
using hexanes/EtOAc (10:1) to give 2.1 and 2.104 (8.05 mg, 0.023 mmol, 64.4% yield) as a
mixture of diastereomers (1:3 based on crude NMR).
Membranolide 2.1: 1H NMR (500 MHz, CDCl3): δ 7.82 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.3 Hz,
1H), 5.22 (d, J = 0.9 Hz, 2H), 4.62 (q, J = 7.1 Hz, 1H), 3.69 (s, 3H), 2.29 (dt, J = 14.3, 2.4 Hz,
1H), 2.09 (br d, J = 14.0 Hz, 1H), 1.79-1.91 (m, 1H), 1.76 (d, J = 7.1 Hz, 3H), 1.68-1.74 (m, 1H),
1.54 (d, J = 14.2 Hz, 1H), 1.46-1.51 (m, 1H), 1.38 (s, 3H), 1.26-1.37 (m, 2H), 0.95 (s, 3H), 0.48
(s, 3H) ppm.
Diastereomer 2.104: 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.3 Hz, 1H), 7.27 (d, J = 8.3 Hz,
1H), 5.19 (s, 2H), 4.61 (q, J = 7.0 Hz, 1H), 3.68 (s, 3H), 2.29 (br d, J = 14.0 Hz, 1H), 2.08 (br d, J
= 13.9 Hz, 1H), 1.71-1.83 (m, 1H), 1.65 (td, J = 9.2, 4.4 Hz, 1H), 1.58 (d, J = 7.0 Hz, 3H), 1.46-
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1.51 (m, 1H), 1.43 (br d, J = 13.9 Hz, 1H), 1.37 (s, 3H), 1.24-1.29 (m, 2H), 0.84 (s, 3H), 0.37 (s,
3H) ppm. HRMS m/z: [M + Na]+ Calcd for C21H28O4Na 367.1885; found 367.1886.

In a 100 mL round bottom flask equipped with a stir bar was added CuCl (0.097 g, 0.98 mmol) in
30% aq. n-butylamine (45.5 mL) to give a blue solution. A small scoopula of NH2OH∙HCl was
added, and the blue solution became clear and colorless and the reaction was purged with argon.
Ethynylbenzene (2.105, 2.15 mL, 19.6 mmol) was added and the reaction mixture was
immediately cooled to 0 °C where it stirred for 2 minutes. A solution of 3-bromoprop-2-yn-1-ol
(2.68,1.66 mL, 23.50 mmol) in THF (5 mL) was added in one portion and the reaction continued
to stir at 0 °C for 15 minutes before warming to room temperature. Whenever the solution turned
blue/green in color another small scoopula of NH2OH∙HCl was added. After stirring at room
temperature for 1 hour the reaction turned amber in color and was deemed complete. The reaction
was quenched with satd. aqueous NH4Cl (50 mL) and extracted with Et2O (3 x 30 mL). The
combined organic layers were dried over MgSO4, filtered and concentrated to give a crude oil that
was further purified by silica gel column chromatography using hexanes/EtOAc (5:1) to give
2.10616 (2.42 g, 15.5 mmol, 79% yield) as an amber oil. 1H NMR (400 MHz, CDCl3): δ7.43-7.50
(m, 2H), 7.25-7.37 (m, 3H), 4.39 (s, 2H), 2.23 (br s, 1H) ppm.
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In a 25 mL round-bottomed flask equipped with a stir bar was added 2.106 (1.06 g, 6.41 mmol)
and 2.67 (1.09 g, 7.68 mmol) in DCM (64.0 mL) at 0 °C. DCC (1.585 g, 7.68 mmol) was added
along with dropwise addition of DMAP (0.039 g, 0.32 mmol) in DCM (10 mL). The reaction
mixture was stirred at 0 °C for 30 min before warming to room temperature where it continued to
stir for 1 hour. The reaction was filtered through a pad of Celite and rinsed with DCM. The filtrate
was concentrated under reduced pressure to give an oily solid that was further purified by silica
gel column chromatography using hexanes/EtOAc (25:1) to give 2.107 (1.49 g, 5.31 mmol, 83%
yield) as a clear colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.44-7.51 (m, 2H), 7.27-7.39 (m,
3H), 4.88 (s, 2H), 0.24 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3): δ 151.9, 132.6, 129.5, 128.4,
121.0, 96.0, 93.5, 79.2, 74.8, 72.9, 72.0, 53.7, -1.0 ppm. HRMS m/z: [M + Na]+ Calcd for
C17H16O2Na 303.0812; found 303.0799.

In a 100 mL reaction vial was added 2.107 (0.063 g, 0.21 mmol) in cyclooctane (43 mL). The
reaction mixture was purged with argon and sealed with a Teflon screw cap and heated to 150 °C
for 48 hours. The reaction was cooled to room temperature and filtered through a plug of silica gel
while rinsing with hexanes to remove the cyclooctane. The rest of the reaction mixture was eluted
with EtOAc and then concentrated to give a crude oil that was purified by silica gel column
chromatography (15:1 hexanes:EtOAc) to give 2.108 (0.045 g, 0.16 mmol, 75% yield) as a light
125

yellow oil that solidified upon standing. 1H NMR (400 MHz, CDCl3): δ 7.48-7.52 (m, 1H), 7.427.46 (m, 1H), 7.37-7.41 (m, 3H), 7.28 (dd, J = 6.8, 3.2 Hz, 2H), 5.32 (s, 2H), 0.05 (s, 9H) ppm.
13

C NMR (101 MHz, CDCl3): δ 171.6, 151.0, 145.6, 144.0, 140.6, 135.3, 131.3, 129.5, 128.1,

127.6, 121.6, 68.9, 1.1 ppm. HRMS m/z: [M + Na]+ Calcd for C17H18O2SiNa 305.0968; found
305.0968.

In 20 mL scintillation vial wrapped in aluminum foil and equipped with a stir bar was added 2.108
(0.039 g, 0.14 mmol) in ACN (1 mL). NBS (0.130 g, 0.730 mmol) was added and the vial was
purged with argon then capped. The reaction mixture was stirred at room temperature for 24 hours
at room temperature. The solvent was removed under vacuum and the resulting crude solid was
purified by silica gel column chromatography using hexanes/EtOAc (6:1) to give 2.109 (0.022 g,
0.076 mmol, 55% yield) as a white solid. The reaction did not go to completion and 2.108 was
recovered for further use. 1H NMR (400 MHz, CDCl3): δ 7.51-7.56 (m, 1H), 7.41-7.48 (m, 4H),
7.29 (dd, J = 7.3, 1.9 Hz, 2H), 5.23 (s, 2H) ppm. 13C NMR (101 MHz, CDCl3): δ 169.2, 149.5,
147.4, 142.9, 142.9, 134.9, 129.4, 128.2, 127.6, 121.4, 97.1, 66.7 ppm. HRMS m/z: [M + Na]+
Calcd for C14H9O2BrNa 310.9678; found
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In a 10 mL culture tube equipped with a stir bar was added Pd(dba)2 (5.09 mg, 8.85 µmol), dppf
(9.82 mg, 0.018 mmol), and thallium(I) acetate (0.058 g, 0.22 mmol) in THF (0.8 mL). The
reaction vial was purged with argon and stirred for 5 minutes at room temperature. At which time
a solution of 2.22 (0.104 g, 0.553 mmol) and 2.109 (0.032 g, 0.11 mmol) in THF (0.2 mL) was
added and the reaction was purged with argon, capped and heated to 80 °C for 20 hours. The
reaction was cooled and filtered through a pad of Celite while rinsing with Et2O. The filtrate was
concentrated to give a crude oil that was purified by silica gel column chromatography using
hexanes/EtOAc (8:1) to give 2.110 (0.018 g, 0.064 mmol, 58% yield) as a pale-yellow oil. 1H
NMR (400 MHz, CDCl3): δ 7.57 (d, J = 7.9 Hz, 1H), 7.36-7.47 (m, 5H), 7.26 (d, J = 1.2 Hz, 1H),
5.30 (s, 2H), 4.06 (s, 2H), 3.64 (s, 3H) ppm. HRMS m/z: [M + Na]+ Calcd for C17H14O4Na
305.0784; found 305.0779
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Chapter 3
Enantioselective Total Synthesis of the Cannabinoids – A Route for Analog Development

3.1

Introduction to phytocannabinoids
Plants have been a wealthy source of chemical diversity that have proven to be

therapeutically beneficial for centuries.1 Ancient eastern medicine has relied heavily on plants and
plant extracts to treat a myriad of ailments and is still used in modern times for homeopathic
practices. In most cases, there is a main biologically active constituent in plants, or their extracts,
responsible for the observed therapeutic effect. The purification of plant extracts has led to the
discovery of many drugs that are now used to fight disease and to treat a wide variety of
indications.1-4

Figure 3.1: Common phytocannabinoids found in Cannabis extracts. THCa and CBDa are the major
cannabinoids while the others are minor constituents.
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Cannabis plants of the sativa and indica species are known to contain biologically active
compounds (Figure 3.1) that have been used to treat pain, anxiety, and infection since 2000 BCE
(Before Common Error).5 In the United States, two cannabinoids have made their way through
FDA approval and to the market. In 1985, the most infamous bioactive compound found in
Cannabis extracts, ∆9-tetrahydrocannabinol (∆9-THC, 3.1), was approved for the treatment of
nausea and vomiting in chemotherapy patients and for AIDS-related anorexia.6 Naturally occurring
3.1 is not used in the pharmaceutical formulation. Instead, an identical synthetic version of 3.1 was
chosen, mainly for a reliable purity profile, and is marketed by AbbVie as Marinol® (Dronabinol).6
3.1 is most commonly known for its psychoactive properties and has been scrutinized by society
in the past. Oddly enough, the stigma related to ∆9-THC has prompted the Drug Enforcement
Agency (DEA) to schedule plant derived ∆9-THC as a drug with no currently accepted medical
use (DEA Schedule 1).
A hemp derived cannabinoid, cannabidiol (CBD, 3.2), has become the second cannabinoid
approved in the United States. 3.2 gained FDA approval in 2018 for the treatment of severe seizures
associated with Dravet-syndrome and Lennox-Gastaut syndrome in children and is marketed under
the trade name Epidiolex® (cannabidiol) by GW Pharmaceuticals.7 The non-psychoactive
properties of 3.2, along with its medical efficacy and low-risk of abuse, resulted in the DEA
rescheduling of Epidiolex to a Schedule V drug. DEA rescheduling of the plant derived
cannabinoid 3.2 has made history in the United States. The U.S. government may be starting to
realize that the cannabinoids have medical use after all as we start to see an increase in research
funding opportunities in this area. Before long, Marinol and Epidiolex may find themselves alongside other cannabinoids as FDA approved drugs for other therapeutic indications.
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Although cannabinoids have proven themselves worthy as a therapeutic, it wasn’t until the
1930s that biologically active constituents of Cannabis resin were purified and partially identified
by Thomas Wood and Robert Cahn.8-9 Purified extracts from Cannabis plants containing a
bioactive compound were termed cannabinol. The chemical structure of the bioactive constituent
was fully confirmed via chemical synthesis by Lord Alan Todd (U.K.) and Roger Adams (U.S.).910

Isolation and purification methods of Cannabis extracts outlined by Wood and Cahn allowed

for further identification of other biologically active compounds such as 3.1 and 3.2.11-12 In the
early years of cannabinoid research there was a debate on the double bond position of 3.1 (Figure
3.2). The structural debate was concluded when Adams’ synthesis of 3.1 and ∆8-THC (3.7) from
CBD confirmed that the ∆9 isomer is the natural occurring isomer of THC.13-14

Figure 3.2: The two alkene isomers of THC. Conventional IUPAC numbering of fused ring systems where ∆
indicates the position of a double bond is illustrated.

Once the structures of 3.1 and 3.2 were identified and efficient purification methods had
been established, the discovery of their biological targets was pursued. Far-reaching progress
towards the target elucidation of 3.1 and 3.2 had been made in the late 1980’s and throughout the
1990’s with the discovery of two independent biological targets.15-19 Target identification for 3.1
and 3.2 ushered in extensive research that led to the discovery of the endocannabinoid system – a
vital signaling network to maintain homeostasis in animals.20-21 Among the many receptors and
enzymes within the endocannabinoid system, the G-protein coupled receptors (GPCRs) CB1 and
CB2 were initially found to interact with 3.1 and 3.2.16, 18
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With advancements in instrument sensitivity over the last 50 years, over 500 different
compounds have been identified in the Cannabis plant, 120 of which are cannabinoids.22-23 Many
of the newly discovered cannabinoids are scarce in the plant extracts and have yet to be biologically
evaluated, creating a new demand for chemical synthesis. There are over 30 syntheses reported in
the literature of the most common cannabinoids 3.1, 3.2 and cannabinol (CBN, 3.3), with only a
few encompassing direct routes to 3.2.23 Far fewer synthetic routes are reported for minor
cannabinoids such as cannabichromene (CBC, 3.4)24-25 and cannabicyclol (CBL, 3.6)26-27 than for
3.1. Most of the syntheses of 3.1 rely on synthetic steps that require acidic conditions and result in
isomerization of the cyclohexene double bond (∆9 to ∆8)28 shown in Figure 3.2. Unfortunately, the
∆8-THC isomer is more thermodynamically stable than the most naturally abundant ∆9 isomer and
is the main product isolated in many chemical syntheses.

Scheme 3.1: The biosynthesis of phytocannabinoid precursors.

Some of the phytocannabinoids found in Figure 3.1 have structural similarities with
varying oxidation states and ring structures. It should be noted that the phytocannabinoids are
biosynthesized from geranyl pyrophosphate (GPP, 3.13) and olivetolic acid 3.14, the latter derived
from acetyl-CoA (3.8) and malonyl-CoA (3.9) (Scheme 3.1).29 3.14 contains a carboxylic acid
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orthogonal to the phenol found in most phytocannabinoids isolated from the Cannabis plant. The
carboxylic acid derived from 3.14 was absent in the cannabinoids first isolated from plant extracts
due to the earlier extraction conditions. An aromatic prenyltransferase is responsible for coupling
3.13 and 3.14 leading to cannabigerol acid (CBGa, 3.6a) followed by further enzymatic conversion
to other phytocannabinoids such as those in Figure 3.1.30 The genome of the full biosynthetic
pathway has recently been sequenced and can be exploited in yeast models for the complete
biosynthesis of common cannabinoids that even allows access to some novel cannabinoid
analogs.31

3.2

The endocannabinoid system
One of the most important neuronal signaling pathways is the endocannabinoid system

(ECS), spanning the central and peripheral nervous system.32 The intriguing biological activity of
the cannabinoids had struck curiosity throughout the scientific community since the initial
discovery of 3.1, which motivated scientists to further understand its mechanism of action. In 1988,
Howlett and colleagues elucidated the cellular mechanism and target of 3.1 in the central nervous
system (CNS).16 Since the discovery of the ECS, it is believed that this signaling pathway is
responsible for a multitude of physiological responses such as appetite, pain sensation, mood,
fertility, post- and prenatal development.33-35
The groundbreaking work of Howlett revealed that the cannabinoids interact with a
receptor primarily located in the brain, now known as the cannabinoid receptor CB1. CB1 is
associated with a GPCR complex and, when activated by 3.1, inhibits adenylate cyclase in a
reversible and enantioselective manner.16,

36

The structure of CB1 was later determined

serendipitously in 1990 by Matsuda and colleagues after they identified a cDNA (SKR6) of a 473-
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amino acid sequence that suggested it was a member of the GPCR family.37 It was realized that
receptors known to interact with cannabinoids were present in the cell lines used in the studies of
Matsuda, prompting the researchers to test cannabinoids as ligands against the cloned GPCR. The
expression of the GPCR in a stable cell-line resulted in a cannabinoid-responsive GPCR,
ultimately revealing the structure of CB1.37
Shortly after the discovery of the CB1 receptor, a research group at Cambridge discovered
another GPCR that was not localized in the brain but could be found in macrophages.38 Gene
amplification using polymerase chain reaction (PCR) identified six clones showing homology to
the GPCR family. One of the six clones identified at Cambridge had shown homology to the
recently reported sequence of the CB1 GPCR and treatment with known cannabinoids with high
affinity to CB1 was examined. Surprisingly, 3.2 was found to have a higher affinity than 3.1 in
competitive binding assays.36 The newly discovered cannabinoid GPCR is now described as the
CB2 receptor due to its higher affinity towards 3.2 relative to 3.1. It is now thought that the CB2
receptor is responsible for the peripheral effects associated with the cannabinoids and could be a
promising drug target.38

Figure 3.3: Structural comparison of anandamide 3.15 and Δ9-THC (3.1). A double bond isomerization event
of anandamide clearly shows how THC could mimic the overall structure of iso-anandamide.
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Once the structure of CB1 was elucidated, William Devane and colleagues were able to
identify arachidonylethanolamide, most commonly known as anandamide (3.15) (Figure 3.3), as
the endogenous ligand for the CB1 receptor.15 Anandamide contains a varying degree of rotatable
bonds that are able to adopt confirmations that resembles that of the cannabinoids shown in Figure
3.1, resulting in similar biological effects.15 The discovery of anandamide laid the foundation
necessary for further exploration to understand the biological role of the endocannabinoid system.
A number of cell-signaling pathways have been associated with two endocannabinoids, 3.15 and
2-arachidonyl glycerol,20 that have implications in maintaining homeostasis.39 Even though other
arachidonic acid derivatives and proteins have been observed to interact with CB1 and CB2, most
research on the endocannabinoid system has revolved around the cannabinoids and
endocannabinoids.40
In 2016 the first crystal structure of CB1 was published with the highly potent antagonist
AM6538 bound within the receptor.41-42 The crystal structural revealed key interactions of the
antagonist with amino acid residues that stabilize its inactive form. Even though the crystal
structure of CB1 was obtained with an antagonist, molecular docking simulations with
endocannabinoids and exogenous ligands were able to provide insight to its active state. Following
the initial disclosure of the CB1 receptor’s crystal structure, a new report revealed a crystal
structure with a THC agonist (AM11542) in its active state.43 Now that a crystal structure of 3.1’s
biological target exists with an agonist and antagonist bound in the active site, rational drug design
can be employed to expedite drug discovery efforts targeting CB1.
The ECS is a marvel of the biological realm and rivals the central and peripheral nervous
systems in its intricacy. Research efforts are ongoing to unveil the complexity and biological
implications for which the ECS is responsible. With recent developments in chemical biology,
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chemical probes are in development to identify other protein targets within the ECS. Contrary to
popular belief, the observed biological effects of the cannabinoids are not fully associated with the
ECS, which suggests there are other biochemical targets yet to be discovered. There has been
progress in identifying new targets of the cannabinoids and other biological molecules associated
with the ECS and will be discussed below. Inconsistencies within the literature regarding newly
identified cannabinoid targets exist, which can be mostly attributed to a lack of reliable chemical
probes – underlining the demand for new probes to aid in further research endeavors.

3.3

Additional targets of the cannabinoids
While it is widely known that 3.1 and 3.2 are exogenous ligands of CB1 and CB2, these

cannabinoids, as well as the endocannabinoids, have other biological targets that are often
overlooked. The complex pharmacology associated with the ECS suggests that there might be
other receptors and modulators of this system. It has been known for some time that the
cannabinoids also interact with GPCRs within the serotonin,44 dopamine,45 adenosine46 adenosine
and opioid receptor families.47 Recently, other GPCRs (GPR18 and GPR55) as well as a set of
class A orphan GPCRs (GPR3, GPR6, GPR12) have been postulated as putative biochemical
targets of the cannabinoids.48 Of the newly discovered GPCRs that interact with the cannabinoids,
only GPR18 and GPR55 have proven to be targets of a wide variety of phytogenic, synthetic and
endogenous cannabinoids.36 Substantial therapeutic potential exists in the realm of cancer49-50 and
metabolic disorders51-52 for both GPR18 and GPR55 while the latter is also associated with pain,53
vascular function54 and motor coordination.55
Most of the cannabinoid targets discussed thus far have been GPCRs, however, there are
also reports of 3.1 interacting with non-GPCR targets such as peroxisome proliferator-activated
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receptor gamma (PPARγ) as an agonist.56 The agonistic effect associated with 3.1 and PPARγ may
be responsible for some of 3.1’s vascular relaxation and anti-tumor properties.57 Cation-channels
TRPV2, TRPV3 and TRPV4 are also known to interact with 3.1 agonistically.58-59 Overall,
extensive studies have proven that the cannabinoids play a more critical biological role than
previously conceived. It should become apparent that the pharmacology of the cannabinoids
cannot be attributed solely to the ECS and further research is needed to fully understand and access
novel therapeutic targets of the cannabinoids.

3.4

Naegleria fowleri, the “brain-eating amoeba”
Our lab gained an initial interest in the cannabinoids by their ability to inhibit the growth

of Naegleria fowleri,60 commonly known as the “brain-eating amoeba.” The free-living amoeba
N. fowleri causes primary amebic meningoencephalitis (PAM), a fatal disease of the CNS.61 As the
name brain-eating amoeba suggests, N. fowleri localizes itself in the brain where it feeds on brain
matter causing brain swelling, resulting in death with a mortality rate of >95%.62 N. fowleri enters
the nasal cavity and attaches itself to the nasal mucosa where it migrates along the olfactory nerve
and into the CNS.63 Two primary modes of pathogenicity are associated with N. fowleri: 1) a
sucker-like surface structure known as a “food cup” is used to digest brain matter and 2) it releases
cytolytic molecules composed of acid hydrolases, neuraminidases, phosphoryl lipases and
phospholipolytic enzymes that further facilitate destruction of nerves.64 Given the rarity of the
disease caused by N. fowleri infection (138 infections in the U.S. in 55 years),65 there are no clinical
trials to date, but treatment with amphotericin B is the most widely accepted treatment option.64
With the toxicity issues associated with amphotericin B,66 and the alarming mortality rate
of N. fowleri PAM, there is a need for more efficacious and less detrimental treatment options. One
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essential requirement for a potential therapeutic agent to be active against N. fowleri is blood-brain
barrier permeability. A potent inhibitor of N. fowleri proliferation in vitro would be useless if the
inhibitor cannot pass the membrane barrier where the organism is localized. 3.1 and other
cannabinoids are known for their permeability and localization within the brain.36 This
physicochemical property in conjugation with the anti-amoebic activity against N. fowleri, makes
the cannabinoids ideal lead compounds for the development of new therapeutics. 59
Initial screening of cannabinoid derivatives and common metabolites against N. fowleri in
anti-proliferation assays has shown promising activity in vitro and mild activity in in vivo mice
models. 3.1 inhibits the growth of N. fowleri at 5-20 µg/mL concentrations and prevents
enflagellation and encystment but was unable to inhibit mobility.60 Oxidized metabolites of 3.1
have been reported to be two-fold more potent than 3.1 in vitro while 3.2 was twice as potent.61
The data generated in the seminal studies of cannabinoids as anti-amoebic agents suggests that
cannabinoids may be promising therapeutics for N. fowleri PAM, however, further SAR and
pharmacokinetic (PK) optimization would be required. The mechanism of action for the amoebic
anti-proliferation associated with cannabinoids is unknown but is thought to involve the ECS of
N. fowleri based on a study involving the endocannabinoids.67 Our lab is working to develop novel
analogs and molecular probes using methodology discussed below (vide infra) to further evaluate
cannabinoids as anti-amoebic agents against N. fowleri and elucidate their mechanism of action.

3.5

Synthetic strategies towards ∆9-THC and CBD
As previously mentioned, there have been many synthetic approaches towards 3.1’s

scaffold with most of them relying on acid-catalyzed electrophilic aromatic substitution (EAS) of
chiral allylic alcohols (3.17, 3.18, 3.19) and olivetol (3.20) (Scheme 3.2). The main drawback to
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an EAS approach is the isomerization from 3.1 to 3.7 during the progression of the reaction. Olefin
isomerization observed in acid-mediated coupling for the synthesis of 3.1 and its analogs seems to
have been circumvented using catalytic BF3∙OEt2 with careful reaction monitoring and catalyst
loading.68 Strained terpenoid alcohol cis-verbenol (3.19) has been used in acid-mediated EAS
strategies with functionalized resorcinols to provide 3.1 and 3.2 scaffolds, accompanied by 3.7.69
Enantiopure allylic alcohols such as 3.17 and 3.18 are accessible from inexpensive terpene
feedstocks [(+) and (-)-limonene] and are prepared in four synthetic steps or less.70-71 Utilizing the
chiral pool to control the stereocenters within the cannabinoid scaffold is an attractive route for
analog development.

Scheme 3.2: Acid mediated EAS coupling of 3.20 with terpenoid allylic alcohols to give 3.1, 3.2 and 3.7.

Elegant enantioselective approaches to 3.1 exist that highlight the usefulness of transition
metal catalysis developed in recent years. In 2007, Trost and colleagues showcased a molybdenumcatalyzed asymmetric allylic alkylation (AAA) using chiral ligand 3.22 developed in their
laboratory to set the benzylic stereocenter of 3.1 in high enantiomeric excess (ee) (Scheme 3.3).73
Trost’s synthesis of 3.1 also utilized a ruthenium ring-closing metathesis (RCM) to install the
cyclohexene moiety, which prevents olefin isomerization.72 Fortunately, the second stereocenter
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could be controlled via epimerization under alkaline conditions to give the desired enantiomer of
3.1 after deprotection and ring closure of the pyran ring.

Scheme 3.3: Trost’s synthesis of 3.1 utilizing a Mo catalyzed AAA strategy.

Another exquisite approach to 3.1 involved a stereodivergent iridium dual catalyst system
developed by Carreira and co-workers to access all possible stereoisomers of 3.1.73 Carreira’s
catalyst system was able to affect an enantio and diastereoselective α-allylation of aldehyde 3.26
with allylic alcohol 3.25 in the presence of chiral ligands (R)/(S)-L and chiral amines (R)/(S)-A to
fully control the contiguous stereocenters found in 3.1 (Scheme 3.4). The remarkable
transformation outlined in Scheme 3.4 provides a route to the challenging cis-isomers of 3.1 in
either enantiomerically pure form with excellent diastereomeric ratios (drs) (1:15 to 1:20) and
enantiomeric ratios (99:1) and could be performed on a gram scale.74 A drawback to both Trost’s
and Carreira’s approaches is the use of elaborate chiral ligand systems that are not readily available
to most research groups exploring synthetic organic chemistry.
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Scheme 3.4: Carreira's stereodivergent route to 3.1 utilizing an Ir dual catalyst system.

Another noteworthy enantioselective route to 3.1 is that of the Evans’ group who utilized a
chiral Copper-catalyzed Diels-Alder reaction to set a stereocenter at carbon 6a (see Figure 3.2),
which ultimately led to ent-3.1.74 Other Diels-Alder approaches have been utilized to synthesize
racemic (or low enantiopurity) 3.175-76 and 3.3.77-78 The most recent synthesis to date of 3.1, besides
the one disclosed herein, made use of a novel chiral N-heterocyclic carbene (NHC) catalyst.
Coupling of a functionalized cyclobutane with a cinnamic acid fluoride facilitated by an NHC to
provide 3.7, which was isomerized to 3.1 in 13 steps from olivetol.79 Using a NHC-mediated
coupling of a cinnamic acid halide and a functionalized cyclobutane allowed for slight
modification of the cyclohexene moiety and the arene of 3.1 but again was limited by an exotic
NHC catalyst and cylcobutane coupling partners.
In order to completely review the many syntheses of 3.1 that exist, whether enantiopure or
racemic, would require extensive descriptions of obscure synthetic designs, which is beyond the
scope of this discussion. At this point, most noteworthy syntheses of 3.1 have been discussed. It
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comes as a surprise that amongst all syntheses of 3.1, there were only three reports of an
enantioselective synthesis of 3.2 via different routes (not including the route disclosed herein).
Reviewing the known syntheses of 3.2 allows for a reflection on their scarcity and the minimal
synthetic efforts towards analog development.

Scheme 3.5: Enantioselective syntheses of 3.2 that differ from the common Lewis acid coupling routes.

The first synthetic route toward 3.2 was already shown above. Olivetol (3.20) can be
coupled to the same allylic alcohols as discussed in Scheme 3.3 under Lewis acidic conditions,
albeit with shorter reaction times and low temperatures, to obtain 3.2 in 45% yields at best.80 A
more peculiar route to 3.2 involves an alpha arylation of 3,9-dibromocamphor (3.31) with lithiated
olivetol 3.32 followed by ring opening of 3.33 using Na-naphthalenide and reduction of the
carbonyl through the enol phosphate to provide 3.2 in 38% yield (Scheme 3.5, A).81 Another
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interesting approach to access 3.2 utilizes the cuprate of lithiated olivetol 3.36 to achieve a 1,4addition to α-iodoenone 3.35 followed by elimination of the iodide and trapping of the enolate as
an enol phosphate 3.38 (Scheme 3.35, B).82 Nickel-catalyzed coupling with MeMgCl and
deprotection of the methyl aryl ethers afforded 3.2.82
The novel approaches that give rise to 3.2 provide synthetic value and allow access to the
natural product in an enantio and regioselective manner. From an analog development perspective,
route B provides more opportunities by functionalizing the α-iodoenone 3.35 prior to the 1,4addition, however, functional group tolerance may be an issue. Of all the syntheses of 3.1 and 3.2
covered during this discussion and in the literature, most lack modularity, scalability and
practicality – all of which are important for analog development. With the key characteristics of
modularity, scalability and practicality in mind, we sought to develop synthetic methods that would
have strengths in all three.

3.6

Initial synthetic strategy for analog development
To quickly access and evaluate some of the known phytocannabinoids biologically, we

sought a rapid synthesis of 3.1 and 3.2 that might lend itself to further cannabinoid derivatives. As
previously mentioned, one of the drawbacks of using acidic conditions for the direct synthesis of
3.1 or 3.2 is olefin isomerization and lack of control to provide 3.2. An intriguing development
that tackled the isomerization and reactivity control issue had recently been reported by Dethe and
colleagues.68 In the report by Dethe, they suggest that olivetol (3.20) and enantiopure allylic
alcohols (3.17 and 3.18) can be coupled without isomerization by fine-tuning the reaction
conditions to provide 3.1 on >1 gram scales (Scheme 3.6). Careful reaction monitoring and low
catalytic loading of BF3∙OEt2 has also been illustrated to prevent further ring closure to furnish
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3.39-type products in high yields (Scheme 3.6).69 It was hypothesized that the methodology
outlined by Dethe could be used to rapidly synthesize 3.1 and 3.2 as well as a novel analogs for
biological evaluation.

Scheme 3.6: Lewis acid (BF3·OEt2) catalyzed addition of resorcinols and allylic alcohols to give derivatives of
3.1 and 3.2.

3.6.1 Retrosynthetic analysis and initial analog rationale
It has been repeatedly mentioned that many chemical syntheses of cannabinoid analogs
have relied heavily on acid catalyzed couplings of resorcinol derivatives with allylic alcohols
(Scheme 3.3 and 3.7) to give mixtures of 3.1, 3.2 and 3.7. However, many research groups have
adopted the acid-catalyzed coupling methodology for the synthesis of varying aromatic derivatives
of 3.1, which provided enough material for biological evaluation. The lack of regiocontrol yields
mixtures of isomers from one reaction, which could be useful from a medicinal chemistry
standpoint to increase analog output per synthetic step.
It was determined that Lewis acid coupling of resorcinols and allylic alcohols would be a
sufficient platform for analog development. Based on previous work in the field, the aliphatic
appendage found on the cannabinoids aids in its biological activity.83 It is thought that this aliphatic
chain is required for blood-brain barrier permeability and would be a logical place to explore.83 As
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depicted in the retrosynthetic analysis (Scheme 3.7), a variety of resorcinol analogs could be
coupled to known allylic alcohols 3.17 and 3.18 using catalytic amounts of BF3∙OEt2 to rapidly
access a range of cannabinoid analogs such as 3.39 and 3.40.

Scheme 3.7: Retrosynthetic analysis of THC and CBD derivatives using a Lewis acid coupling strategy.

Resorcinol derivatives are easily accessible from commercially available sources in few
synthetic steps or could be purchased directly from chemical vendors. Allylic alcohols 3.17 and
3.18 are derived from inexpensive (+)-limonene using straight-forward literature procedures.68, 71
Using a strategy where inexpensive commercially available or easily accessible coupling partners
containing the desired stereochemistry was enticing. Obtaining intermediates 3.39 and 3.40 where
R = halide or a boronic acid/ester would an advantageous to forge new C-C or C-heteroatom bonds
for analog development (Scheme 3.8). Well-developed palladium chemistry such as SuzukiMiyaura,84 Stille,85-86 or Sonogashira,85 could be performed at the final step of the synthesis to
achieve high analog output.
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Scheme 3.8: Retrosynthetic analysis for late-stage functionalization of 3.1 and 3.2 derivatives.

3.7

Early attempts toward THC and CBD

3.7.1 Lewis acid couplings
To utilize our retrosynthetic analysis for rapid analog development, it was imperative to
reproduce the reported Lewis acid couplings of resorcinols and allylic alcohols. 3.1 and 3.2 were
the first targets to validate the strategy. Commercially available olivetol 3.20 was used as the
resorcinol coupling partner with either allylic alcohol 3.17 or 3.18. Both alcohols were synthesized
from (+)-limonene 3.44 (Scheme 3.9) in a few synthetic steps as reported in the literature.68, 71 3.44
was oxidized via epoxidation (mCPBA) or chromate ester allylic oxidation to give (S)-carvone
(3.45) and 3.46, respectively. Ring opening of epoxide 3.45 using dimethylamine, subsequent
oxidation to the N-oxide and Hoffmann-elimination gave tertiary alcohol 3.18. Conversely,
cyclohexenone 3.46 was reduced using Luche conditions (NaBH4, CeCl3) to give a diastereomeric
mixture of the secondary alcohol 3.17.
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Scheme 3.9: Synthesis of allylic alcohols from (+)-limonene for Lewis acid mediated couplings with
resorcinols.

Alcohols 3.17 and 3.18 were used in Lewis acid mediated couplings with olivetol (3.20) in
attempts to the synthesize 3.1 and 3.2. Using BF3∙OEt2 in 10 mol % or 50 mol % at various reaction
times and temperatures led to complex mixtures. 3.1 and 3.2 could be isolated from the reaction
mixtures after extensive purification in much lower yields than those reported. Since coupling of
3.20 and alcohols 3.17 and 3.18 were successful with respects to synthesizing 3.1 and 3.2, we
attempted the acid-mediated coupling with bromoresorcinol 3.50. The required resorcinol is
accessible from 3,5-dimethoxybromobenzene (3.49) by deprotection with pyridinium
hydrochloride in quantitative yields (Scheme 3.10). To our surprise, an undesirable regioisomer
3.51 (26%) was obtained from the coupling of 3.50 and 3.18 using 10% BF3∙OEt2 at 0 °C, as seen
in Scheme 3.11.
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Scheme 3.10: Lewis acid coupling of bromo resorcinol and allylic alcohols towards bromo derivatives
of 3.1 and 3.2

It has been confirmed in recent syntheses that the regioselectivity of Lewis acid couplings
of resorcinol derivatives can lead to the same undesirable regioisomers as we have observed.87
Corrections have been made to previously reported syntheses of related compounds but there has
yet to be a correction to the seminal paper from which we drew our inspiration. With low yields of
the initial attempts to synthesize 3.1 and 3.2 and the unfortunate regioisomer obtained from the
coupling between allylic alcohols 3.17 and 3.18 and bromoresorcinol 3.50, a new route was
pursued using a more novel approach.

3.7.2 Tandem Mitsunobu-Claisen rearrangement
It was realized that a similar Mitsunobu-Claisen rearrangement as described in Chapter 2
(Scheme 2.5), could be used to yield 3.2 in a two-step process or potentially in one-pot. If an
etherification could be affected between olivetol 3.20 with an appropriate enantiopure tertiary
allylic alcohol 3.18, the aryl allylic ether may undergo a Claisen rearrangement directly to 3.2.
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However, tertiary aryl ethers are difficult to synthesize from alcohols or phenols and typically
cannot be formed by SN2 mechanisms. Stereospecificity in the Mitsunobu reaction is required to
control the stereochemistry of the ether, which will ultimately be translated through the Claisen
rearrangement to the desired stereochemistry found in 3.2. Reports of Mitsunobu reactions
occurring on tertiary alcohols do exist and undergo complete inversion of stereochemistry.88
Although the reports to synthesize tertiary stereocenters via Mitsunobu reactions used modified
conditions to achieve optimized yields >90%, we sought to test our hypothesis using traditional
Mitsunobu conditions with the prospects of optimization at a later stage.
A Mitsunobu reaction was carried out using enantiopure allylic tertiary alcohol 3.18 and
olivetol (3.20) under standard conditions (DIAD, PPh3, THF or toluene, Scheme 3.11). The
reaction was kept at room temperature to avoid the Claisen rearrangement and to assess the
Mitsunobu reaction efficiency. Stirring at room temperature for days and adding excess DIAD,
PPh3 and 3.18 didn’t increase the conversion of 3.20. Heating the reaction at 120 °C in a closed
vessel allowed the reaction to slightly progress and initiated the Claisen rearrangement to give 3.2
in a 15% yield with a few side products that were not identified. We were delighted to access 3.2
through a novel tandem Mitsunobu-Claisen rearrangement, albeit in low yields (15%), that has
potential for reaction optimization to increase the yield and substrate scope.

Scheme 3.11: A Mitsunobu-Claisen rearrangement with 3.20 and allylic alcohol 3.18.
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In attempts to increase the yield and ease of the developed Mitsunobu-Claisen
rearrangement, a one-pot microwave assisted approach was explored using traditional reagents for
the Mitsunobu reaction. It was found that using toluene as the solvent provided marginally better
yields than using THF when heated in the microwave (20% vs. 15% yield). It was also imperative
to start the Mitsunobu at 0 °C and allow it to warm to room before heating in the microwave.
With semi-optimized reaction procedures, 3.2 can be obtained via a one-step protocol by
the assistance of a microwave in a 20% yield. The inversion of stereochemistry from the Mitsunobu
reaction between 3.20 and 3.18 allows for the desired 1,3-chirality transfer to give enantiopure 3.2
following the Claisen rearrangement. Overall, a Mitsunobu-Claisen rearrangement of 3.20 and
3.18 can be performed in sequential steps over 48 hours or a one-pot process in a microwave where
the latter seems to be slightly superior. Even though the rearrangement only provides access to 3.2,
3.1 can be obtained by carefully treating 3.2 with BF3∙OEt2.
The low yields observed can be attributed to the unfavorable Mitsunobu reaction on a
tertiary alcohol. Methods to increase the yields are known in the literature and include using
different phosphines and diazocarboxylates that inherently increase the reactivity of the activated
alcohol center and accelerate the rate of reaction.86 Optimization of the Mitsunobu reaction using
known modifications has yet to be explored but may prove fruitful for this novel one-step
procedure to 3.2.
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Scheme 3.12: Mechanistic rationale for the formation of 3.2 under Mitsunobu conditions. A) the MitsunobuClaisen rearrangement or B) a possible SN2' pathway.

There is a possibility of an alternative reaction mechanism (Scheme 3.12, B) under the
developed Mitsunobu-Claisen reaction conditions that could also provide 3.2. An SN2’ reaction on
the activated tertiary alcohol by the electron rich aromatic ring could allow for a transposition of
the double bond and elimination of triphenylphosphine oxide. However, under normal Mitsunobu
reaction conditions before heating, 3.2 is not detected by TLC or LC-MS. For now, we propose
that aryl ether 3.53 forms under Mitsunobu conditions while heating the reaction facilitates a
Claisen rearrangement to provide 3.2 (Scheme 3.12, A). Full mechanistic study of this reaction is
required to unequivocally prove the proposed Mitsunobu-Claisen rearrangement.
To make use of the developed methodology for analog development, bromoresorcinol 3.50
and alcohol 3.18 were subjected to the same reaction conditions (Scheme 3.13). The
regioselectivity of the reaction was hypothesized to be the same as the Mitsunobu-Claisen
rearrangement observed with 3.20 due to the size of the bromine atom on 3.50 relative to the
aliphatic pentyl chain of 3.20. We were surprised to only observe 3.51 in 10% yield as the sole
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regioisomer. The regioselectivity issues encountered with Lewis acid mediated couplings
mentioned above seemed to have occurred with the alternate reaction pathway as well.

Scheme 3.13: Exploiting the Mitsunobu-Claisen rearrangement with 3.18 and 3.52.

Bromoresorcinol 3.50 could be functionalized to a desired analog prior to the reaction with
hopes that the regioselectivity would be the same as it was with 3.20. The most efficient route to
analog development would have been to introduce diversity through the C-Br bond of 3.52 via
organometallic reactions at the last step of the synthesis. Early-stage modifications increases the
overall number of synthetic steps to access each analog which decreases the overall efficiency of
the synthesis. More importantly, the Mitsunobu-Claisen approach would only allow for quick
functionalization of the aromatic ring the 3.2 and 3.1. In order to probe the western hemisphere of
the cannabinoids, new chiral allylic alcohols like 3.18 would need to be prepared, which may not
be trivial. To introduce greater diversity within the cannabinoid scaffold, we set out to develop a
practical and more modular approach towards the cannabinoids with 3.1 and 3.2 as our initial
synthetic targets.
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3.8

A practical and modular route toward the cannabinoids

Scheme 3.14: Retrosynthetic analysis for a convergent and modular enantioselective synthesis of 3.1 and 3.2.

To develop a practical and modular approach to the cannabinoids, it was important to make
appropriate disconnections that result in a convergence of two austere units that can be modified
in the simplest sense. Modularity was not the only important consideration when developing our
approach; enantioselectivity was also a key requirement for this. The two contiguous stereocenters
found in the cannabinoids 3.1 and 3.2 could be controlled via an Ireland-Claisen rearrangement of
an appropriate chiral allylic ester 3.57 (Scheme 3.14). The Ireland-Claisen rearrangement is a
powerful [3,3] sigmatropic rearrangement that transfers the chirality of an allylic ester to the α and
β carbons through a chair or boat-like transition state for acyclic and cyclic esters, respectfully, as
discussed in Chapter 2.89-90 We envisioned that both 3.1 and 3.2 could be accessible via the post
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Ireland-Claisen rearrangement carboxylic acid 3.56, serving as the common intermediate.
Diverging from 3.56, the carboxylic acid provides a useful synthon that could be converted into
an ester or ketone which followed by an RCM would install the northern hemisphere of the
cannabinoids (Figure 3.4). The resulting cyclohexene originating from the esterification of 3.56
could be quickly converted to 3.1 while the ketone derived from 3.56 could provide 3.2 (Scheme
3.14).

Figure 3.4: Regions of 3.1 and 3.2 capable of modification using the disclosed synthetic route.

The esterification event of functionalized carboxylic acid 3.58 and allylic alcohol 3.59 is
where our route converges (Scheme 3.14), providing modularity for future analog development.
One could envision introducing chemical diversity throughout the northern hemisphere of 3.1 and
3.2 by functionalizing carbons 3, 4 and 6 of the carboxylic acid coupling partners 3.58 (Scheme
3.14). On the other hand, the aromatic ring of alcohol 3.59 could be modified prior to the
esterification giving rise to arene analogs. Our newly proposed route can also introduce diversity
in the southern hemisphere of the tetrahydropyran ring system (the location of the geminal
dimethyl group, Figure 3.4) for analogs of 3.1 via Grignard additions. Conversely, the propenyl
group within the southern hemisphere of 3.2 could be modified prior to the RCM by generating a
variety of ketones and olefins. Having the ability to functionalize at least four unique sites of the
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cannabinoids makes our new approach more suitable for analog development compared to
previously reported routes.

3.8.1 Ireland-Claisen rearrangement: controlling the cannabinoid stereochemistry
One of the hallmarks of our new approach is the use of an Ireland-Claisen rearrangement
to set both stereocenters found in the cannabinoids. The trans-tetrahydropyran system of 3.1 had
been envisioned to arise from an Ireland-Claisen rearrangement between an (E)-allylic ester that
can be deprotonated under kinetic conditions to give an (E)-enolate. Once the enolate forms, it can
be trapped as a silyl ketene acetal (SKA) which typically undergoes rearrangement under thermal
conditions. With control of olefin and enolate geometry, the relative stereochemistry of the
rearrangement can be predicted using a six-membered chair-like transition state.91 To test our
hypothesis, we developed a model system (Scheme 3.15) using an appropriate cinnamyl ester 3.62
that can undergo an Ireland-Claisen rearrangement followed by RCM to provide a trans-substituted
cyclohexene 3.64.

Scheme 3.15: An Ireland-Claisen rearrangement model for 3.1 and 3.2.
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Cinnamyl alcohol 3.61 contained the desired (E)-olefin geometry which was coupled to
carboxylic acid 3.58, derived from diethylmalonate and 3-methyl-3-butenol,92 under Steglich
conditions to give cinnamyl ester 3.62. A variety of Ireland-Claisen conditions were attempted to
rearrange the cinnamyl ester. It was found that KHMDS in toluene followed by trapping with
TMS-Cl/pyridine or TMS-Cl/Et3N provided the highest yields (>72 %) of what is believed to be
the desired diastereomer. In order to maintain high yields and high diastereoselectivity for the
rearrangement, anhydrous solvent and reagents were required. We were pleased to observe a single
diastereomer in good yields from the Ireland-Claisen rearrangement; however, it was still unclear
whether we had obtained the correct diastereomer.
The post Ireland-Claisen product was esterified to methyl ester 3.63 and subjected to an
RCM using Grubbs’ 2nd generation catalyst to give cyclohexene 3.64. Since none of the
intermediates obtained provided crystalline material for an X-ray crystal structure, we turned to
NMR for structural elucidation of 3.64. The 1H NMR spectra provided good resolution of Ha’s
neighboring protons. A splitting pattern of a doublet of doublets of doublets (ddd) was observed
for Ha (ddd, J = 11.1, 9.2, 3.1 Hz) which agreed with the three neighboring protons (Figure 3.5).
With further investigation of the coupling constants associated with Ha, it was clear that two of
the three neighboring protons had a trans-relationship with respect to Ha (two of the three signals
having greater coupling constants, Hz). A similar structure of 3.64 has been previously reported
with nearly identical coupling constants.93

156

Figure 3.5: Structural analysis of 3.68 using 1H NMR. The chair structures show a typical anti-relationship
while the half-chair is incapable of forming complete anti-conformations.

It is thought that the 9.2 Hz coupling constant observed in the 1H NMR corresponds with
the coupling between Ha and Hb. A 2D-NOE NMR experiment was also performed on 3.64 to
further support our hypothesis. If Ha and Hb were trans to one another, it was thought that a signal
corresponding to Ha and Hb coupling would not be observed in the NOE NMR spectra.
Interestingly, the 2D-NOE provided a weak coupling signal between Ha and Hb, which can be
attributed to the half-chair nature of the cyclohexene (Figure 3.5) where the two protons (Ha and
Hb) are unable to adopt a complete anti-conformation. Given the initial analysis of the 1H NMR
spectra where two of the three coupling constants observed were large (J = 11.1 and 9.2 Hz), we
were confident that 3.64 was the desired diastereomer and decided to proceed with the synthesis
of 3.1 and 3.2.

157

3.8.2 Syringaldehyde as a precursor to the cannabinoids
Equipped with a method to set the two contiguous stereocenters of the cannabinoids via
Ireland-Claisen rearrangement, the requisite chiral allylic alcohol became our priority. Controlling
the chirality of alcohol 3.59 could be accomplished by a variety of well-established methods;
however, it was important to maintain a versatile handle at the aliphatic chain region of the
cannabinoids for further analog development. Syringaldehyde (3.60) was chosen as an inexpensive
starting material that could serve as a suitable and flexible starting point for the overall synthesis
of the cannabinoids and their analogs. The aldehyde of 3.60 could provide a surrogate to the pentyl
chain, as well as novel modifications to the cannabinoid scaffold, while the phenol lends itself to
a triflate that introduces a unique platform for cross-coupling reactions to install the allylic moiety
of 3.59.
For the synthesis of 3.1 and 3.2, syringaldehyde was subjected to a Wittig olefination
(Scheme 3.16) using Wittig reagent 3.65 derived from 1-bromobutane and triphenylphosphine.
There have been reports of protic functional groups undergoing Wittig reactions under mild and
aqueous conditions or in the presence of protic solvents.94 Despite the mild Wittig conditions
within the literature, we found that the reaction proceeded smoothly and in the highest yields using
an excess amount of NaHMDS to give olefin 3.66, which was hydrogenated to give phenol 3.67
in 81% yield over two steps. Triflation of phenol 3.67 to generate triflate 3.68 set the stage for
palladium couplings to give rise to enone 3.71 via Heck-reaction of methyl vinyl ketone 3.69, or
to the desired allylic alcohol directly using a chiral allylic alcohol 3.70 (Scheme 3.16).
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Scheme 3.16: Palladium coupling approach towards chiral allylic alcohol 3.59.

Triflate 3.68 was subjected to a wide variety of Heck-coupling conditions using various Pd
catalytic systems and coupling partners such as methyl vinyl ketone, methyl acrylate and allyl
alcohol with little to no avail. Other Pd cross-coupling reactions such as the Sonogashira, Stille
and Suzuki reactions were attempted to forge a new carbon-carbon bond with the aryl triflate 3.68,
none of which were successful. It was thought that the electron rich aryl ring 3.68 retards the
oxidative addition of Pd into the aryl-OTf bond, halting the catalytic cycle at the first step.
Catalysts with electron rich phosphines such as dppf and alkyl phosphines that increase the rate of
oxidative addition95 also proved unfruitful in the Heck-coupling as well as other Pd couplings.
After exhaustive efforts to form a new C-C bond with triflate 3.68 that would be useful
towards the synthesis of the desired chiral allylic alcohol 3.59, syringaldehyde 3.60 was deemed
unsuitable due to its inherent electronic properties. A new route was undertaken that would allow
for the synthesis of α-β unsaturated ketone 3.71 via an adopted method reported by Trost and
colleagues.72 A variety of asymmetric reductions could be applied to enone 3.71 as an alternative
route to the target allylic alcohol 3.59.
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3.8.3 Synthesis of an advanced chiral intermediate from olivetol
Our novel approach towards a chiral intermediate for the synthesis of 3.1 and 3.2 was
thwarted by an unsuccessful Pd cross-coupling reaction of triflate 3.68 derived from
syringaldehyde. Fortunately, an alternative approach starting from commercially available olivetol
had been realized to obtain 3.71. It was envisioned that a chiral 1,2-reduction would be able to set
the desired (S)-enantiomer of 3.59. Many chiral reductions exist using transition metal catalysis
with chiral ligands, such as the Ru-catalyzed Noyori reduction, which has proven useful in
pharmaceutical development in recent years.96 Before relying on organometallic chemistry again,
we explored a more conventional approach using commercial chiral borane reducing agents such
as oxazaborolidine (CBS ligand) or diisopinocamphenylborane chloride (DIP-Cl).

Scheme 3.17: Synthesis of chiral secondary allylic alcohol 3.59 via CBS reduction.

To begin, our new strategy took flight with the protection of olivetol as the
bis(methoxy)aryl ether 3.72 by treatment with dimethylsulfate and K2CO3 in nearly quantitative
yield (Scheme 3.17). Formylation of 3.72 by ortho-lithiation and quenching with DMF gave
aldehyde 3.73 which was subjected to an aldol condensation with acetone to provide (E)-enone
3.71 in 72% yield over two-steps. With enone 3.71 in hand, a chiral reduction was employed to set
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the desired secondary alcohol stereocenter. After screening a variety of reaction conditions using
(+)-DIP-Cl or (-)-CBS/BH3 reductive conditions, the CBS reduction proved superior and provided
3.59 in excellent yield and modest enantioselectivity (77% ee) (Scheme 3.17).
It was essential to use anhydrous toluene at -78 °C and an alkaline work-up with aqueous
NaOH to obtain high yields and >75% ee for the CBS reduction. Quenching the reaction under
neutral or acidic conditions appeared to have isomerized the desired secondary stereocenter to the
benzylic alcohol 3.75 as seen in Scheme 3.17. Under acidic conditions, alcohol 3.59 can be
protonated and eliminated to form a carbocation intermediate that is stabilized by the electron rich
conjugated system of 3.59.2. The mechanistic rationale also explains the drop in % ee when the
reaction was quenched and worked up using aqueous acidic conditions.

Scheme 3.18: Mechanistic rationale for the isomerization of 3.59 in the presence of acid.

3.8.4 Accessing a common intermediate for the synthesis of THC and CBD
With access to enantioenriched allylic alcohol 3.59, we set our eyes on the Ireland-Claisen
rearrangement of chiral allylic ester 3.57 to set both stereocenters of 3.1 and 3.2. To access the
requisite allylic ester 3.57, enantiopure alcohol 3.59 was coupled to the previously synthesized
carboxylic acid 3.58 via Steglich coupling (Scheme 3.19) as previously mentioned in our model
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system. It was earlier hypothesized that the (S)-enantiomer of the desired allylic ester 3.57 would
undergo the rearrangement to give carboxylic acid 3.56. The stereochemistry of 3.56 could be
translated to that of 3.1 and 3.2. Using the chair-like transition-state model for acyclic IrelandClaisen rearrangements as seen in Scheme 3.19, the diastereoselectivity of the rearrangement can
be predicted as in our model system.
Under kinetic chelation conditions, deprotonation of esters favors the (E)-enolate which
can be trapped as the (E)-silyl ketene acetal 3.57.1. With both olefin geometries set, the
rearrangement proceeds upon warming to room temperature, which is a departure from what was
required with the less sterically congested model system, setting the subsequent stereocenters
shown in Scheme 3.19. Our initial model outlined the diastereoselectivity of the rearrangement
and we anticipated it would give the desired diastereomer of 3.56 based on the initial data. In fact,
upon treating ester 3.57 with the optimized reaction conditions outlined above, the Ireland-Claisen
rearrangement went smoothly to give carboxylic acid 3.56 in 77% yield. We were delighted to
obtain 3.56 as a crystalline solid that could be recrystallized to 94% ee in 52% overall yield.

Scheme 3.19: A chair-like transition state model for the Ireland-Claisen rearrangement of ester 3.57.
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An X-ray crystal structure was obtained that unequivocally proved the correct diastereomer
was obtained from the Ireland-Claisen rearrangement (Figure 3.6). The trans-relationship between
the α and β hydrogens of the carboxylic acid in 3.56 can be clearly seen in Figure 3.6. Even though
we were blessed by a crystalline material that could be recrystallized to achieve high enantiopurity
of 94% ee, there was room for improvement in this route to increase practicality, efficiency and
enantioselectivity. An alternative approach that would avoid the use of chiral boranes and
recrystallizations to obtain high enantiopurity was pursued using an enzymatic kinetic resolution
(EKR) to complete the synthesis of 3.1 and 3.2.

Figure 3.6: X-ray crystal structure of 3.56 that defines the stereochemistry.
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3.8.5 Enzymatic kinetic resolutions
Enzymatic resolutions were essential in the enantioselective synthesis of membranolide
(Chapter 2) by resolving the stereocenter of the secondary allylic alcohol isophorol 2.27. An EKR
strategy was thought to be applicable to the synthesis of the cannabinoids by resolving racemic
secondary allylic alcohol 3.59 by an enantioselective esterification event (Scheme 3.20). Although
an EKR can provide enantiopure products, the overall yields cannot exceed 50%. However, if the
enzyme is inexpensive and efficient enough, the utility of this methodology may be more practical
than relying on chiral borane reducing reagents – especially on larger scales for future analog
development. Another highlight of using an enzymatic resolution is that it gives access to both
enantiomers in enantiopure forms that could be used to synthesize ent-3.1 and ent-3.2.

Scheme 3.20: An enzymatic resolution strategy to access enantiopure 3.59

An enzyme screening campaign was carried out to identify an appropriate enzyme and acyl
donor combination that gives high enantioselectivity while also meeting our criteria of being
inexpensive and scalable. Amongst the enzymes screened were Amano Lipase PS (Burkholderia
cepacia), Subtilisin protease (Bacillus licheniformis), Lipozyme® TL IM lipase (Thermomyces
lanuginosus), Alcalase ® 2.5L endopeptidase (Bacillus licheniformis), and Savinase 12T protease
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(Bacillus licheniformis). These commercially available enzymes are known for their ability to
either stereoselectively esterify alcohols in the presence of an acyl donor or stereoselectively
cleave esters to give enantiopure esters and alcohols. Most of the enzymes were purchased as
immobilized formulations that were known to be resistant to organic solvents.
Reaction screening preceded using racemic allylic alcohol 3.59 with different solvents,
bases and acyl donors (Scheme 3.20). It was quickly realized that Amano Lipase PS and Savinase
12T were the only enzymes that were capable of the esterification with any appreciable yield or
stereoselectivity. Savinase 12T was found to esterify the (S)-enantiomer of 3.59 while Amano
Lipase PS esterified the (R)-enantiomer. By using Amano Lipase PS, the desired (S)-enantiomer
of 3.59 could be obtained due to the selective nature of the enzyme. In attempts to optimize the
reaction conditions using Amano Lipase PS, we were unable to achieve high yields or enantiomeric
excess (best attempts were roughly 30% yield and 80% ee).
We then turned toward Savinase 12T to optimize the kinetic resolution of 3.59. The
stereoselectivity of Savinase 12T was more notable than all other enzymes screened, however, a
cleavage step would be required after purification of the enzymatic resolution in order to obtain
3.59 in enantiopure form. Several solvents, bases and acyl donors were used to optimize the yield
and stereoselectivity of the resolution. The optimal conditions were to use THF as the solvent,
Et3N as a base to facilitate the reaction and vinyl butyrate as the acyl donor (Scheme 3.21). The
resulting butyrate ester 3.78 was saponified with NaOH in EtOH to give 3.59 in 41% yield and
>98% ee over two steps. It should be noted that (R)-3.59 was also obtained in high enantiopurity
(93-95% ee) and could be used for the synthesis of ent-3.1 and ent-3.2.
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Scheme 3.21: Enzymatic kinetic resolution of (±)-3.59 using Savinase 12T.

After the optimized reaction conditions had been determined for the EKR of 3.59, we
discovered that the enzymatic resolution was amenable to scale (>10 g scales) to reliably provide
3.59 in 98% ee. The ability of Savinase12T to esterify the desired enantiomer of 3.59 could be
exploited to resolve 3.59 and perform the next esterification event with an appropriate acyl donor.
Directly accessing 3.57 from the EKR could cut down on two synthetic operations and provide
3.57 in high enantiopurity. To determine if Savinase12T was able perform an EKR to 3.57,
activated esters of carboxylic acid 3.58 were synthesized and evaluated (Scheme 3.22). Racemic
alcohol 3.59 was treated with the optimized resolution conditions in the presence of acyl donors
3.79-81. Savinase 12T was able to esterify and resolve racemic 3.59 to give the desired ester 3.57
in excellent ee and good yields (relative to the theoretical 50% yield).
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Scheme 3.22: Enzymatic kinetic resolution (±)-3.59 with acyl donors of 3.58.

The EKR of 3.59 with acyl donors of 3.58 could be accompanied with a caveat that excess
acyl donor (>2 equivalents) is required to achieve high conversions. Purifications of the EKR
reaction mixtures were troublesome when attempting to recover (R)-3.59 when using 4chlorophenol and 4-methoxyphenol activated esters (3.80 and 3.81) due to co-elution of the phenol
by-product with (R)-3.59. The use of trifluoroethanol activated ester (3.79) was slightly superior
to the phenol variants and allowed for easier purifications. Unfortunately, carboxylic acid 3.58 is
a valuable intermediate that requires considerable effort, reagents and solvents to obtain in four
synthetic steps from diethylmalonate. Therefore, it becomes impractical to synthesize the activated
esters to ultimately waste an entire equivalent or more in the EKR. From practical and scalable
senses, which are two main requirements of the hallmarks for our synthesis, using acyl donors of
3.58 was less efficient than using commercially available vinyl butyrate 3.77.
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3.8.6 Completion of an enantioselective synthesis of Δ9-THC and CBD
With an efficient route that allows access to ample amounts of chiral precursors in >98%
ee, we were able to complete the synthesis of 3.1 and 3.2 from common intermediate 3.56. As seen
in Scheme 3.23, our route diverges at this stage, giving rise to both 3.1 and 3.2. For the synthesis
of 3.1, carboxylic acid 3.56 was esterified to the methyl ester 3.54 and subjected to an RCM using
Grubbs’ 2nd generation catalyst to provide cyclohexene 3.82 in 85% yield over two steps. In a two
pot, three transformation protocol adopted by Carreira and colleagues,73 cyclohexene 3.82 was
treated with excess MeMgI at 0 °C followed by evaporation of the solvent under vacuum then
heating to 160 °C. As a result of treating 3.82 with excess MeMgI, a double Grignard addition to
the methyl ester and bis-deprotection of the methyl aryl ethers gave access to a deprotected tertiary
alcohol intermediate that was used without further purification. The crude mixture was subjected
to mild Lewis acid conditions (ZnBr2) in the presence of a desiccant (MgSO4) to close the
tetrahydropyran ring and provide 3.1 in 57% yield over three transformations.
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Scheme 3.23: The final synthetic steps toward 3.1 and 3.2 diverging from common intermediate 3.56.

Conversely, carboxylic acid 3.56 was treated with MeLi to give ketone intermediate 3.59
(retrosynthesis Scheme 3.15, pg. 152) that was subjected to an RCM to obtain cyclohexene 3.83
in 50% yield over two steps (Scheme 3.23). A Wittig olefination using MePPh3Br in the presence
of KOtBu followed by bis-deprotection of the methyl aryl ethers using excess MeMgI afforded 3.2
in 51% yield over the two steps. Both synthesized 3.1 and 3.2 agreed with the reported specific
rotations and NMR spectra in the literature (see Appendix).
We have now developed a practical and enantioselective synthesis of the cannabinoid core
that is amenable to scale and can provide access to novel analogs that were not available by earlier
routes. Our approach utilized an inexpensive EKR that gives rise to synthetic intermediates with
high enantiopurity of either enantiomer. Having access to both enantiomers, our synthetic
methodology could allow for the synthesis of ent-cannabinoid analogs for future biological
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evaluation and direct comparison to determine the importance of chirality within the cannabinoid
family. More importantly, our developed approach is one of the most modular syntheses towards
the cannabinoids, allowing for functionalization of the northern and southern hemispheres as well
as the aliphatic chain region. We are currently pursuing novel analog development using our
synthetic methods for further biological evaluation and our progress is discussed below.

3.9

Progress toward analog development
Our interest in the cannabinoids stems from the intriguing biological activity of

endocannabinoids and phytocannabinoids against N. fowleri. Pioneering work by Cao and
colleagues at the USF Byrd Alzheimer’s Institute has shown that cannabinoids such as 3.1 and 3.2
may be involved with amyloid plaque degradation in Alzheimer’s mice models.97 The exciting
discovery that 3.1 and 3.2 may prove to be therapeutically useful in Alzheimer’s has further
motivated us. Not only can the outlined synthetic methodology be used to produce analogs
inaccessible by traditional routes, it can be used as a platform to develop chemical probes for
further investigation in biological systems that interact with the cannabinoids.
One of the main priorities was to develop an intermediate capable of late stage
modifications for rapid analog development. The first site of interest, as mentioned previously, is
the aliphatic chain region of the cannabinoids. A late stage C-H activation strategy was envisioned
to install a boronic ester meta to the phenols found in the cannabinoid core (location of the aliphatic
chain region). This boronic ester could be used directly in Suzuki couplings or converted into a
halide for use in a variety of transition metal catalyzed C-C or C-N/O/S bond forming reactions
(Stille, Sonogashira, Ullman, Buchwald-Hartwig, etc.) for late stage derivatization.84, 98-100
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Figure 3.7: Future cannabinoid analogs for biological evaluation and chemical probes to determine unknown
targets of the cannabinoids.

Another point of interest for cannabinoid analog development is the northern hemisphere.
Unfortunately, 3.1 is not thermally stable and is prone to isomerization and oxidation. In fact, 3.1
is not bench stable and undergoes oxidative aromatization under ambient conditions in the
presence of oxygen and UV light to CBN.101 We hypothesize that by extending or contracting the
cyclohexene ring to 7 or 5 membered carbocycles (3.86.1-2, Figure 3.7) oxidative aromatization
could be prevented. A bench stable analog of 3.1 would be more suitable as a commercial
therapeutic if bioactivity is maintained.
One of the more exciting prospects we are interested in is the development of chemical
probes for mechanism of action elucidation and new target discovery of the cannabinoids. Our
proposed late stage boronic ester or halide intermediate 3.84.1-2 could be used to incorporate a
biotinylated linker or fluorescent probe (Figure 3.7) that can be further used as a chemical biology
tool for mechanistic investigations in N. fowleri assays or Alzheimer’s models. The same late-stage
intermediate could also be used to introduce a photolabile diazirine for further biological target
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identification as well as aid in mechanistic understanding in biological systems and cannabinoid
pharmacology. 102-104

3.9.1 Late stage meta-borylation: access to an invaluable intermediate
Recent synthetic methods have been developed that allow for meta-borylation of aromatic
rings bearing directing groups through a C-H activation strategy using iridium catalytic
systems.105-106 Hartwig is one of the pioneers in this field and has showcased the applicability of
this transformation in late-stage syntheses.91 One of the known directing groups are methyl aryl
ethers, which are present in late-stage intermediates of our synthesis. To synthesize an intermediate
capable of undergoing late-stage meta-borylation via iridium catalysis, we envisioned beginning
our synthesis with inexpensive 1,3-dimethoxybenzene (3.89) to afford late-stage cannabinoid
intermediates capable of undergoing C-H meta-borylation.

Scheme 3.24: Synthesis towards a late-stage intermediate for meta-borylation.

Slight modifications of our route were used to access the target intermediate resulting in
more straightforward procedures with less purification. Departure towards our late-stage

172

intermediate began with 1,3-dimethoxybenzene (3.89) which was formylated via ortho-lithiation
with a DMF quench followed by an aldol condensation to give enone 3.90 in high yields without
the use of column chromatography (Scheme 3.24). Reduction of enone 3.90 with NaBH4 provided
racemic allylic alcohol 3.91 which was successfully resolved using our EKR methodology. Nearly
identical yields and enantiopurity were obtained, further outlining the utility of this method.
Enantiopure alcohol 3.92 was coupled to carboxylic acid 3.58 to give ester 3.93 that underwent an
Ireland-Claisen rearrangement uneventfully in comparable yields and diastereoselectivity to give
the carboxylic acid intermediate that was immediately esterified to ester 3.94.
To determine if our late-stage intermediates were capable of the proposed meta-borylation
strategy, ester 3.94 was subjected to an RCM to give cyclohexene derivative 3.95 (Scheme 3.25).
A meta-borylation could be carried out on 3.95 or at a later stage as seen in Scheme 3.25. The CH meta-borylation methodology is known to have good functional group tolerance when using the
correct catalytic system; however, it wasn’t clear that the reaction conditions would isomerize the
olefin in the closed tetrahydropyran intermediate 3.97.
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Scheme 3.25: Late-stage meta-borylation of 3.95 and future routes for analog development.

It was decided to investigate the C-H meta-borylation chemistry using cyclohexene 3.95
before further advancing the synthesis to a later stage intermediate. We were absolutely delighted
to achieve the borylation in near quantitative yields (98%) to provide boronic ester 3.96 (Scheme
3.25). To our knowledge, this is the first boronic ester/acid of a cannabinoid analog capable of late
stage derivatization. It should be noted that meta-halogenation can also be achieved using the same
methodology in the presence of copper (I) halide salts,105 giving rise to invaluable intermediates.

3.10

Conclusion and future direction
An enantioselective synthesis of 3.1 and 3.2 has been achieved using a practical, scalable

and modular route. Utilizing what is now thought of as “classical” chemistry along with modern
methods, we were able to control the contiguous stereocenters using a “classical,” yet reliable,
Ireland-Claisen rearrangement and modern transition metal chemistry to further advance the
synthesis. An inexpensive and efficient kinetic enzymatic resolution has been developed, giving
rise to enantiopure intermediates capable of accessing both enantiomers of the cannabinoids.
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Evidence exists that our optimized Ireland-Claisen rearrangement could be used under nonchelation controlled enolate formation, in the presence HMPA, ultimately resulting in the
diastereomers of the cannabinoids.107 Modification of the diastereoselectivity by the use of HMPA
makes our synthesis formally stereodivergent in the sense that both enantiomers and diastereomers
of 3.1 and 3.2 are accessible, depending on the enantiomers and reaction conditions used.
The power of the developed methodology has been outlined using an inexpensive starting
material, 1,3-dimethoxybenzene (3.89) giving rise to a late-stage intermediate capable of rapid
analog development. Countless analogs can stem from our synthesis, encompassing nearly all
hemispheres of the cannabinoids. Our lab is currently exploring a variety of analogs throughout
the cannabinoid core with a focus at the aliphatic chain region through the penultimate boronic
ester 3.96. Analogs obtained utilizing our synthetic methods will be used for further biological
evaluation in N. fowleri and Alzheimer’s models and can be extended to other therapeutic areas of
the cannabinoids. Biological probes are now attainable via this route and will be reported on in
due course. The synthetic work regarding the cannabinoids within this dissertation has laid the
foundation for further scientific advancement and understanding in the cannabinoid realm.
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3.12

Chapter 3: Experimental procedures

In a 30 mL microwave vial equipped with a stir bar was added 3.18 (0.202 g, 0.111 mmol) and
PPh3 (0.319 g, 1.22 mmol) in toluene (4 mL) at 0 °C. DIAD (0.237 mL, 0.246 g, 1.22 mmol) was
added dropwise to the stirring reaction mixture. The reaction stirred for 2 minutes before a solution
of 3.18 (0.158 mL, 0.985 mmol) in toluene (2 mL) was added dropwise. The reaction stirred for 5
minutes at 0 °C before warming to room temperature. Once at room temperature, the reaction was
placed in a microwave reactor and heated to 120 °C (800 W) for 3 hours. At which time the solvent
was removed under reduced pressure to give a crude oil that was purified by silica gel column
chromatography using hexanes/EtOAc (12:1) to give 3.21 (0.062 g, 0.197 mmol, 20% yield) as a
light-yellow oil. 1H NMR (500 MHz, CDCl3): δ 6.27 (br s, 1H), 6.17 (br s, 1H), 5.97 (br s, 1H),
5.57 (br s, 1H), 4.66 (s, 1H), 4.60-4.72 (m, 1H), 4.56 (s, 1H), 3.82-3.88 (m, 1H), 2.40-2.46 (m,
2H), 2.38 (dd, J = 10.8, 3.1 Hz, 1H), 2.18-2.28 (m, 1H), 2.05-2.13 (m, 1H), 1.79 (s, 5H), 1.65 (s,
3H), 1.52-1.56 (m, 2H), 1.23-1.37 (m, 4H), 0.87 (t, J = 7.0 Hz, 3H) ppm. 13C NMR (126 MHz,
CDCl3): δ 149.4, 143.0, 140.0, 124.1, 113.7, 110.8, 109.7, 107.9, 46.1, 37.2, 35.5, 31.5, 30.6, 30.4,
28.4, 23.7, 22.5, 20.5, 14.0 ppm.
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In a 250 mL round-bottomed flask was pyridin-1-ium chloride (19.9 g, 173 mmol) and 1-bromo3,5-dimethoxybenzene 3.49 (5.02 g, 23.1 mmol). The reaction vessel was capped with a vacuum
adapter and the solid mixture was heated to 210 °C for 4 hours (vented under a house vacuum). At
which time the reaction was complete (TLC). The molten mixture was carefully poured into 50
mL of water and extracted with EtOAc (3 x 75 mL), washed with water (40 mL) and brine (2 x 30
mL). The resulting organic layer was dried over Na2SO4, filtered and concentrated to give 3.502
(4.31 g, 22.8 mmol, 99% yield) as a white solid that was used without further purification. 1H
NMR (400 MHz, CDCl3) δ 6.57 (d, J = 2.05 Hz, 2H), 6.26 (t, J = 2.05 Hz, 1H), 4.88 (s, 2H) ppm.

In a 30 mL microwave vial equipped with a stir bar was added PPh3 (0.827 g, 3.15 mmol) and 3.50
(0.497 g, 2.63 mmol) in toluene (5 mL) at 0 °C. A solution of DIAD (0.613 mL, 3.15 mmol) and
3.18 (0.422 mL, 2.63 mmol) in toluene (5 mL) was added dropwise. The reaction mixture stirred
at 0 °C for 15 min before warming to room temperature where it stirred for 1 hour. The reaction
vial was placed in a microwave reactor and heated to 120 °C (800 W) for two hours. Further
heating results in an increase of by-products and inseparable mixtures. The solvent was removed
under reduced pressure the crude reaction mixture was purified by column chromatography using

184

hexanes/EtOAc (15:1-6:1) to give 3.51 (0.087 g, 0.269 mmol, 10% yield) as a light-yellow oil. 1H
NMR (500 MHz, CDCl3): δ 6.62 (d, J = 2.6 Hz, 1H), 6.31 (d, J = 2.6 Hz, 1H), 6.27 (s, 1H), 5.55
(br s, 1H), 5.11 (br s, 1H), 4.62 (s, 1H), 4.37 (s, 1H), 3.93-4.00 (m, 1H), 2.49 (td, J = 10.5, 3.9 Hz,
1H), 2.17-2.26 (m, 1H), 2.06-2.13 (m, 1H), 1.77-1.84 (m, 5H), 1.70 (s, 3H) ppm.

In a 500 mL round-bottomed flask equipped with a stir bar was added 3.58-1 (11.7 mL, 116 mmol)
in dry DCM (200 mL) to give a clear colorless solution. NEt3 (17.7 mL, 128 mmol) was added and
the solution was cooled to 0 °C. Methanesulfonyl chloride (MsCl) (9.96 mL, 128 mmol) was added
dropwise over 5 min then stirred for 1 h at 0 °C. The reaction mixture was diluted with DCM (200
mL), washed with 1 N aqueous HCl (200 mL), satd. aqueous NaHCO3 (250 mL) and brine (200
mL). The combined organic layer was dried over Na2SO4, filtered, and the solvent was removed
under reduced pressure to give 3.58-23 as an orange-yellow oil that was used in the next step
without further purification.

In a 1 L round-bottomed flask equipped with a stir bar was added NaH (7.11 g, 178 mmol, 60%
wt) and NaI (2.41 g, 16.1 mmol) in THF (334 mL) at 0 °C. Diethyl malonate 3.58-3 (24.6 mL, 161
mmol) was added dropwise and the reaction was heated to reflux for 30 min before 3.58-2 (31.8
g, 194 mmol) was added dropwise over 10 min. The resulting reaction mixture was heated for 16
h at 85 °C. Once complete (TLC), the reaction mixture was cooled to room temperature and
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quenched with satd. aq. NH4Cl (600 mL). The mixture was extracted with EtOAc (3 x 300 mL),
washed with brine (400 mL), dried over Na2SO4, filtered, and concentrated to give a yellow oil.
The crude was purified by silica gel column chromatography using hexanes/EtOAc (19:1) to afford
3.58-43 (34.4 g, 151 mmol, 93% yield). 1H NMR (400 MHz, CDCl3):  4.73 (s, 1 H), 4.67 (s, 1
H), 4.17 (q, J = 7.0 Hz, 4 H), 3.27 - 3.34 (m, 1 H), 2.00 - 2.05 (m, 4 H), 1.69 (s, 3 H), 1.24 ppm
(t, J = 7.0 Hz, 6 H) 13C NMR (101 MHz, CDCl3):  169.4, 144.0, 111.1, 61.2, 51.3, 35.2, 26.6,
22.1, 14.0 ppm.

In a 250 mL round-bottomed flask equipped with a stir bar was added 3.58-4 (9.92 g, 43.4 mmol)
in a mixture of water and methanol (1:1, 100 mL). Lithium hydroxide monohydrate (9.11 g, 217
mmol) was added and the mixture was heated to 95 °C for 5 h. The reaction mixture was cooled
to room temperature and then diluted with 100 mL of water, acidified with concentrated HCl to a
pH of 1 and the aqueous layer was extracted with dichloromethane (4 x 100 mL). The combined
organic layers were dried over Na2SO4, filtered, and the solvent evaporated. The product 3.58-53
was obtained as a white solid which was used without further purification or characterization.

In a 25 mL round-bottomed flask equipped with a stir bar 3.58-5 (2.25 g, 12.8 mmol) in pyridine
(5.29 mL) and water (0.265 mL). The mixture was heated to reflux for 14 h then cooled to room
temperature. Once cool, pyridine was removed under reduced pressure and the residue was
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dissolved in 20 mL of water and acidified with conc. HCl to a pH of 1. The aqueous solution was
extracted with DCM (3 x 40 mL), dried over Na2SO4, filtered, and the solvent removed under
reduced pressure to give a yellow-orange oil. The crude product was purified by silica gel column
chromatography using hexanes/EtOAc (30:1 to 1:1) to afford 3.583 (1.32 g, 10.2 mmol, 79% yield)
as clear light-yellow oil. 1H NMR (400 MHz, CDCl3):  11.06 - 12.19 (m, 1 H), 4.73 (s, 1 H), 4.68
(d, J = 0.8 Hz, 1 H), 2.34 (t, J = 7.4 Hz, 2 H), 2.05 (t, J = 7.4 Hz, 2 H), 1.77 (app. quin, J = 7.5
Hz, 2 H), 1.70 (s, 3 H) ppm. 13C NMR (101 MHz, CDCl3):  180.4, 144.5, 110.7, 36.9, 33.4, 22.4,
22.1 ppm. 9

In a 250 mL round-bottomed flask equipped with a stir bar was added 3.58 (2.65 mg, 20.7 mmol)
in DCM (83 mL). The solution was cooled to 0 °C then DCC (5.12 g, 24.8 mmol) and DMAP
(0.025 g, 0.21 mmol) were added. To this mixture 3.61 (3.05 g, 22.7 mmol) was added and stirred
at 0 °C for 30 min before warming to room temperature where it stirred for 15 h. The reaction
mixture was vacuum filtered through Celite and the filtrate was washed with 1 N aqueous HCl (50
mL) then satd. NaHCO3 (50 mL). The combined organic layer was dried over Na2SO4, filtered and
concentrated to give an oily solid. Further purification by silica gel column chromatography using
hexanes/EtOAc (15:1) gave 3.62 (4.19 g, 17.2 mmol, 83% yield) as a clear colorless oil. IR (neat):
3070, 3039, 2940, 1737, 1454. 1142, 698 cm-1. 1H NMR (500 MHz, CDCl3):  7.39 (d, J = 6.8
Hz, 2 H), 7.32 (t, J = 7.6 Hz, 2 H), 7.23 - 7.29 (m, 1 H), 6.65 (d, J = 16.1 Hz, 1 H), 6.24 - 6.34 (m,
1 H), 4.72 - 4.79 (m, 3 H), 4.70 (s, 1 H), 2.35 (t, J = 7.6 Hz, 2 H), 2.07 (t, J = 7.6 Hz, 2 H), 1.81
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(app. quin, J = 7.6 Hz, 2 H), 1.72 (s, 3 H) ppm. 13C NMR (126 MHz, CDCl3):  173.4, 144.7,
136.2, 134.1, 128.6, 128.0, 126.6, 123.3, 110.7, 64.9, 37.0, 33.7, 22.7, 22.2 ppm. HRMS m/z: [M
+ Na]+ Calcd for C16H20O2Na 267.1356; found 267.1361.

In a 50 mL round-bottomed flask equipped with a stir bar was added anhydrous toluene (9 mL)
and potassium bis(trimethylsilyl)amide (KHMDS) (4.09 mL, 2.05 mmol, 0.5 M in toluene) at -78
°C under an argon atmosphere. To the cold stirring solution 3.62 (0.2 g, 0.8 mmol) in anhydrous
toluene (9 mL) was added dropwise and stirred at -78 °C for 1 h. In a separate conical flask was
prepared a solution of TMS-Cl (0.530 mL, 4.09 mmol) and NEt3 (0.513 mL, 3.68 mmol) in
anhydrous toluene (5 mL) that was added dropwise to the reaction mixture at -78 °C. The reaction
stirred for an additional 10 min at -78 °C before warming to room temperature. Once at room
temperature, the reaction was heated to reflux for 12 h. The resulting reaction mixture was cooled
to room temperature and quenched with aqueous satd. NH4Cl (20 mL) and 1 N aqueous HCl (10
mL). The aqueous layer was extracted with EtOAc (3 x 20 mL), dried over Na2SO4, filtered and
concentrated to give a yellow oil that was further purified by silica gel column chromatography
using hexanes/EtOAc (4:1) to give 3.62.1 (0.148 g, 0.606 mmol, 74% yield) as a clear light-yellow
oil. IR (neat): 3476-2380 (br. COOH dimer), 3078, 3033, 2936, 1707, 1454, 1208, 1268, 1242,
1186, 1160, 996, 921, 892, 765, 702, 527 cm-1. 1H NMR (400 MHz, CDCl3)  7.20 - 7.26 (m, 2
H), 7.13 - 7.18 (m, 3 H), 5.88 (dt, J = 16.8, 9.8 Hz, 1 H), 5.05 - 5.13 (m, 2 H), 4.70 (s, 1 H), 4.65
(s, 1 H), 3.46 (t, J = 9.8 Hz, 1 H), 2.71 (td, J = 10.3, 3.1 Hz, 1 H), 1.90 - 2.07 (m, 2 H), 1.82 (dddd,
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J = 13.4, 10.1, 6.6, 3.5 Hz, 1 H), 1.67 - 1.76 (m, 1 H), 1.66 ppm (s, 3 H) ppm.

13

C NMR (101

MHz, CDCl3)  180.2, 144.6, 141.7, 138.6, 128.5, 127.6, 126.7, 116.8, 110.7, 52.8, 50.2, 35.2,
28.3, 22.3 ppm. HRMS m/z: [M + Na]+ Calcd for C16H20O2Na 267.1356; found 267.1351.

In a 200 mL round-bottomed flask equipped with a stir bar was added 3.62.1 (1.3 g, 5.3 mmol) in
ACN (26 mL). K2CO3 (2.21 g, 15.9 mmol) was added and stirred for 10 min before MeI (0.998
mL, 15.9 mmol) was added dropwise. The reaction mixture was heated to 60 °C for 15 h. Once
the reaction was complete (TLC) it was quenched with aqueous satd. NH4Cl (35 mL) and
partitioned in a separatory funnel with EtOAc (50 mL). The aqueous layer was then extracted with
EtOAc (3 x 50 mL), washed with brine (50 mL), dried over Na2SO4, filtered and concentrated to
give a crude orange oil. The crude oil was further purified by silica gel column chromatography
using hexanes/EtOAc (9:1) to give 3.63 (1.30 g, 5.05 mmol, 95% yield) as a clear light-yellow oil.
IR (neat): 3078, 3033, 2951, 1737, 1160, 705 cm-1. 1H NMR (400 MHz, CDCl3)  7.25 - 7.30 (m,
2 H), 7.16 - 7.21 (m, 3 H), 5.93 (dt, J = 17.1, 9.6, Hz, 1 H), 5.09 - 5.17 (m, 2 H), 4.73 (s, 1 H), 4.68
(d, J = 1.2 Hz, 1 H), 3.48 (t, J = 9.8 Hz, 1 H), 3.38 (s, 3 H), 2.75 (td, J =10.4, 3.5 Hz, 1 H), 1.96 2.03 (m, 2 H), 1.81 - 1.90 (m, 1 H), 1.73 - 1.81 (m, 1 H), 1.70 (s, 3 H) ppm. 13C NMR (101 MHz,
CDCl3)  175.0, 144.8, 142.1, 139.0, 128.4, 127.6, 126.6, 116.7, 110.5, 53.4, 51.1, 50.6, 35.5, 28.6,
22.3 ppm. HRMS m/z: [M + Na]+ Calcd for C17H22O2Na 281.1512; found 281.1512.
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In a 10 mL round-bottomed flask equipped with a stir bar was added 3.63 (0.1 g, 0.4 mmol) in
DCM (4 mL). The solution was degassed by bubbling nitrogen through it for 15 min at 0 °C.
Grubbs’ 2nd gen. catalyst (6.57 mg, 7.74 µmol) was added to the solution and the reaction mixture
was stirred at room temperature for 12 h. A second portion of Grubbs’ 2nd gen. catalyst (3.29 mg,
3.87 µmol) was added and the reaction mixture was stirred at room temperature for another 6 h.
The solvent was removed under reduced pressure to give a dark red oil. The crude oil was purified
by silica gel column chromatography using hexanes/EtOAc (10:1) to give 3.64 (78.4 mg, 0.340
mmol, 88% yield) as a clear colorless oil. IR (neat): 3067, 3033, 2951, 1737, 1167, 765, 705 cm-1.
1

H NMR (400 MHz, CDCl3)  7.23 - 7.29 (m, 2 H), 7.14 - 7.20 (m, 3 H), 5.34 (s, 1 H), 3.66 - 3.72

(m, 1 H), 3.53 (s, 3 H), 2.51 (ddd, J = 11.1, 9.2, 3.1 Hz, 1 H), 2.08 - 2.19 (m, 1 H), 2.02 - 2.08 (m,
1 H), 1.94 - 2.01 (m, 1 H), 1.81 - 1.92 (m, 1 H), 1.72 ppm (s, 3 H) ppm.

13

C NMR (101 MHz,

CDCl3)  175.8, 144.6, 134.1, 128.3, 127.9, 126.4, 123.8, 51.4, 48.3, 44.5, 29.1, 25.8, 23.5 ppm.
HRMS m/z: [M + H]+ Calcd for C15H19O2 231.1380; found 231.1377. A 2D NOESY experiment
was performed to determine the trans-relationship within the cyclohexene ring system (vide infra).
Similar NOE correlations were observed within the literature.4 Furthermore, the coupling constant
observed at Ha corresponds with a trans-ring system.5

190

In a 250 mL round-bottomed flask equipped with a stir bar was added PPh3 (9.57 g, 36.5 mmol)
in toluene (46 mL). The reaction was cooled to 0 °C and 3.65-1 (3.94 mL, 36.5 mmol) was added
dropwise. The solution stirred for 2 hours at 0 °C before warming to room temperature. The
reaction mixture was filtered through a sintered glass funnel and the precipitate was washed with
hexanes (250 mL). The solid was collected and dried to give 3.656 (12.1 g, 30.3 mmol, 83% yield)
as a white solid. 1H NMR (500 MHz, CDCl3): δ 7.58-7.94 (m, 15 H), 3.47-3.63 (m, 2 H), 1.381.55 (m, 4 H), 0.88 (br t, J = 6.8 Hz, 3 H) ppm.

In a 500 mL round-bottomed flask equipped with a stir bar was added 3.60 (10.1 g, 54.9 mmol),
3.65 (28.5 g, 71.4 mmol) in anhydrous THF (55 mL) at -78 °C. NaHMDS (78 mL, 110 mmol, 1.4
M) was added dropwise to the cold stirring solution. After stirring at -78 °C for 30 minutes, the
reaction mixture was warmed to room temperature where it stirred for an additional 1.5 hours. At
which time the reaction was quenched with 100 mL of 5 M aqueous NH4Cl solution and partitioned
in a separatory funnel with 3:1 hexanes/EtOAc (3:1, 150 mL) and 50 mL of additional water. The
aqueous layer was extracted with hexanes/EtOAc (3:1; 3 x 150 mL). The combined organic layers
were washed with brine (3 x 150 mL), dried over Na2SO4, filtered and concentrated to give a crude
oil. The crude oil was adsorbed onto silica gel and purified by silica gel column chromatography
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using hexanes/EtOAc (3:1) to give 3.66 (10.3 g, 46.3 mmol, 84% yield) as a yellow oil. 1H NMR
(500 MHz, CDCl3): δ 6.52 (s, 2 H), 6.33 (br d, J = 11.7 Hz, 1 H), 5.58 (dt, J = 11.7, 7.3 Hz, 1 H),
5.53 (br s, 1 H), 3.85-3.90 (s, 6 H), 2.28-2.35 (m, 2 H), 1.49 (app. sext, J = 7.4 Hz, 2 H), 0.95 (t, J
= 7.4 Hz, 3 H) ppm. HRMS m/z: [M + Na]+ Calcd for C13H18O3Na 245.1148; found 245.1138.

In a 250 mL round-bottomed flask equipped with a stir bar was added 3.66 (4.21 g, 18.9 mmol)
and Pd/C (1.05 g, 0.945 mmol, 10 % w/w) in EtOAc (95 mL). The reaction vessel was vacuumpurged with argon three times then placed under an atmosphere of hydrogen and stirred at room
temperature for 15 hours. The reaction was filtered through a pad of Celite and rinsed with EtOAc
(200 mL). The filtrate was concentrated under reduced pressure to give a crude oil. Further
purification by silica gel column chromatography using hexanes/EtOAc (3:1) gave 3.67 (4.12 g,
18.3 mmol, 97% yield) as a light-yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.41 (s, 2 H), 5.36 (br
s, 1 H), 3.88 (s, 6 H), 2.46-2.63 (m, 2 H), 1.52-1.67 (m, 2 H), 1.27-1.38 (m, 4 H), 0.84-0.94 (m, 3
H) ppm. 13C NMR (126 MHz, CDCl3): δ 146.8, 134.1, 132.6, 104.9, 56.2, 36.2, 31.5, 31.5, 22.6,
14.1 ppm. HRMS m/z: [M + Na]+ Calcd for C13H20O3Na 247.1305; found 247.1299.
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In a 25 mL round-bottomed flask equipped with a stir bar was added 3.67 (0.205 g, 0.914 mmol)
in DCM (4 mL). The reaction vessel was placed under argon and pyridine (0.148 mL, 1.83 mmol)
was added then cooled to 0 °C. Once cool, triflic anhydride (0.191 mL, 1.12 mmol) was added
dropwise then stirred for an additional 30 min at 0 °C before warming to room temperature. Once
complete, the reaction mixture was diluted with Et2O (15 mL) and quenched with 10% aqueous
HCl (20 mL). The mixture was partitioned in a separatory funnel and washed with 10% aqueous
HCl (2 x 10 mL), neutralized with aq. sat. aqueous NaHCO3 (3 x 10 ml), washed with brine (10
mL), dried over MgSO4, filtered and concentrated to give a crude oil. Further purification by silica
gel column chromatography using hexanes/EtOAc (4:1) gave 3.68 (0.308 g, 0.864 mmol, 95%
yield) as a bright yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.43 (s, 2H), 3.87 (s, 6H), 2.55-2.60
(m, 2H), 1.62 (dt, J = 15.1, 7.5 Hz, 2H), 1.31-1.38 (m, 4H), 0.91 (t, J = 6.9 Hz, 3H) ppm. 13C NMR
(126 MHz, CDCl3): δ 152.0, 144.1, 126.0, 118.7, 104.8, 56.1, 36.6, 31.5, 31.0, 22.5, 14.0 ppm.
HRMS m/z: [M + H]+ Calcd for C14H20F3O5S 357.0978; found 357.0947.

In a 500 mL round-bottomed flask equipped with a stir bar was added 3.20 (10 g, 56 mmol) and
K2CO3 (23 g, 0.17 mol) in acetone (150 mL). Me2SO4 (15.9 mL, 166 mmol) was added dropwise
for 5 min at room temperature then heated to 80 °C for 12 h under argon. The reaction mixture
was vacuum filtered and rinsed with Et2O (250 mL). The filtrate was washed with 1N HCl (175
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mL), brine (100 mL x 2), dried over MgSO4, filtered and concentrated to give an orange oil. The
crude oil was further purified by silica gel column chromatography using hexanes/EtOAc (9:1) to
give 3.726 (11.3 g, 54.2 mmol, 98% yield) as a yellow-orange oil. 1H NMR (400 MHz, CDCl3) 
6.35 (d, J = 2.3 Hz, 2 H), 6.30 (t, J = 2.3 Hz, 1 H), 3.78 (s, 6 H), 2.55 (t, J = 7.4 Hz, 2 H), 1.57 1.66 (m, 2 H), 1.28 - 1.38 (m, 4 H), 0.90 ppm (t, J = 6.6 Hz, 3 H) ppm.

13

C NMR (101 MHz,

CDCl3)  160.7, 145.4, 106.4, 97.5, 55.2, 36.3, 31.5, 31.0, 22.5, 14.0 ppm. HRMS m/z: [M + H]+
Calcd for C13H21O2 209.1536; found 209.1527.

In a flame dried 500 mL double-neck round-bottomed flask equipped with a stir bar was added
3.72 (10 g, 48 mmol) and tetramethylethylenediamine (TMEDA) (8.69 mL, 57.6 mmol) in
anhydrous THF (192 mL) at -78 °C under argon to give a yellow solution. Once cool, secbutyllithium (41.2 mL, 1.4 M in hexanes, 57.6 mmol) was added dropwise over 10 min and the
reaction continued to stir at -78 °C for 30 min before warming to 0 °C where the mixture continued
to stir for an additional 60 min. At which time anhydrous DMF (4.46 mL, 57.6 mmol) in anhydrous
THF (10 mL) was added dropwise to the reaction mixture over 2 min. The reaction continued to
stir at 0 °C for 30 min before warming to room temperature. Once at room temperature, the reaction
stirred for an additional 60 min before quenching with satd. aq. NH4Cl (75 mL) and DI water (25
mL). The aqueous layer was extracted with EtOAc (3 x 150 mL) and the combined organic layers
were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated to give a crude
yellow oil. The crude oil was purified by silica gel column chromatography using hexanes/EtOAc
(4:1) to give 3.736 (9.62 g, 40.5 mmol, 85% yield) as a yellow oil. The remaining starting material
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was also recoverable and could be reused. 1H NMR (400 MHz, CDCl3)  10.42 (s, 1 H), 6.36 (s,
2 H), 3.86 (s, 6 H), 2.57 (t, J = 7.4 Hz, 2 H), 1.58 - 1.65 (m, 2 H), 1.29 - 1.35 (m, 4 H), 0.88 (t, J
= 6.6 Hz, 3 H) ppm. 13C NMR (126 MHz, CDCl3)  188.9, 162.2, 152.5, 112.2, 103.9, 55.9, 37.2,
31.5, 30.5, 22.5, 14.0 ppm. HRMS m/z: [M + H]+ Calcd for C14H21O3 237.1485; found 237.1483.

In a 500 mL round-bottomed flask equipped with a stir bar was added 3.73 (9.62 g, 40.6 mmol) in
DI water (203 mL). A solution of acetone (14.9 mL, 203 mmol) and 2.5 M NaOH (55.3 mL, 138
mmol) was added quickly and the reaction mixture was heated to 60 °C for 12 h. The reaction
mixture was cooled to room temperature and diluted with Et2O (100 mL) and the aqueous layer
was extracted with Et2O (3 x 150 mL). The combined organic layers were washed with 1 N HCl
(150 mL), brine (75 mL), dried over Na2SO4, filtered and concentrated to give an orange oil. The
crude oil was purified by silica gel column chromatography using hexanes/EtOAc (5:1) to give
3.71 as a yellow oil that solidified into a light yellow waxy solid (10.1 g, 362 mmol, 89% yield).
1

H NMR (400 MHz, CDCl3)  7.96 (d, J = 16.8 Hz, 1 H), 7.12 (d, J = 16.4 Hz, 1 H), 6.38 (s, 2

H), 3.87 (s, 6 H), 2.58 (t, J = 7.6 Hz, 2 H), 2.35 (s, 3 H), 1.57 - 1.68 (m, 2 H), 1.34 (d, J = 3.1 Hz,
4 H), 0.90 (t, J = 6.4 Hz, 3 H) ppm. 13C NMR (126 MHz, CDCl3)  200.6, 160.0, 147.7, 135.1,
129.3, 109.7, 103.9, 55.7, 36.9, 31.5, 30.8, 26.9, 22.5, 14.0 ppm. HRMS m/z: [M + H]+ Calcd for
C17H25O3 277.1804; found 277.1797.
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In a 100 mL round-bottomed flask equipped with a stir bar was added 3.71 (4.15 g, 15.1 mmol) in
ethanol (65.3 mL) at 0 °C. Once cool, NaBH4 (0.625 g, 16.5 mmol) was added and the reaction
mixture stirred at 0 °C for 2.5 h before warming to room temperature where it stirred for 8 h. The
solvent was removed under vacuum and the crude oil was diluted in EtOAc (100 mL) and DI water
(75 mL). The aqueous layer was extracted with EtOAc (3 x 150 mL) and the combined organic
layers were washed with brine (120 mL), dried over Na2SO4, filtered and concentrated to give an
opaque oil that was purified by silica gel column chromatography using hexanes/EtOAc (3:1) to
give (±)- 3.59 (3.9 g, 14 mmol, 93% yield) as a clear colorless oil that solidified upon standing. IR
(neat): 3424, 2959, 2933, 2858, 1610, 1577, 1458, 1420, 1119, 1052, 981, 828 cm-1. 1H NMR (400
MHz, CDCl3)  6.81 (d, J = 16.1 Hz, 1 H), 6.62 (dd, J = 16.2, 7.0 Hz, 4 H), 6.36 (s, 2 H), 4.344.49 (m, 1 H), 3.82 (s, 6 H), 2.55 (t, J = 7.4 Hz, 2 H), 1.56-1.62 (m, 3 H), 1.34 (d, J = 6.2 Hz, 3
H), 1.27-1.33 (m, 4 H), 0.88 (t, J = 7.0 Hz, 3 H) ppm. 13C NMR (126 MHz, CDCl3)  158.3, 143.7,
136.5, 120.1, 111.2, 104.1, 70.8, 55.6, 36.6, 31.5, 31.0, 23.4, 22.5, 14.0 ppm. HRMS m/z: [M +
Na]+ Calcd for C17H26O3Na 301.1774; found 301.1765.

In a 250 mL double neck round-bottomed flask equipped with a stir bar was added 3.71 (2.1 g, 7.2
mmol) in toluene (145 mL) at -78 °C under argon. Once cool, a solution of (R)-CBS ligand 3.74
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(7.96 mL, 7.96 mmol, 1 M in toluene) was added dropwise over 5 min then stirred for an additional
10 min. A solution of BH3•THF complex (8 mL, 8 mmol, 1 M in THF) was added dropwise over
5 min and the reaction mixture continued to stir for 30 min at -78 °C. The reaction mixture was
carefully quenched with cold 1 M aqueous NaOH (50 mL). The aqueous bilayer was extracted
with EtOAc (3 x 50 mL), washed with satd. aqueous NaHCO3 (50 mL) and brine (50 mL). The
organic layer was dried over Na2SO4, filtered and concentrated to give an oily solid. The crude
was further purified by silica gel column chromatography using a gradient of hexanes/EtOAc (4:1
to 2:1) to give (-) 3.59 (1.9 g, 6.8 mmol, 94% yield, ee 77%) as a clear colorless oil that solidified
upon standing. HPLC Analysis: Chiralcel AD-H (hexane:iso-propanol 85:15, 1.0 mL/min), t rmajor 5.82 min, t r-minor 6.61 min. [α]20D = -13 (c = 0.1, CHCl3). IR (neat): 3424, 2959, 2933,
2858, 1610, 1577, 1458, 1420, 1119, 1052, 981, 828 cm-1. 1H NMR (400 MHz, CDCl3)  6.81 (d,
J = 16.1 Hz, 1 H), 6.62 (dd, J = 16.2, 7.0 Hz, 4 H), 6.36 (s, 2 H), 4.34-4.49 (m, 1 H), 3.82 (s, 6 H),
2.55 (t, J = 7.4 Hz, 2 H), 1.56-1.62 (m, 3 H), 1.34 (d, J = 6.2 Hz, 3 H), 1.27-1.33 (m, 4 H), 0.88 (t,
J = 7.0 Hz, 3 H) ppm.13C NMR (126 MHz, CDCl3)  158.3, 143.7, 136.5, 120.1, 111.2, 104.1,
70.8, 55.6, 36.6, 31.5, 31.0, 23.4, 22.5, 14.0 ppm. HRMS m/z: [M + Na]+ Calcd for C17H26O3Na
301.1774; found 301.1765.
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In a 50 mL round-bottomed flask equipped with a stir bar was added Savinase 12T (2.38 g, 100%
w/w) in anhydrous THF (17.1 mL) to give a white suspension. Et3N (1.19 mL, 8.55 mmol), vinyl
butyrate (3.25 mL, 25.6 mmol) and (±) 3.59 (2.38 g, 8.55 mmol) were added and the reaction
vessel was purged with argon. The reaction continued to stir at room temperature for 3 days while
reaction progress was monitored by chiral HPLC. At which time the reaction mixture was vacuum
filtered through a pad of Celite and rinsed with EtOAc (100 mL). The solvents were removed
under reduced pressure to give a light-yellow oil that was purified by silica gel column
chromatography using hexanes/EtOAc (10: 1) with 2% Et3N to give 3.78 (1.22 g, 3.51 mmol, 41%
yield) as a clear light yellow oil.
Compound 3.78 was dissolved in a 5% NaOH solution of ethanol and water (5:1, 43 mL) and
heated to reflux for 3 h. At which time the ester was no longer visible by TLC and the reaction was
cooled to room temperature. Ethanol was removed under reduced pressure and the residue was
diluted with DI water (20 mL) and DCM (50 mL). The aqueous layer was extracted with DCM (3
x 50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give
(S)-3.59 (1.21 g, 3.50 mmol, 99% yield, ee >98%) as a light yellow oil without further purification.
HPLC Analysis: Chiralcel AD-H (hexane:2-propanol 85:15, 1.0 mL/min), t r-major 5.82 min, t rminor 6.61 min.
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In a 100 mL round-bottomed flask equipped with a stir bar was added (S)-3.59 (1.32 g, 4.67 mmol)
in DCM (47 mL) at 0 °C. DCC (1.34 g, 6.54 mmol) and DMAP (0.057 g, 0.47 mmol) were added
to the cold solution along with 3.58 (0.838 mL, 4.67 mmol). The reaction continued to stir at 0 °C
for 1 h before it was warmed to room temperature where it stirred for 15 h. Once the reaction was
complete (TLC) the solid was filtered and rinsed with DCM (25 mL). The resulting filtrate was
washed with 1 N aqueous HCl (25 mL), satd. aq. NaHCO3 (25 mL), brine (25 mL) then filtered
and concentrated to give an oily solid. The crude material was purified by column chromatography
using hexanes/EtOAc (20:1 to 10:1) and 2% Et3N to give 3.57 (1.68 g, 4.32 mmol, 93% yield,
>98% ee) as a clear colorless oil. HPLC Analysis: Chiralcel AD-H (hexane:2-propanol 98:2, 1.0
mL/min), t r-major 5.63, t r-minor 5.13 min. [α]20D = -59 (c = 0.1, CHCl3). IR (neat): 2933, 2862,
1733, 1610, 1577, 1458, 1420, 1238, 1204, 1160, 1119, 1096, 1041, 981, 892, 828 cm-1. 1H NMR
(400 MHz, CDCl3) δ 6.89 (d, J = 16.0 Hz, 1 H), 6.54 - 6.62 (m, 1 H), 6.35 (s, 2 H), 5.51 (app.
quin, J = 6.6 Hz, 1 H), 4.71 (s, 1 H), 4.66 - 4.69 (m, 1 H), 3.82 (s, 6 H), 2.54 (t, J = 7.8 Hz, 2 H),
2.30 (t, J = 7.4 Hz, 2 H), 2.04 (t, J = 7.4 Hz, 2 H), 1.78 (app. quin, J = 7.6 Hz, 2 H), 1.70 (s, 3 H),
1.56 - 1.64 (m, 2 H), 1.38 (d, J = 6.6 Hz, 3 H), 1.27 - 1.34 (m, 4 H), 0.88 (t, J = 6.4 Hz, 3 H) ppm.
13

C NMR (101 MHz, CDCl3) δ 172.9, 158.4, 144.9, 143.9, 131.4, 122.1, 110.9, 110.5, 104.1, 72.9,

55.6, 37.1, 36.6, 34.2, 31.5, 31.0, 22.9, 22.5, 22.2, 20.7, 14.0 ppm. HRMS m/z: [M + Na]+ Calcd
for C24H36O4Na 411.2506; found 411.2498.
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In a 50 mL round-bottomed flask equipped with a stir bar was added Savinase 12T (1 g, 50% w/w)
in THF (14.4 mL). 3.79 (vide infra, 2.26 g, 10.7 mmol), (±) 3.59 (2.08 g, 7.21 mmol) and Et3N
(1.1 mL, 7.2 mmol) were added to the vigorously stirred solution. The reaction vessel was purged
with argon and stirred at room temperature for 5 days. The reaction was deemed complete (chiral
HPLC analysis) and vacuum filtered through a pad of Celite while rinsing with EtOAc. The filtrate
was concentrated under reduced pressure and purified by silica gel column chromatography using
hexanes:EtOAc (15:1) and 2% Et3N to give 3.57 (1.18 g . 3.03 mmol, 42% yield, >98% ee) as a
clear light-yellow oil. HPLC Analysis: Chiralcel AD-H (hexane:2-propanol 98:2, 1.0 mL/min), t
r-major 5.63, t r-minor 5.13 min. [α]20D = -59 (c = 0.1, CHCl3). 1H NMR (400 MHz, CDCl3): 
6.89 (d, J = 16.0 Hz, 1 H), 6.54 - 6.62 (m, 1 H), 6.35 (s, 2 H), 5.51 (app. quin, J = 6.6 Hz, 1 H),
4.71 (s, 1 H), 4.66 - 4.69 (m, 1 H), 3.82 (s, 6 H), 2.54 (t, J = 7.8 Hz, 2 H), 2.30 (t, J = 7.4 Hz, 2
H), 2.04 (t, J = 7.4 Hz, 2 H), 1.78 (app. quin, J = 7.6 Hz, 2 H), 1.70 (s, 3 H), 1.56 - 1.64 (m, 2 H),
1.38 (d, J = 6.6 Hz, 3 H), 1.27 - 1.34 (m, 4 H), 0.88 ppm (t, J = 6.4 Hz, 3 H) ppm. 13C NMR (101
MHz, CDCl3) δ 172.9, 158.4, 144.9, 143.9, 131.4, 122.1, 110.9, 110.5, 104.1, 72.9, 55.6, 37.1,
36.6, 34.2, 31.5, 31.0, 22.9, 22.5, 22.2, 20.7, 14.0 ppm. HRMS m/z: [M + Na]+ Calcd for
C24H36O4Na 411.2506; found 411.2498.
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In a 150 mL double necked round-bottomed flask equipped with a stir bar was added KHMDS
(14.4 mL, 7.23 mmol, 0.5 M in toluene) in anhydrous toluene (20 mL) at -78 °C. Once cooled, a
solution of 3.57 (0.932 g, 2.39 mmol) in anhydrous toluene (19.2 mL) was added via addition
funnel over 10 min and stirred for 1 h at -78 °C. A solution of anhydrous pyridine (0.871 mL, 10.7
mmol) and TMS-Cl (1.56 mL, 11.9 mmol) in anhydrous toluene (9.57 mL) was added via addition
funnel over 5 min and continued to stir at -78 °C for 10 min before warming to room temperature
where it stirred for an additional 4 h. The reaction was quenched with satd. aqueous NH4Cl (25
mL) followed by 1 M aqueous HCl (20 mL) and stirred vigorously for 20 min. The layers were
partitioned in a separatory funnel and extracted with EtOAc (3 x 50 mL). The combined organic
layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated to give an
oily solid. The crude material was further purified by silica gel column chromatography using
hexanes/EtOAc (4:1) to give 3.56 (0.712 g, 1.87 mmol, 77% yield, 77% ee) as a white crystalline
solid that could be recrystallized using hexanes to 94% ee in a 52% overall yield. Utilizing 3.59
from the kinetic enzymatic resolution with ee > 98% provides the rearranged product with an ee >
98%. HPLC Analysis: Chiralcel AD-H (hexane:2-propanol 95:5, 1.0 mL/min), t r-major 6.16 min,
t r-minor 7.39. [α]20D = +38 (c = 0.1, CHCl3) at > 98% ee. Melting point range: 113-115 °C. IR
(neat): 3300-2500 (br, COOH dimer), 3074, 3011, 2929, 2858, 2664, 1704, 1610, 1584, 1458,
1424, 1231, 1126, 974, 892, 821 cm-1. 1H NMR (500 MHz, CDCl3)  6.32 (s, 2 H), 5.77 (ddd, J =
15.2, 9.3, 1.5 Hz, 1 H), 5.54 (dq, J = 15.2, 6.4 Hz, 1 H), 4.71 (s, 1 H), 4.68 (s, 1 H), 4.04 (t, J =
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10.3 Hz, 1 H), 3.77 (s, 6 H), 3.18 (td, J = 10.8, 3.4 Hz, 1 H), 2.51 (t, J = 7.8 Hz, 2 H), 1.98 - 2.04
(m, 2 H), 1.79 - 1.86 (m, 1 H), 1.71 (s, 3 H), 1.64 - 1.73 (m, 1 H), 1.63 (dd, J = 6.4, 1.5 Hz, 3 H),
1.55 - 1.60 (m, 2 H), 1.29 - 1.37 (m, 4 H), 0.90 (t, J = 6.8 Hz, 3 H) ppm. 13C NMR (126 MHz,
CDCl3) δ 180.1, 157.9, 145.4, 142.7, 130.9, 127.0, 116.0, 110.1, 104.9, 55.8, 47.5, 42.0, 36.5, 35.7,
31.7, 31.0, 29.5, 22.6, 22.4, 17.9, 14.1 ppm. HRMS m/z: [M + H]+ Calcd for C24H37O4 389.2686;
found 389.2676. The stereochemistry of this compound was established by single crystal X-ray
crystallography.

In a 25 mL round-bottomed flask equipped with a stir bar was added 3.56 (0.331 g, 0.849 mmol)
in toluene/methanol (6:1, 42.5 mL) at 0 °C. TMS-diazomethane (0.467 mL, 0.934 mmol, 2.0 M in
hexanes) was added dropwise to the stirred solution. The evolution of N2 was evident and the
reaction mixture warmed to room temperature once N2 evolution ceased. After 30 min, the solvents
were removed under reduced pressure and the crude material was further purified by silica gel
column chromatography using hexanes/EtOAc (9:1) to give 3.54 (0.330 g, 0.820 mmol, 97% yield)
as a clear colorless oil. [α]20D= +29 (c = 0.1, CHCl3). IR (neat): 2933, 2858, 1737, 1610, 1584,
1458, 1424, 1227, 1160, 1126, 974, 892, 825 cm-1. 1H NMR (500 MHz, CDCl3):  6.32 (s, 2 H),
5.80 (ddd, J = 15.2, 9.5, 1.7 Hz, 1 H), 5.55 (dq, J = 15.1, 6.4 Hz, 1 H), 4.70 (s, 1 H), 4.68 (s, 1 H),
4.03 (t, J = 10.0 Hz, 1 H), 3.79 (s, 6 H), 3.27 (s, 3 H), 3.16 (td, J = 11.0, 3.4 Hz, 1 H), 2.51 (t, J =
7.3 Hz, 2 H), 1.96 (t, J = 7.8 Hz, 2 H), 1.76 - 1.84 (m, 1 H), 1.71 (s, 3 H), 1.65-1.71 (m, 1 H), 1.63
(dd, J = 6.6, 1.7 Hz, 3 H), 1.56 - 1.60 (m, 2 H), 1.27 - 1.34 (m, 4 H), 0.89 ppm (t, J = 7.1 Hz, 3 H)
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ppm. 13C NMR (126 MHz, CDCl3):  176.0, 157.9, 145.6, 142.6, 131.1, 127.0, 116.3, 109.9, 104.8,
55.9, 50.7, 48.0, 42.4, 36.4, 35.9, 31.6, 31.0, 29.5, 22.5, 22.5, 17.9, 14.1 ppm. HRMS m/z: [M +
Na]+ Calcd for C25H38O4Na 425.2662; found 425.2660.

In a 100 mL round-bottomed flask equipped with a stir bar was added 3.54 (0.306 g, 0.745 mmol)
in degassed DCM (38 mL, degassed with N2 flow for 15 min) under argon. Grubbs’ 2nd generation
catalyst (0.048 g, 0.075 mmol) was added to the reaction mixture. The vessel was evacuated and
purged with argon then heated to 40 °C for 12 h. An additional 0.05 equiv. of Grubbs’ 2nd
generation catalyst (0.024 g, 0.038 mmol) was added to the reaction mixture and heated to 40 °C
for 3 h. The reaction was cooled to room temperature and the solvent was removed under reduced
pressure to give a reddish oil. The crude oil was purified by silica gel column chromatography
using hexanes/EtOAc (9:1) to provide 3.826 (0.236 g, 0.655 mmol, 88% yield) as a clear lightyellow oil. [α]20D= -137 (c = 0.1, CHCl3) lit. [α]25D= -138.4 (c = 1.0, CHCl3). 1H NMR (400 MHz,
CDCl3) δ 6.33 (s, 2 H), 5.15 (s, 1 H), 4.19 - 4.26 (m, 1 H), 3.73 (s, 6 H), 3.45 (s, 3 H), 3.16 (ddd,
J = 12.6, 10.3, 2.9 Hz, 1 H), 2.53 (t, J = 7.8 Hz, 2 H), 2.07 - 2.20 (m, 1 H), 2.01 (d, J = 13.7 Hz,
2 H), 1.93-1.80 (m, 1 H), 1.65 (s, 3 H), 1.56 - 1.63 (m, 2 H), 1.29 - 1.37 (m, 4 H), 0.89 (t, J = 7.0
Hz, 3 H) ppm.

13

C NMR (126 MHz, CDCl3) δ 176.7, 158.6, 142.5, 130.9, 124.6, 117.4, 105.0,

56.0, 51.1, 43.4, 36.4, 34.8, 31.6, 31.0, 29.4, 27.1, 23.3, 22.6, 14.1 ppm. HRMS m/z: [M + Na]+
Calcd for C22H32O4Na 383.2193; found 383.2193.
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In a 25 mL round-bottomed flask equipped with a stir bar was added 3.82 (0.022 g, 0.061 mmol)
in Et2O (2.63 mL) at 0 °C. The reaction vessel was evacuated and purged with argon. MeMgI
(0.203 mL, 0.610 mmol, 3.0 M in Et2O, 10 equiv.) was added dropwise to the reaction mixture
then warmed to room temperature after addition. The reaction mixture stirred at room temperature
for 30 min until the starting material was no longer present (TLC). The solvent was removed under
reduced pressure to give a crude oil that was heated to 160 °C for 2 h using a house vacuum (150
mbar). The reaction was cooled to room temperature and diluted with Et2O (5 mL), then quenched
with satd. aq. NH4Cl (10 mL). The aqueous layer was extracted with Et2O (3 x 15 mL), washed
with brine (15 mL), dried over MgSO4 and filtered to give an oil. The crude oil was dissolved in
DCM (3 mL) and added dropwise to a separate round bottomed flask containing MgSO4 (0.029 g,
0.24 mmol) and ZnBr2 (0.019 g, 0.085 mmol), which stirred at room temperature for 8 h. The
reaction mixture was quenched with satd. aq. NH4Cl (10 mL) and the aqueous layer was extracted
with DCM (3 x 15 mL). The combined organic layers were dried over MgSO4, filtered and
concentrated to give a crude oil that was purified by column chromatography using hexanes:Et2O
(20:1) to provide 3.17 (0.011 g, 0.035 mmol), 57%) as a clear light yellow oil. [α]20D= -150 (c =
0.1, CHCl3) lit. [α]25D= -152 (c = 1.0, CHCl3).7 1H NMR (500 MHz, CDCl3):  6.27 - 6.30 (m, 1
H), 6.26 (d, J = 1.5 Hz, 1 H), 6.12 (d, J = 1.6 Hz, 1 H), 4.72 (s, 1 H), 3.15 - 3.22 (m, 1 H), 2.42
(td, J = 7.7, 2.2 Hz, 1 H), 2.12 - 2.18 (m, 3 H), 1.87 - 1.94 (m, 1 H), 1.67 (s, 3 H), 1.64 - 1.69 (m,
1 H), 1.50 - 1.56 (m, 2 H), 1.40 (s, 3 H), 1.37 - 1.43 (m, 1 H), 1.25 - 1.32 (m, 4 H), 1.08 (s, 3 H),
0.86 (t, J = 6.8 Hz, 3 H) ppm. 13C NMR (126 MHz, CDCl3):  154.7, 154.1, 142.8, 134.4, 123.7,
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110.1, 109.0, 107.5, 77.2, 45.8, 35.5, 33.5, 31.5, 31.2, 30.6, 27.6, 25.0, 23.4, 22.5, 19.3, 14.0 ppm.
HRMS m/z: [M + Na]+ Calcd for C21H30O2Na 337.2138; found 337.2131.

In a flame-dried 25 mL round-bottomed flask equipped with a stir bar was added 3.56 (0.315 g,
0.811 mmol) in ether (8 mL). The flask was cooled to 0 °C and methyllithium (MeLi) (1.28 mL,
2.03 mmol, 1.6 M in Et2O) was added dropwise via syringe before warming to room temperature
over 1 h. The reaction stirred overnight at room temperature. Once complete (TLC), the reaction
was quenched with satd. aqueous NH4Cl (25 mL) and the aqueous layer was extracted with DCM
(3 x 20 mL). The combined organic layers were dried with MgSO4, filtered, and concentrated. The
resulting crude oil was purified by silica gel column chromatography using a gradient of
hexanes/EtOAc (9:1 to 4:1) to give 3.55 (0.225 g, 0.582 mmol, 71.8% yield) as a colorless oil.
[α]20D= +45.1 (c = 1, CHCl3). IR (neat): 2933, 2858, 1711, 1581, 1458, 1424, 1231, 1126, 974,
892, 825 cm-1. 1H NMR (400 MHz, CDCl3):  6.30 (s, 2 H), 5.76 (ddd, J = 15.0, 9.6, 1.6 Hz, 1 H),
5.51 (dq, J = 15.2, 6.4 Hz, 1 H), 4.69 (s, 1 H), 4.65 (s, 1 H), 3.96 (t, J = 10.2 Hz, 1 H), 3.78 (s, 6
H), 3.25 (td, J = 10.9, 3.1 Hz, 1 H), 2.48 (t, J = 7.8 Hz, 2 H), 1.83 - 1.95 (m, 2 H), 1.76 - 1.82 (m,
1 H), 1.75 (s, 3 H), 1.68 (s, 3 H), 1.63 - 1.67 (m, 1 H), 1.61 (dd, J = 6.2, 1.6 Hz, 3 H), 1.52 - 1.58
(m, 2 H), 1.27 - 1.33 (m, 4 H), 0.87 ppm (t, J = 6.8 Hz, 3 H) ppm. 13C NMR (101 MHz, CDCl3):
 213.2, 157.5, 145.7, 142.9, 131.2, 126.7, 115.8, 109.9, 104.7, 55.7, 54.7, 42.1, 36.4, 35.8, 31.6,
30.9, 29.4, 28.8, 22.5, 22.3, 17.9, 14.0 ppm. HRMS m/z: [M + H]+ Calcd for C25H39O3 387.2894;
found 387.2892.
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In a 15 mL round-bottomed flask equipped with a stir bar was added 3.55 (0.051 g, 0.13 mmol) in
DCM (6.5 mL) (Degassed with N2 flow for 15 min). Grubbs 2nd generation catalyst (0.006 g, 0.007
mmol) was added and the vessel was sealed with a septum and vacuum purged with argon. The
reaction mixture was stirred for 10 h at 40 °C. Another portion of Grubbs’ 2nd generation catalyst
(0.006 g, 0.007 mmol) was added to the reaction mixture and it continued to stir for 5 h at 40 °C.
The solvent was removed under vacuum and the crude oil was purified by silica gel column
chromatography using a gradient of hexanes/EtOAc (14:1- 9:1) to give 3.83 (0.031 g, 0.090 mmol,
69.6% yield) as a tan oil. [α]20D= -146.1 (c = 1, CHCl3). IR (neat): 3007, 2959, 2929, 2858, 1707,
1584, 1458, 1424, 1234, 1119, 828, 758, 672, 601 cm-1. 1H NMR (400 MHz, CDCl3):  6.32 (s, 2
H), 5.13 (s, 1 H), 4.10 - 4.19 (m, 1 H), 3.72 (s, 6 H), 3.25 (ddd, J = 12.6, 10.3, 2.9 Hz, 1 H), 2.51
(t, J = 7.4 Hz, 2 H), 2.05 - 2.17 (m, 1 H), 1.93 - 2.02 (m, 1 H), 1.85 - 1.93 (m, 4 H), 1.70 - 1.84
(m, 1 H), 1.64 (s, 3 H), 1.53 - 1.62 (m, 2 H), 1.24 - 1.37 (m, 4 H), 0.88 (t, J = 7.0 Hz, 3 H) ppm.
C NMR (101 MHz, CDCl3):  213.5, 158.4, 142.8, 131.0, 124.8, 117.2, 104.9, 55.9, 51.1, 36.4,
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34.6, 31.6, 31.0, 29.5, 28.6, 26.5, 23.3, 22.5, 14.0 ppm. HRMS m/z: [M + H]+ Calcd for C22H33O3
345.2424; found 345.2427.
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In a 10 mL round-bottomed flask equipped with a stir bar was added 3.83 (0.022 g, 0.064 mmol)
and bromo(methyl)triphenylphosphorane (0.027 g, 0.077 mmol) in THF (1.0 mL) under argon.
The solution was stirred at room temperature before adding potassium tert-butoxide (8.6 mg, 0.077
mmol) in THF (0.30 mL) dropwise. The mixture was stirred until full consumption of the starting
material was observed (TLC, 12 h). The solvent was evaporated, and the residue was diluted with
hexanes to precipitate triphenylphosphine oxide. After filtration, a 10% aqueous acetic acid
solution (10 mL) and hexanes (15 mL) were added and the aqueous layer was extracted with
hexanes (3 x 10 mL). The combined organic layers were washed with satd. aqueous NaHCO3 (10
mL), dried with MgSO4, filtered and solvent was removed under reduced pressure. The crude
product was purified by silica gel column chromatography using hexanes:EtOAc (6:1) to provide
3.83.1 (18 mg, 0.052 mmol, 82%) as a light yellow oil. [α]20D= -158.2 (c = 1, CHCl3). 1H NMR
(400 MHz, CDCl3):  6.32 (s, 2 H), 5.20 (s, 1 H), 4.42 - 4.45 (m, 1 H), 4.40 - 4.42 (m, 1 H), 3.94
- 4.02 (m, 1 H), 3.72 (s, 6 H), 2.89 (td, J = 10.5, 4.7 Hz, 1 H), 2.52 (t, J = 7.8 Hz, 2 H), 2.11 - 2.25
(m, 1 H), 1.93 - 2.02 (m, 1 H), 1.69 - 1.78 (m, 2 H), 1.66 (s, 3 H), 1.56 - 1.63 (m, 5 H), 1.29 - 1.38
(m, 4 H), 0.89 (t, J = 6.8 Hz, 3 H) ppm. 13C NMR (101 MHz, CD3OD):  158.7, 149.0, 141.7,
130.2, 126.1, 118.5, 108.9, 104.4, 54.8, 45.2, 36.0, 36.0, 31.4, 30.9, 30.4, 29.5, 22.3, 22.2, 18.0,
13.1 ppm. HRMS m/z: [M + H]+ Calcd for C23H35O2 343.2632; found 343.2632.

207

In a 15 mL round-bottomed flask equipped with a stir bar was added 3.83.1 (0.051 g, 0.15 mmol)
in anhydrous ether (0.487 mL) under argon at room temperature. MeMgI (0.195 mL, 0.584 mmol,
3 M in Et2O) was added dropwise and the solution was heated to 160 °C for 1.5 h under reduced
pressure (house vacuum). The reaction mixture was cooled to room temperature, diluted with Et2O
(5 mL) and quenched with satd. aqueous NH4Cl (5 mL). The aqueous layer was extracted with
Et2O (3 x 15 mL), dried over Na2SO4, filtered and concentrated to give a tan oil. The crude product
was purified by column chromatography using hexanes/Et2O (15:1) to provide 3.21 (28.4 mg,
0.0905 mmol, 62% yield) as a light-yellow oil. [α]20D= -131.3 (c = 1, EtOH), lit. [α]19D= -129 (c =
.49, EtOH).1 1H NMR (400 MHz, CDCl3):  6.07 - 6.36 (m, 2 H), 5.95 (br s, 1 H), 5.54 (s, 1 H),
4.60 - 4.77 (m, 2 H), 4.53 (s, 1 H), 3.78 - 3.87 (m, 1 H), 2.41 (t, J = 7.4 Hz, 2 H), 2.32-2.38 (m, 1
H), 2.14 - 2.29 (m, 1 H), 2.01 - 2.12 (m, 1 H), 1.77 (s, 3 H), 1.68 - 1.85 (m, 2 H), 1.63 (s, 3 H),
1.53 (app. quin, J = 7.4 Hz, 2 H), 1.20 - 1.35 (m, 4 H), 0.85 (t, J = 7.0 Hz, 3 H) ppm. 13C NMR
(101 MHz, CD3OD):  156.0, 148.8, 141.3, 132.9, 125.8, 114.5, 109.1, 106.9, 45.0, 36.0, 35.2,
31.2, 30.6, 30.3, 29.3, 22.3, 22.2, 18.1, 13.0. HRMS m/z: [M + H]+ Calcd for C21H31O2 315.2319;
found 315.2318.

In a 500 mL round-bottomed flask equipped with a stir bar was added DCC (11.3 g, 54.6 mmol)
and DMAP (0.953 g, 7.81 mmol) in DCM (195 mL) at 0 °C. To this cold solution, 3.58 (5.01 g,
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39.1 mmol) was added along with 2,2,2-trifluoroethanol (5.85 g, 4.21 mL, 58.5 mmol). The
reaction continued to stir at 0 °C for 30 min before warming to room temperature where it
continued to stir for an additional 12 h. At this point, acetic acid (1.1 mL, 19 mmol) was added to
the reaction mixture and it stirred for an additional 1 h. The reaction mixture was then filtered
through a pad of Celite and rinsed with an additional 100 mL of DCM. The filtrate was washed
with 1N HCl (150 mL), neutralized with satd. NaHCO3 (150 mL), dried over Na2SO4, filtered and
concentrated to give an oily solid. The crude material was purified by short-path vacuum
distillation (50-55 °C @ 4 mm Hg) to give 3.79 (5.81 g, 27.6 mmol, 71%) as a clear colorless oil.
IR (neat): 2936, 2858, 2121, 1763, 1454, 1417, 1286,1167, 1137, 981, 895 cm-1. 1H NMR (400
MHz, CDCl3):  4.69 (s, 1 H), 4.63 (s, 1 H), 4.40 (q, J = 8.3 Hz, 2 H), 2.35 (t, J = 7.4 Hz, 2 H),
1.97 - 2.03 (m, 2 H), 1.75 (app. quin, J = 7.5 Hz, 2 H), 1.65 ppm (s, 3 H).

In a 1 L double- necked round-bottomed flask was added a solution of 3.89 (19.1 mL, 145 mmol)
and TMEDA (24.7 mL, 164 mmol) in THF (200 mL) at 0 °C. n-BuLi (109 mL, 174 mmol, 1.6 M)
was added dropwise and the reaction mixture stirred for 30 min at 0 °C. DMF (13.5 mL, 174 mmol)
was added dropwise and the reaction continued to stir for 1 hour at 0 °C. The reaction was slowly
quenched with 4 M aqueous HCl (50 mL). THF was removed under vacuum then hexanes (300
mL) was added and the mixture stirred at 10-15 °C for 30 minutes. The resulting suspension was
filtered and washed with water and dried in an oven to give 3.89.18 (21.1 g, 126 mmol, 87% yield)
a golden solid that was used without further purification. 1H NMR (500 MHz, CDCl3): δ 10.51 (s,
1 H), 7.45 (t, J = 8.4 Hz, 1 H), 6.58 (d, J = 8.5 Hz, 2 H), 3.90 (s, 6 H) ppm. 13C NMR (101 MHz,
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CDCl3):  189.4, 162.1, 135.9, 114.2, 103.8, 56.0 ppm. HRMS m/z: [M + H]+ Calcd for C9H11O3
167.0703; found 167.0707.

In a 1L round-bottomed flask equipped with a stir bar was added 3.89.1 (18.1 g, 109 mmol) in
water (545 mL). A solution of acetone (40.1 mL, 545 mmol) and NaOH (148 mL, 371 mmol, 2.5
M in water) were added quickly and the reaction mixture was heated to 60 °C for 12 hours. The
reaction mixture was vacuum filtered and rinsed with water (250 mL). The filter cake was dried in
an oven to give 3.904 (20.2 g, 98.1 mmol, 90% yield) as a yellow solid that was used without
further purification. 1H NMR (400 MHz, CDCl3): δ 7.96 (d, J = 16.6 Hz, 1 H), 7.25-7.30 (m, 1 H),
7.15 (d, J = 16.6 Hz, 1 H), 6.55 (d, J = 8.4 Hz, 2 H), 3.87 (s, 6 H), 2.36 (s, 3 H) ppm. 13C NMR
(101 MHz, CDCl3):  200.5, 160.0, 134.8, 131.5, 130.3, 112.1, 103.7, 55.8, 27.0 ppm. HRMS m/z:
[M + H]+ Calcd for C12H15O3 207.1016; found 2017.1024.

In a 500 mL round-bottomed flask equipped with a stir bar was added 3.90 (10.1 g, 49.1 mmol) in
EtOH (242 mL) at 0 °C. Once cool, NaBH4 (2.04 g, 53.9 mmol) was added and the reaction mixture
stirred at 0 °C for 2.5 hours before warming to room temperature where it stirred for 24 hours.
Once complete, the solvent was removed under vacuum and the residue was dissolved in Et2O
(150 mL) and DI water (200 mL). The aqueous layer was extracted with ether (3 x 150 mL) and
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the combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and
concentrated to give a crude oil. Further purification by silica gel column chromatography using
hexanes/EtOAc (3:1) gave 3.91 (9.63 g, 46.2 mmol, 94% yield) as a clear colorless oil. 1H NMR
(500 MHz, CDCl3): δ 7.14 (t, J = 8.1 Hz, 1 H), 6.86 (br d, J = 16.2 Hz, 1 H), 6.71 (br d, J = 6.8 Hz,
1 H), 6.55 (d, J = 7.7 Hz, 2 H), 4.45 (br s, 1 H), 3.81-3.87 (m, 6 H), 1.60 (br s, 1 H), 1.32-1.41 (m,
3 H) ppm. HRMS m/z: [M + Na]+ Calcd for C12H16O3Na 231.0992; found 231.0990.

In a 100 mL round-bottomed flask equipped with a stir bar was added 3.91 (4.11 g, 19.7 mmol),
triethylamine (2.74 mL, 19.7 mmol) and Savinase 12T (4.1 g, 100 wt%) in THF (39.4 mL). Vinyl
butyrate (7.49 mL, 59.1 mmol) was added and the reaction vessel was purged with argon. After 4
days the reaction mixture was filtered through a pad of Celite and the filtrate was concentrated
under reduced pressure. The crude material was purified by silica gel column chromatography
using a gradient of hexanes/EtOAc (9:1-4:1) to provide 3.92.1 (2.5 g, 8.98 mmol, 45.6% yield)
and (R) 3.59 (1.9 g, 9.12 mmol, 46.3% yield) as orange oils.
3.92.1 1H NMR (400 MHz, CDCl3): δ 7.12 (t, J = 8.3 Hz, 1 H), 6.91 (d, J = 16.3 Hz, 1 H), 6.63
(dd, J = 16.3, 6.9 Hz, 1 H), 6.52 (d, J = 8.3 Hz, 2 H), 5.52 (app. quin, J = 6.5 Hz, 1 H), 3.82 (s, 6
H), 2.28 (t, J = 7.4 Hz, 2 H), 1.61-1.71 (m, 2 H), 1.39 (d, J = 6.4 Hz, 3 H), 0.94 (t, J = 7.4 Hz, 3
H) ppm.

13

C NMR (101 MHz, CDCl3): δ 173.0, 158.6, 132.6, 128.3, 121.8, 113.5, 103.8, 72.6,

55.7, 36.7, 20.7, 18.5, 13.6 ppm.
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Butyl ester 3.92 was saponified using the following procedure: In 250 mL round-bottomed flask
equipped with a stir bar was added 3.92.1 (3.51 g, 12.6 mmol) in a 5% aq. NaOH solution (21 mL)
and ethanol (105 mL). The reaction mixture was heated to 90 °C for 3 hours. The reaction was
cooled to room temperature and the solvent was removed under reduced pressure. The residue was
diluted with DI water (50 mL) and DCM (50 mL) and the aqueous layer was extracted with DCM
(3 x 50 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated to give
(S) 3.59 (2.62 g, 12.5 mmol, 99% yield) as a yellow oil that solidified upon standing. [α]20D= -24.5
(c = 1, CHCl3), 1H NMR (500 MHz, CDCl3): δ 7.14 (t, J = 8.1 Hz, 1 H), 6.86 (br d, J = 16.2 Hz, 1
H), 6.71 (br d, J = 6.8 Hz, 1 H), 6.55 (d, J = 7.7 Hz, 2 H), 4.45 (br s, 1 H), 3.81-3.87 (m, 6 H), 1.60
(br s, 1 H), 1.32-1.41 (m, 3 H) ppm. 13C NMR (101 MHz, CDCl3): δ 158.5, 137.6, 128.1, 119.9,
113.8, 103.9, 70.7, 55.7, 23.4 ppm. HRMS m/z: [M + Na]+ Calcd for C12H16O3Na 231.0992; found
231.0990. HPLC Analysis: Chiralcel AD-H (hexane:2-propanol 85:15, 1.0 mL/min), t r-major
8.150 min, t r-minor 9.123 min.

In a 250 mL round-bottomed flask equipped with a stir bar was added 3.92 (4.41 g, 21.2 mmol) in
DCM (141 mL) at 0 °C. DCC (5.24 g, 25.4 mmol), DMAP (0.259 g, 2.12 mmol) and 3.58 (3.41
mg, 25.4 mmol) were added to the cold solution. The reaction mixture continued to stir at 0 °C for
1 hour before warming to room temperature where the reaction stirred for 15 h. The reaction
mixture was filtered and rinsed with DCM and the resulting filtrate was concentrated to give of an
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oily solid. The crude was further purified by silica gel column chromatography using
hexanes/EtOAc (9:1, 2% Et3N) to give 3.93 (6.42 g, 20.2 mmol, 95% yield) as a yellow oil. [α]20D=
-75.8 (c = 1, CHCl3), 1H NMR (400 MHz, CDCl3): δ 7.14 (t, J = 8.4 Hz, 1 H), 6.94 (d, J = 16.3
Hz, 1 H), 6.65 (dd, J = 16.3, 7.0 Hz, 1 H), 6.54 (d, J = 8.4 Hz, 2 H), 5.54 (t, J = 6.5 Hz, 1 H), 4.73
(s, 1 H), 4.70 (s, 1 H), 3.84 (s, 6 H), 2.30-2.36 (m, 2 H), 2.03-2.11 (m, 2 H), 1.76-1.85 (m, 2 H),
1.72 (s, 3 H), 1.41 (d, J = 6.4 Hz, 3 H) ppm. 13C NMR (101 MHz, CDCl3): δ 172.9, 158.6, 144.9,
132.5, 128.4, 121.9, 113.5, 110.6, 103.8, 72.7, 55.7, 37.1, 34.2, 22.9, 22.2, 20.7 ppm. HRMS m/z:
[M + Na]+ Calcd for C19H26O4Na 341.1723; found 341.1718.

In a double-necked 100 mL round-bottomed flask was KHMDS (18.6 mL, 9.29 mmol, 2 M in
toluene) in toluene (25 mL) at -78 °C. Once cool 3.93 (0.986 g, 3.11 mmol) in toluene (25 mL)
was added dropwise and stirred at -78 °C for 1 hour. A solution of pyridine (1.13 mL, 13.9 mmol)
and TMS-Cl (2.01 mL, 15.5 mmol) in toluene (12.5 mL) was added dropwise. The reaction
continued to stir at -78 °C for 10 minutes before warming to room temperature where it stirred for
4 hours. The reaction was quenched with satd. aqueous NH4Cl (25 mL) and 1 N aqueous HCl (20
mL) then diluted with EtOAc (20 mL). The layers were partitioned in a separatory funnel and the
aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed
with brine (50 mL), dried over Na2SO4, filtered and concentrated to give a crude oil. Further
purification by silica gel column chromatography using hexane/EtOAc (4:1) gave 3.93.1 (0.732 g,
2.29 mmol, 74.2% yield) as an off-white solid. [α]20D= +46.6 (c = 1, CHCl3). 1H NMR (400 MHz,
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CDCl3): δ 11.46 (br s, 1H), 7.07 (t, J = 8.3 Hz, 1H), 6.47 (d, J = 8.3 Hz, 2H), 5.73-5.87 (m, 1H),
5.55 (br dd, J = 14.9, 6.6 Hz, 1H), 4.70 (br d, J = 11.9 Hz, 2H), 4.08 (t, J = 10.0 Hz, 1H), 3.73 (s,
6H), 3.12 (td, J = 10.7, 3.4 Hz, 1H), 1.98 (br t, J = 7.7 Hz, 2H), 1.75-1.85 (m, 1H), 1.72 (s, 3H),
1.66 (br s, 1H), 1.63 (d, J = 6.3 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3): δ 181.7, 158.2, 145.4,
130.6, 127.5, 127.3, 118.8, 110.1, 104.7, 55.9, 47.6, 42.1, 35.6, 29.5, 22.4, 17.9 ppm. HRMS m/z:
[M + Na]+ Calcd for C19H26O4Na 341.1723; found 341.1715.

In a 25 mL round-bottomed flask equipped with a stir bar was added 3.93.1 (0.151 g, 0.474 mmol)
in toluene (4 mL) and methanol (0.7 mL) at 0 °C. TMS-Diazomethane (0.285 mL, 0.569 mmol)
was added dropwise to the cold stirring solution. After stirring at 0 °C for 30 minutes the reaction
was warmed to room temperature and continued stirring for 30 more minutes. At which time the
solvents were removed under reduced pressure to give a crude oil. Further purification by silica
gel column chromatography using hexanes/EtOAc (9:1) gave 3.94 (0.149 g, 0.448 mmol, 95%
yield) as a clear colorless oil. 1H NMR (400 MHz, CDCl3 δ 7.08 (t, J = 8.3 Hz, 1 H), 6.50 (d, J =
8.3 Hz, 2 H), 5.82 (ddd, J = 15.1, 9.5, 1.1 Hz, 1 H), 5.52-5.62 (m, 1 H), 4.70 (br d, J = 9.6 Hz, 2
H), 4.10 (t, J = 10.2 Hz, 1 H), 3.81 (s, 6 H), 3.28 (s, 3 H), 3.20 (td, J = 10.9, 3.6 Hz, 1 H), 1.942.01 (m, 2 H), 1.77-1.88 (m, 1 H), 1.67-1.76 (m, 4 H), 1.64 (d, J = 5.4 Hz, 3 H) ppm. 13C NMR
(101 MHz, CDCl3): δ 175.8, 158.1, 145.5, 130.8, 127.5, 127.2, 119.1, 109.9, 104.6, 55.9, 50.7,
47.9, 42.4, 35.8, 29.5, 22.4, 17.9 ppm. HRMS m/z: [M + Na]+ Calcd for C20H28O4Na 355.1879;
found 355.1889.
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In a 100 mL round-bottomed flask equipped with a stir bar was added 3.94 (0.753 g, 2.27 mmol)
in DCM (23 mL) (degassed with N2 flow for 15 min). To this solution Grubb’s 2nd gen. (0.073 g,
0.113 mmol) was added and the vessel was sealed with a septum and vacuum-purged with argon.
The reaction mixture stirred 15 h at room temperature. At which time the solvent was evaporated
under reduced pressure and the crude material was purified by silica gel column chromatography
using hexanes/EtOAc (6:1) to give 3.95 (0.384 g, 1.32 mmol, 58% yield). Unreacted starting
material 3.94 (0.256 g, 0.772 mmol, 38% yield) was obtained to calculate a 92% base on recovered
starting material (BRSM) yield. [α]20D= -112.7 (c = 1, CHCl3). 1H NMR (400 MHz, CDCl3): δ
7.10 (t, J = 8.3 Hz, 1 H), 6.50 (d, J = 8.3 Hz, 2 H), 5.13 (br s, 1 H), 4.21-4.31 (m, 1 H), 3.74 (s, 6
H), 3.44 (s, 3 H), 3.12-3.23 (m, 1 H), 2.08-2.20 (m, 1 H), 1.93-2.06 (m, 2 H), 1.80-1.92 (m, 1 H),
1.65 (s, 3 H) ppm. 13C NMR (101 MHz, CDCl3): δ 176.6, 158.9, 131.1, 127.4, 124.3, 120.2, 104.7,
56.0, 51.1, 43.2, 34.9, 29.4, 27.0, 23.3 ppm. 13C NMR (101 MHz, CDCl3): δ 175.8, 158.1, 145.5,
130.8, 127.5, 127.2, 119.1, 109.9, 104.6, 55.9, 50.7, 47.9, 42.4, 35.8, 29.5, 22.4, 17.9 ppm. HRMS
m/z: [M + Na]+ Calcd for C17H22O4Na 313.1410; found 313.1415.
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In a 20 mL scintillation vial equipped with a stir bar was added 3.95 (0.091 g, 0.310 mmol). A
solution of Ir[(COD)(OMe)]2 (1.534 mg, 2.325 µmol) and dtbpy (1.248 mg, 4.65 µmol) in THF
(0.3 mL) was added to the vial and purged with argon. BisPin (0.079 g, 0.310 mmol) was added
as a solid and the vial was purged with argon, capped and heated to 65 °C for 12 hours. The reaction
was complete (TLC) and the solvent was removed under reduced pressure. The crude reaction
mixture was purified by silica gel column chromatography using hexanes/EtOAc (9:1) to 3.96
(0.127 g, 0.305 mmol, 98% yield) as a clear colorless oil. [α]20D= -128.5 (c = 1, CHCl3). 1H NMR
(400 MHz, CDCl3): δ 6.95 (s, 2 H), 5.11 (br s, 1 H), 4.30 (br d, J = 10.0 Hz, 1 H), 3.80 (s, 6 H),
3.44 (s, 3 H), 3.15-3.24 (m, 1 H), 2.07-2.21 (m, 1 H), 1.93-2.07 (m, 2 H), 1.80-1.93 (m, 1 H), 1.65
(s, 3 H), 1.33 (s, 12 H) ppm. 13C NMR (101 MHz, CDCl3): δ 176.5, 158.4, 131.2, 123.9, 123.8,
110.6, 83.7, 56.1, 51.1, 43.0, 35.1, 29.4, 27.0, 24.9, 24.8, 23.3 ppm. HRMS m/z: [M + Na]+ Calcd
for C23H33O6BNa 439.2267; found 439.2283.

3.12.1 List of references for experimental procedures
1. Choi, Y. H.; Hazekamp, A.; Peltenburg-Looman, A. M. G.; Frédérich, M.; Erkelens, C.;
Lefeber, A. W. M.; Verpoorte, R., NMR Assignments of the Major Cannabinoids and
Cannabiﬂavonoids Isolated from Flowers of Cannabis sativa. Phytochemical Analysis
2004, 15 (6), 345-354.
2. Takase, M.; Narita, T.; Fujita, W.; Asano, M. S.; Nishinaga, T.; Benten, H.; Yoza, K.; Mullen,
K., Pyrrole-Fused Azacoronene Family: The Influence of Replacement with
Dialkoxybenzenes on the Optical and Electronic Properties in Neutral and Oxidized
States. J. Am. Chem. Soc. 2013, 135 (21), 8031-8040.

216

3. Brimioulle, R.; Bach, T., Enantioselective Lewis Acid Catalysis of Intramolecular Enone [2+2]
Photocycloaddition Reactions. Science 2013, 342 (6160), 840-843.
4. Ballerini, E.; Minuti, L.; Piermatti, O., High-Pressure Diels−Alder Cycloadditions between
Benzylideneacetones and 1,3-Butadienes: Application to the Synthesis of (R,R)-(−)- and
(S,S)-(+)-Δ8-Tetrahydrocannabinol. The Journal of Organic Chemistry 2010, 75 (12),
4251-4260.
5. Gouverneur, V. Preparation and Process of Preparation of Fluorinated Compounds.
US20070142632A1, 2007.
6. Trost, B. M.; Dogra, K., Synthesis of (-)-Δ9-trans-Tetrahydrocannabinol: Stereocontrol via
Mo-Catalyzed Asymmetric Allylic Alkylation Reaction. Organic Letters 2007, 9 (5), 861863.
7. A., S. M.; Giuseppe, Z.; Simon, K.; David, S.; M., C. E., Stereodivergent Total Synthesis of
Δ9-Tetrahydrocannabinols. Angewandte Chemie International Edition 2014, 53 (50),
13898-13901.
8. Haight, A. R.; Bailey, A. E.; Baker, W. S.; Cain, M. H.; Copp, R. R.; DeMattei, J. A.; Ford, K.
L.; Henry, R. F.; Hsu, M. C.; Keyes, R. F.; King, S. A.; McLaughlin, M. A.; Melcher, L.
M.; Nadler, W. R.; Oliver, P. A.; Parekh, S. I.; Patel, H. H.; Seif, L. S.; Staeger, M. A.;
Wayne, G. S.; Wittenberger, S. J.; Zhang, W., A Scaleable Synthesis of Fiduxosin. Org.
Process Res. Dev. 2004, 8 (6), 897-902.

217

Chapter 4

Transdermal Delivery of the Cannabinoids: Development of a Transdermal Patch

4.1

Introduction to transdermal delivery systems
An extensive history and background of the cannabinoids has been covered in the previous

chapter including the peculiar pharmacology associated with the cannabinoids. However, routes
for the delivery of cannabinoids had not been discussed and will be addressed in this chapter
There are many ways to administer an active pharmaceutical ingredient (API) into humans
or animals to elicit a therapeutic effect. Different delivery methods are used to increase therapeutic
efficacy by modifying the absorption, distribution, metabolism and elimination (ADME) of an
API.1 The most common routes for drug delivery are oral (a pill or liquid), injectable (intravenous
or intramuscular) pulmonary (an aerosolized formulation), topical (lotion or gel formulation) and
transdermal (in the form of a patch). In an ideal world every drug would be formulated as an oral
dose in the form of a pill that could be taken orally for patient convenience and compliance.
Unfortunately, not all APIs are compatible in oral formulations due to, but not limited to, their
physiochemical properties such as solubility and lipophilicity which directly impacts membrane
permeability and absorption.2
Formulation chemistry addresses the intrinsic problems associated with the physical
properties of an API to adjust its pharmacokinetic properties (ADME) without changing its
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pharmacodynamic performance. Many factors are considered when choosing the right formulation
and delivery method of an API such as dose, solubility, absorption, and patient compliance. For
most oral formulations, water solubility and gastrointestinal (GI) absorption are requirements for
the API to enter the blood-stream while transdermal delivery focuses more on lipophilicity and
distribution.3 However, not all transdermal applications require systematic release of a drug and
may be formulated for a local treatment.

4.1.1 Advantages and disadvantages in transdermal drug delivery
Transdermal delivery offers many advantages over traditional drug delivery methods. The
delivery of an API across the skin membrane directly into systematic circulation allows the API to
evade hepatic first-pass metabolism, a problematic pharmacokinetic parameter in metabolically
unstable drugs.4 Another advantageous effect of transdermal formulations is controlled drug
release. A formulation can be fine-tuned to release a drug over varying periods of time which
influences dose response5 and increases patient compliance. Different excipients and formulation
techniques are available to modulate the ability of an API to permeate the skin and can be directly
incorporated into transdermal formulations.
There are drawbacks and limitations to transdermal delivery systems. Not all drugs pose
the ability to permeate the transdermal membrane, especially ones that are highly hydrophilic or
hydrophobic, even in the presence of known permeation enhancers.6 Other transdermal systems
exist for APIs known to have low skin permeability such as microneedles, thermal ablation and
microdermabrasion, which will not be discussed in this manuscript – see the following reference
for more details.7
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Even APIs with ideal transdermal permeability properties may fail to be efficacious in a
transdermal formulation. Perhaps one of the major drawbacks in transdermal delivery systems is
drug-loading.8 Transdermal formulations are limited by the solubility of the API in the formulation
and the drug concentration required for a therapeutic effect. Different patch designs have addressed
this issue by using imprinted reservoirs that contain larger volumes of the formulation9 but a
concentration threshold exists for every API. In the case where concentration and permeation of
an API is problematic, other patch designs are used as previously mentioned.

4.2

Rationale for a transdermal delivery system of the cannabinoids
The cannabinoids are notorious for their poor water solubility and low oral availability but

high lipophilicity and distribution.10-11 Historically, cannabinoids have been inhaled through the
lungs via pulmonary delivery from smoke by pyrolyzing the plant material. Although the
cannabinoids can efficiently enter the blood-stream through pulmonary delivery in the form of
smoking, it is well known that pyrolyzing organic matter creates a wide-range of carcinogenic and
toxic molecules associated with various diseases including heart-disease and cancer.12-13
The most notorious example of the harmful effects of smoking as a pulmonary delivery
mechanism is tobacco smoke for the delivery of nicotine, which has been associated with severe
health risks. To circumvent the toxicity issues associated with smoking, other delivery methods for
the cannabinoids have been developed including inhalers and nebulizers for pulmonary delivery
and transdermal patches for transdermal delivery.14 Even though smoking may be the most popular
delivery method of the cannabinoids, alternative mechanisms are becoming increasing popular as
more patients who are not in favor of smoking are realizing the medical benefits of the
cannabinoids.
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4.3

Research goal
Our goal was to develop a safe and effective transdermal delivery system for the

cannabinoids that could outperform the current leaders on the market. The cannabinoid, CBD, was
chosen as the model cannabinoid for legal and practical reasons. A transdermal patch formulation
using permeation enhancers, that are generally regarded as safe and effective (GRASE), could be
used to facilitate permeability through the stratum corneum that would provide an alternative
delivery mechanism for the cannabinoids. Toxicity and safety were a primary concern for
transdermal formulation development. It was required that excipients used to formulate our
transdermal patch must have been previously FDA approved in other transdermal products. Good
manufacturing practices (GMP) were also emphasized during the development of our transdermal
delivery system.
A drug-in matrix design was thought to be an ideal staring point to develop a single and
multi-layered transdermal patch, the latter containing a permeable membrane for controlled drug
release. To evaluate our formulations and patch designs an appropriate assay was developed to
determine flux and a scalable permeability factor for each formulation. A newly established assay
design using a skin parallel artificial membrane permeability assay (PAMPA)15 could be used to
evaluate the transdermal properties of each formulation. To our knowledge, this is the first report
of using skin PAMPA to evaluate transdermal formulation of the cannabinoids.

4.4

Skin PAMPA: valuable tool for transdermal patch development
Identification of an assay to evaluate our patch formulations was essential. Traditionally, a

Franz cell diffusion assay has been used to evaluate the effectiveness of a transdermal formulation
for the delivery of an API across a skin membrane.7 Most Franz cell assays use cadaver or pig skin
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as the skin membrane that bridges two compartments, a donor and receptor compartment as seen
in Figure 4.1. For the evaluation of a transdermal patch formulation, the patch is applied to the
skin (donor well) and sampling over time is achieved by removing the solvent from the receptor
well and determining the concentration of API at given time points. Sampling analysis can be
performed using UV spectroscopy, HPLC, HPLC-MS, GC or GC-MS depending on the
concentration and the API examined.

Figure 4.1: Franz cell apparatus.

Franz cell diffusion assays have been established as the crux for preclinical transdermal
formulation discovery as one of the most commonly used in vitro technique that closely correlates
to in vivo data.16-19 However, it becomes difficult to correlate diffusion data generated using Franz
cells to in vivo data when conducted with animal skin, such as pig or rat skin, and the
reproducibility becomes problematic with variations of skin thickness. The low-throughput nature
of this assay as well as the previously mentioned limitation has resulted in the development of
synthetic skin membranes that have increased reliability and correlativity.
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Recently, PAMPA has been used for high-throughput evaluation of gastrointestinal (GI)
and blood-brain barrier (BBB) permeability of a wide variety of APIs.20 The developers of PAMPA
have increased the scope of this methodology by applying it to skin membranes, resulting in
remarkable correlation to Franz cell and in vivo assays.15,21 Skin PAMPA offers a simplistic design
that is capable of analyzing multiple patch formulations in parallel with >14 sample replicates in
a given run. Figure 4.2 represents a skin PAMPA set-up where a modified 96-well plate is used to
create donor wells (patch) and acceptor wells (96-well plate). Patches can be placed directly on an
artificial skin membrane consisting of a proprietary lipid system used to mimic the components of
the biological membrane.15, 22

Figure 4.2: Schematic of skin PAMPA assay.

In order to optimize formulation screening, we decided to evaluate our patch formulations
using the novel skin PAMPA methodology. Typical skin PAMPA parameters consist of an aqueous
phosphate buffer solvent system that maintains a pH of 7.4 and stirring while incubating at 37 °C
to mimic the environment of the circulatory system with sampling over time. Based on our
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observations, standard assay conditions are not optimal for an API with very low water solubility,
such as the cannabinoids, and require extensive optimization. The only parameter that would
directly affect the detection of our API was the constituents within the acceptor well. Due to the
chemical composition of the skin PAMPA artificial membrane, the use of organic solvents for
acceptor wells hasn’t been thoroughly explored until recently.23
Marketed cannabinoid patches were used as prototypes to standardize the skin PAMPA
parameters for the detection of the desired API. Due to legal restrictions, we were only able to use
patches containing CBD as the cannabinoid API in the prototypes – CBD was also used in all of
our transdermal formulations for the delivery of the cannabinoids. At the time of this study, the
only variations in acceptor solvents were the use of PEG 400 (up to 45% w/v),15 an unreported use
of DMSO (up to 10% v/v) and EtOH (up to 30%) with aqueous buffers. It was decided to use
solvents that have been previously used in acceptor and donor wells as a viable starting point to
identify an appropriate acceptor solvent for the cannabinoids under the assumption that the
additives do not negatively impact the skin membrane mimic.
After extensive acceptor well solvent screening, a solvent mixture of propylene glycol
(PG), water and EtOH in a 4:5:4 ratio was identified as a superior acceptor solvent system for the
detection of CBD via transdermal delivery in skin PAMPA. The flux and permeability data for two
prototype patches will be disclosed below when comparing our patch formulations to the leading
competitors. A recent study has further validated that organic solvents such as DMSO and EtOH
up to 50% v/v do not compromise the artificial skin membrane and can be used to reliably obtain
permeability data for transdermal formulations using skin PAMPA.23 With suitable skin PAMPA
parameters for the detection of CBD in hand, we were in the position to begin formulation
development of our own transdermal patches and evaluate their performance using skin PAMPA.
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4.5

Transdermal patch development
One of the most difficult tasks was to identify a reliable technique to produce transdermal

patches on a laboratory scale with consistent drug-loading using an API having poor solubility in
most solvents. A single layered drug-in adhesive (DIA) patch model (Figure 4.3) was chosen as
the platform for our first-generation formulation. The drug-in adhesive model allows for the use
of permeation enhancers within a homogenous mixture of adhesive and drug.

Figure 4.3: Various transdermal patch models.

Other patch designs, such as the reservoir and multi-laminate patches, could be explored
in further product generations. The single-layered DIA design is one of the most simplistic and
scalable transdermal patches which we believed would be a suitable starting point for
formulation development. To our knowledge all cannabinoid transdermal patches on the market
at the time of this study were single-layer DIA patches. In order to produce the DIA patches,
patch materials such as patch backings, release liners and adhesives needed to be selected as well
as permeation enhancers used to assist in the delivery of this API.
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4.5.1 Selection of transdermal patch materials
Transdermal patch making materials such as patch backings and patch liners were
generously supplied by 3M®. The patch backing was chosen based on consumer comfort and
overall compatibility with the formulations. A general clear release liner proved to be suitable for
all patch formulations. Two different patch backings were chosen for evaluation while the release
liner remained constant. The performance of the two patch backings are disclosed below.
Pressure-sensitive acrylate adhesives are commonly used for drug-delivery.9 Three main
properties contribute to an adhesive’s performance, tack (how quickly the bond between the
adhesive and surface forms), peel adhesion (strength of the bond between the adhesive and the
surface) and shear resistance (resistance to moving across the surface where and adhesive is
bound).9 Another critical property that needed to be considered was the functional groups present
on the acrylate polymer. By changing the functional groups present in the adhesive, the solubility
of an API and its interaction with the adhesive can be modulated. Five different adhesives were
selected from Henkel’s Duro-Tak series of products that had mid-grade to high performance in the
three main performance properties and the presence or absence of -OH functional groups.
Many permeation enhancers exist for transdermal patch applications. One of our main
requirements was to use ingredients that are GRASE and have been previously approved in FDA
products. Following our guidelines we had chosen known permeation enhancers oleic acid (shown
to increase transdermal properties of salicylic acid and 5-fluoruracil)24-25, lecithin,26 transcutol
(diethylene glycol monoethyl)27, phosphatidylcholine (Phospholipon 90G)28, labrasol,29 propylene
glycol (PG)30 and a series of essential oils (peppermint, eucalyptus, orange, sandal-wood and teatree)31. The potential mechanism of most permeation enhancers is the disruption of intercellular
lipids and tight-junctions between cells of the stratum corneum, increasing the penetration of an
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API.31 Our transdermal formulations contained different compositions of permeation enhancers
which were guided by FDA approved transdermal patch and topical products.

4.5.2 Transdermal patch formulation design
At the outset, analysis of Prototypes 1 and 2 were done using GCMS to gain a better
understanding of the constituents present in both patches. Initial analysis was performed using
GCMS of patch extracts as well as head-space solid phase microextractions (SPME). Most of the
reported ingredients for both patches were detected, however, prototype 2 used a complex blend
of terpenes and terpenoids that were difficult to fully analyze. Surprisingly, DMSO was detected
by SPME for prototype 1 which was not present on the ingredients list. The use of DMSO as a
permeation enhancer is well understood as it is one of the best skin penetrants known but its use
comes at a severe health risk32 and we sought a much safer alternative.
Based on the dose of marketed cannabinoid patches, we had decided to begin formulation
development using 25 mg (14% w/w) of CBD/patch with a 2 in x 2 in (5.08 cm x 5.08 cm) patch
area. The total concentration of permeation enhancers was set at 10% w/w (not including essential
oils) and was not exceeded to avoid local irritation. After analysis of the terpene profiles of the
previously mentioned essential oils by GC-MS, peppermint oil was chosen to add in all
formulations at 1% w/w. The purpose of using peppermint oil was to provide a pleasant smell as
well as a slight cooling sensation at the application site, however, the terpenes may provide a slight
increase in permeability in human skin.33 Permeation enhancers with varying concentrations were
tested in a drug-in adhesive formulations and their performance was evaluated using skin PAMPA.
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4.5.3 Research-scale production of transdermal patches
With an established formulation plan, a reproducible method to produce transdermal
patches at a 25 mg/patch dose and excipients was required. Adhesive formulations containing the
desired excipients and CBD can be dissolved in an adhesive (containing an organic solvent such
as ethyl acetate or ethanol) to provide homogenous mixtures. Based on a targeted 1.66 x 1.66 in2
(4.22 x 4.22 cm2) patch, it was calculated that an adhesive coating thickness of 1 mm would
provide the desired 25 mg dosing (14% CBD w/w). An applicator blade was used to apply a 1 mm
thick coating on a release liner (Figure 4.4, A).

Figure 4.4: Research scale patch production. A) Applicator blade used to apply precise coating thickness. B)
Laminating apparatus C) Transdermal patch products.

The adhesive coated release liner was dried in a convection oven until no observable
change in mass could be detected (30-45 min at 60 °C). Once the adhesive solvent was removed,
the dried DIA coated liner could be laminated on a patch backing (Figure 4.4, B) to provide single
layered DIA patches. Patches in a uniformly coated region were cut into 4.22 x 4.22 cm squares
and the dose was determine based on the weight of adhesive (after drying) and the percent weight
of CBD in the formulation. Using our patch making technique we were able to successfully
produce patches with an average of 25 mg of CBD per patch (Figure 4.4, C), which were evaluated
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using skin PAMPA. Once the patch dose was determined, selected patches were stored in
aluminum heat-sealable pouches to maintain the integrity of the patch formulation.

4.6

Skin PAMPA evaluation of CBD transdermal patch formulations
A series of transdermal patch formulations (TPFs) were created using our formulation

design and patch making technique to obtain patches with 25 mg doses of CBD. The patches were
evaluated using the skin PAMPA assay parameters discussed in section 4.4 using marketed CBD
patches as positive controls and benchmark standards. Each patch covered approximately 14 wells
on the skin PAMPA plate. Sampling was performed on six selected inner wells for each time point
(0.5, 1, 2.5, 3.5, 6 and 12 hours). The samples were analyzed by LC-MS and the concentration of
CBD was determined using a previously established standard curve.
Two of the most important properties of transdermal formulations are flux and
permeability. The flux (J) is defined as the rate of flow for an API per unit area over time and is
usually reported in the units of µg∙cm-2∙h-1 for transdermal formulations.

𝐽=

𝐼
𝐴

where: 𝐼 = lim

∆𝑞

∆𝑡→0 ∆𝑡

=

𝑑𝑞
𝑑𝑡

A = surface area (cm2)
q = mass of API (µg)
t = time (h)
The flux for transdermal formulations is usually determined by plotting the cumulated API
permeated per square unit of membrane (µg/cm2) vs. time (h) where the slope (µg/cm2∙h) at a
steady state represents flux21 (see example in Graph 4.1 where flux was determined to be 29.5
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µg∙cm-2∙h-1 for TPF5). Flux can be used to describe formulation performance; however, it is
dependent on drug-load and cannot be accurately used to compare formulations where drug-load
varies. To compare formulation performance for our TPF series, flux was used since the drug-load
was set to 25 mg/patch. In order to compare the developed formulations to the competitors (10
mg/patch prototype 1, 30 mg/patch prototype 2) a permeability factor for each formulation was
determined.
The permeability factor for a transdermal formulation can be used to compare formulations
with different drug-loads or drug-concentrations, which is usually expressed as cm∙hr-1 and
associated with a multiplier (103 is used for this study). The flux (µg∙cm-2∙hr-1) of a formulation
can be used to calculate the permeability factor by dividing the flux by the concentration of API
(µg∙cm-3) in a transdermal formulation. For the prototypes, the concentration of CBD within the
DIA matrix was calculated using the drug-load (µg) and density (cm3) of the DIA – density was
determined using the surface area of the patch and the assumption of a 0.01 cm coating thickness
(same as our DIA coating once dried).
Due to time constraints and the sole goal of developing a safe and effective method for the
transdermal delivery of CBD and other cannabinoids, we did not assess all of the permeation
enhancers known or purchased. A formulation (TPF5: 5% w/w transcutol and 5% w/w labrasol
combination with 1% w/w peppermint oil) was identified that performed well in our assay and was
further improved based on our initial findings. Other permeation enhancers such as oleic acid and
PG were evaluated but fell below the limit of detection for our analysis. The permeability
properties of our selected formulations as compared to competitor patches are outlined in Table 1.
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Permeability Profile: TPF5 25 mg/patch
250

(µg/cm2)

200
150
100
50
0
0

2

4

6

8

10

12

Time (h)

(µg/cm2)

Permeability Profile at Steady State:
TPF5 25 mg/patch
100
90
80
70
60
50
40
30
20
10
0

y = 29.483x - 0.1136
R² = 0.9902

0

0.5

1

1.5

2

2.5

3

3.5

Time (h)

Graph 4.1: Example of permeability profiles used to determine flux.

All patches remained fixed during the duration of the assay except for Prototype 2, which
fell off before the last time-point at 12 hours. At least three replicates were obtained for all timepoints and were used to determine the standard deviations. The assay was reproducible and reliable
for most formulations. Prototype 1 fell below the limit of detection for early time-points and the
error associated with the permeability data can be attributed to the analysis (all time-points were
considered when determining flux and permeability in order to make direct comparisons). Another
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source of error can be attributed to inconsistencies in patch coatings for both prototypes and our
formulations since the skin PAMPA wells only cover small segments of the patches where the
coatings may not be completely uniform.

4.6.1 Skin PAMPA data analysis for selected formulations
It was clear from the skin PAMPA data that prototype 2 outperformed prototype 1, having
a higher flux and permeability factor (Table 4.1), making prototype 2 the benchmark formulation.
As mentioned above, many of our earlier formulations failed to provide sufficient CBD
permeability and fell below the limit of detection or had extremely long lag-times. By using the
combination of transcutol and labrasol (TPF5), a synergistic effect was observed from the two
permeation enhancers to reach a flux of 29.5 µg∙cm-2 h-1 (nearly two times the benchmark).
Considering the differences in drug concentration, the permeability factor was also higher than
prototype 2.
TPF5 was first developed as a single layer drug-in adhesive patch. We decided to determine
the effects of a multi-layered (ML) patch with a permeable membrane between two adhesive
layers. The idea of the mL patch was to add a time-release property that could deliver an API over
a longer period depending on the permeable membrane separating the two adhesive layers. TPF5ML contained two separated layers of TPF5 resulting in a 50 mg/patch overall dose. The flux and
permeability factor of TPF5-ML both had increased by 33% and 168%, respectively.

232

Table 4.1: Selected transdermal patch permeability data generated using skin PAMPA over 12 hours. Flux
was determined at steady state for each formulation. All samples were analyzed by LC-MS and
concentrations were determined using a CBD standard curve. mL = multi-layer, OH = OH functionalized
adhesive

In order to produce the mL patch, we had to change the patch backing to an impermeable
aluminum backing. Our initial patch backing was breathable and flexible for consumer comfort.
Using a less permeable patch backing prevents reverse diffusion of the formulation into the patch
material, forcing the forward diffusion into the skin membrane which could explain the observed
results. However, this hypothesis wasn’t further tested due to time constraints and the desire to
create a product with a high level of comfort.
Further development of the TPF5 formulation led to the discovery of the TPF5-OH series.
An acrylate-based adhesive containing hydroxyl (-OH) functional groups was one of our
preselected adhesives to explore in transdermal patch formulations. Modification of the original
TPF5 formulation to incorporate the -OH functionalized adhesive led to TPF5-OH. The difference
in transdermal permeability between TPF5 and TPF5-OH was shocking. As seen in Table 1, the
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use of the -OH adhesive had increased the flux and the permeability factor by 481% relative to
TPF5 and a 966% increase relative to the marketed benchmark standard.
The observed increase in flux and permeability using a -OH functionalized adhesive can
be rationalized by three plausible mechanisms: the increased hydrophilic adhesive matrix 1)
creates a diffusion gradient where the hydrophobic API is forced into the membrane, 2) the
hydrophilic environment facilitates micelle formation with labrasol and transcutol containing the
API that enhances the diffusion through the membrane and 3) the hydrophilic nature of the
adhesive wets the surface of the membrane creating pores where the API can flow.
With the surprising permeability results of TPF5-OH we decided to move forward with the
formulation by examining a mL layer patch (25 mg/patch) and increasing the drug-load to 50
mg/patch. It was thought that the mL patch would allow for a slower delivery rate over a longer
period while raising the drug concentration would increase flux and the overall amount of drug
delivered. Based on the skin PAMPA data (Table 4.1) we were able to cover a wide-range of
delivery rates using the TPF5-OH formulation with three different patches.
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Graph 4.2: A line and bar graph representation of accumulated permeability of CBD for selected patch
formulations.

The overall drug delivery for each transdermal patch formulation can be visualized in
Graph 4.2. By knowing the surface area of the patch and the surface area of each well, the overall
patch permeability in milligrams was extrapolated. The percent drug delivery for each patch was
calculated using the overall amount permeated and is a practical representation of patch
performance (Graph 4.3). The permeability profiles in Graph 4.2 show a decrease in flux over

235

time and most likely would not reach 100% drug release within 24 hours – presumably due to a
decrease in the concentration gradient.

Percent CBD Released
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Graph 4.3: Percent CBD released for selected patch formulations.

The drug-release profiles in Graph 4.3 outlines the effectiveness of our transdermal patch
formulations to deliver CBD across the artificial skin PAMPA membrane. Both competitors appear
to release roughly the same percentage (~5%) of CBD within experimental error (Prototype 2
would presumably have had greater percent release if it was able to adhere to the skin PAMPA
plate for the full duration of the assay) while TPF5-OH achieved 63% drug-release. The modified
TPF5-OH-ML patch with a 25 mg/patch had a lower permeability and drug-release profile due to
the decrease in drug concentration of the two DIA layers. Each of the TPF5 formulations was able
to withstand the assay conditions and remained intact throughout the course of the assay. Further
time-points up to 24 hours could have been taken; however, it was not within the scope of this
study.
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4.7

Conclusion and outlook of our transdermal delivery system of the cannabinoids
A method to develop and assess transdermal delivery systems for the cannabinoids has

been established. With the use of skin PAMPA, we have discovered a medium throughput means
to evaluate transdermal patches to deliver cannabinoids with good reproducibility and efficiency.
Skin PAMPA alleviates the need to obtain cadaver or pig skin required for Franz cell assays,
making formulation analysis more practical and straightforward. At the time of our study, there
had been only one report of a transdermal patch analysis using skin PAMPA, which was performed
by the inventors as a proof of concept. This work remains the first instance for the evaluation of a
cannabinoid transdermal delivery system using skin PAMPA.
The TPF5-OH transdermal patch has proven to be far superior to the two marketed patches
as demonstrated by its increasing flux, permeability and percent drug release. The synergistic effect
of transcutol and labrasol has been translated to the transdermal delivery of the cannabinoids and
further enhanced using a hydrophilic -OH functionalized adhesive. A hydrophilic adhesive has
resulted in a 600% increase in drug delivery for our initial TPF5 formulation. Further examination
of the -OH adhesive with other permeation enhancer may lead to improved transdermal properties
for future patch generations. A more thorough investigation of permeation enhancers for
transdermal delivery of the cannabinoids can now be accomplished using skin PAMPA.
It is important to note that the in vitro permeability data obtained using skin PAMPA does
not necessarily correlate directly to in vivo permeability performance. Further evaluation of our
transdermal patch formulations in animal models would provide a better understanding of their in
vivo properties. The data represented in this chapter describes transdermal permeability properties
for formulations that were used to make relative comparisons to marketed patches. Skin PAMPA
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was used as a tool to guide preclinical formulation development and the data generated using this
method is most likely an overestimation with respect to in vivo activity.
The overall goal of this study was to develop a safe and effective transdermal delivery
system for the cannabinoids. We were able to achieve our goal and meet all expectations with the
development of TPF5-OH that exceeded cannabinoid delivery of the leading transdermal patches
on the market. Since our initial discovery, the TPF5-OH formulation has been translated to other
cannabinoids such as THC and THC: CBD blends and has made it to the market where thousands
of patches have been produced on industrial scales. The far-reaching benefits of our transdermal
delivery system have provided a safe and effective alternative dosing mechanism for the
cannabinoids that are being used by thousands of patients for a myriad of ailments. This work has
inspired future patch generations that continue to provide reliable medicine in the medical
marijuana industry.
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General Experimental Information
Unless otherwise noted, all materials were obtained from commercial suppliers and used without
further purification. All reactions with air- and/or moisture-sensitive compounds were performed
under an argon atmosphere in a flame-dried or oven-dried reaction flask, and reagents were added
via syringe or cannula. Dry THF and toluene were obtained via distillation from sodium
benzophenone ketyl. Preparative chromatography was carried out using Sorbtech silica gel (60 Å
porosity, 40-63

m particle size) in fritted MPLC cartridges and eluted with Thomson Instrument

SINGLE StEP pumps. Thin layer chromatography analyses were conducted with 200 m
precoated Sorbtech fluorescent TLC plates. Plates were visualized by UV light and by staining
with a variety of stains such as acidic anisaldehyde, acidic vanillin, ceric ammonium nitrate or
iodine vapor. LC-MS data was obtained using an Agilent 1100 HPLC/MSD system equipped with
a diode array detector running an acetonitrile/water gradient and 0.1% formic acid. High resolution
mass spectral data were obtained using an Agilent 6540 QTOF mass spectrometer. Nuclear
magnetic resonance spectrometry was run on a Varian Inova 500 MHz or a Varian Inova 400 MHz
spectrometer, and chemical shifts are listed in ppm correlated to the solvent used as an internal
standard. Optical rotations were performed on a Rudolph Research Analytical Autopol IV
polarimeter (λ 589) using a 700-μL cell with a path length of 1-dm. Enantiomeric excess (ee) was
determined using a Varian Prostar HPLC with a 210 binary pump and a 335 diode array detector
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or using a Agilent 7890A GC system coupled to an Agilent 7200 Accurate-Mass Q-TOF MS. IR
spectra were obtained using Agilent Cary 630 FTIR.
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Chapter 2 Characterization Data

A-2.1 Selected NMR spectra
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*This is a genuine spectrum used for comparisons
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A-2.2 Chiral GCMS chromatograms

A-2.3 Single crystal X-ray crystallography data:
The X-ray diffraction data for 2.65 was measured on Bruker D8 Venture PHOTON II CPAD
diffractometer equipped with a Cu Kα INCOATEC ImuS micro-focus source (λ = 1.54178 Å).
Indexing was performed using APEX3 (Difference Vectors method).1 Data integration and
reduction were performed using SaintPlus.2 Absorption correction was performed by multi-scan
method implemented in SADABS.3 Space group was determined using XPREP implemented in
APEX3 [1]. The structure was solved using SHELXT,4 and refined using SHELXL-2018 (full309

matrix least-squares on F2)5 through OLEX2 interface program.6 All hydrogen atoms were placed
in geometrically calculated positions and were included in refinement process using riding model
with isotropic thermal parameters. The absolute configuration of chiral atom was established to be
S. Crystal data and refinement conditions are shown in Table A-2.1.
Table A-2.1: Single X-ray crystallography data.

Identification code
ZS_MEM_12_05
Empirical formula
C17H21BrO2
Formula weight
337.25
Temperature/K
99.99
Crystal system
monoclinic
Space group
P21
a/Å
13.3889(5)
b/Å
13.4377(5)
c/Å
17.3180(7)
α/°
90
β/°
92.338(2)
γ/°
90
3
Volume/Å
3113.2(2)
Z
8
3
ρcalcg/cm
1.439
-1
μ/mm
3.585
F(000)
1392.0
3
Crystal size/mm
0.16 × 0.1 × 0.02
Radiation
CuKα (λ = 1.54178)
2Θ range for data collection/° 5.106 to 156.538
Index ranges
-16 ≤ h ≤ 16, -17 ≤ k ≤ 16, -21 ≤ l ≤ 21
Reflections collected
52549
Independent reflections
12985 [Rint = 0.0828, Rsigma = 0.0719]
Data/restraints/parameters
12985/1/733
2
Goodness-of-fit on F
1.057
Final R indexes [I>=2σ (I)] R1 = 0.0560, wR2 = 0.1424
Final R indexes [all data]
R1 = 0.0649, wR2 = 0.1500
-3
Largest diff. peak/hole / e Å 1.35/-0.92
Flack parameter
0.011(12) (Br heavy atom present)
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A-2.4 List of references:
1. Bruker (2019). APEX3 Bruker AXS Inc., Madison, Wisconsin, USA.
2. Bruker (2019) SAINT V8.35A. Data Reduction Software.
3. Sheldrick, G. M. SADABS. Program for Empirical Absorption Correction.1996, University of
Gottingen, Germany.
4. XT, G.M. Sheldrick, Acta Cryst. 2015. A71, 3-8
5. XL, Sheldrick, G. M. Acta Cryst. 2008, A64, 112-122.
6. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H., OLEX2: A
complete structure solution, refinement and analysis program. J. Appl. Cryst. 2009, 42,
339-341
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Chapter 3 Characterization Data

A-3.1 Selected NMR spectra
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A-3.2 Chapter 3 chiral HPLC chromatograms
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± 3.57

3.57

*No other peak had the same UV signal.
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± 3.56
3.59

3.56
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A-3.3 Single X-ray crystallography data
The X-ray diffraction data for 3.56 was measured on Bruker D8 Venture PHOTON 100 CMOS
system equipped with a Cu Kα INCOATEC ImuS micro-focus source (λ = 1.54178 Å). Data
integration and reduction were performed using SaintPlus 6.01.1 Absorption correction was
performed by multi-scan method implemented in SADABS.2 The space group was determined
using XPREP implemented in APEX3.3 Structure was solved using SHELXT,4 and refined using
SHELXL-2014 (full-matrix least-squares on F2)5-7 through OLEX2 interface program.8 All
ordered non-hydrogen atoms were refined anisotropically. Some of low occupancy, disordered
atoms were refined isotropically. All hydrogen atoms were placed in geometrically calculated
positions and were included in the refinement process using riding model with isotropic thermal
parameters: Uiso(H) = 1.2(1.5)Ueq(-CH,-CH2, (-CH3,-OH)). The absolute configuration was set
according to Flack parameter value and was the same as anticipated from the synthesis. It was also
confirmed Bijvoet-Pair Analysis and Bayesian Statistics Methods (Tables A-3.2)9,10. P2  1 for all
cases and is the probability that the current model is correct assuming two possibilities – one out
of two enantiomers present. Crystal data and refinement conditions are shown in Table A-3.1.
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Notes: Disordered aliphatic chain of one molecule was refined using restraints. The asymmetric
unit contains four conformationally different molecules (Z’=4).
Table A-3.1: Single X-ray crystallography data.

Identification code
Empirical formula
Formula weight
Temperature/K
Crystal system
Space group
a/Å
b/Å
c/Å
α/°
β/°
γ/°
Volume/Å3
Z
ρcalcg/cm3
μ/mm-1
F(000)
Crystal size/mm3
Radiation
2Θ range for data
collection/°
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ (I)]
Final R indexes [all data]
Largest diff. peak/hole / e
Å-3
Flack parameter

ZS_14_14_99_ee
C24H36O4
388.53
100
monoclinic
P21
12.3869(4)
29.1517(9)
13.0917(4)
90
97.962(2)
90
4681.8(3)
8
1.102
0.580
1696.0
0.155 × 0.075 × 0.025
CuKα (λ = 1.54178)
6.064 to 133.186
-14 ≤ h ≤ 14, -34 ≤ k ≤ 34, -15 ≤ l ≤ 14
64916
16354 [Rint = 0.0960, Rsigma = 0.0671]
16354/627/1126
1.065
R1 = 0.0551, wR2 = 0.1085
R1 = 0.0772, wR2 = 0.1183
0.17/-0.18
-0.01(11)
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Table A-3.2: Bijvoet-Pair Analysis and Bayesian Statistics Method parameters and data.

Space Group:
Wavelength:
Flack x:
Parsons z:

P21
1.54178
-0.01(11)
0.02(11)

Student-T Prob. Plot
Sample Size:
Corr. Coeff:
Intercept:
Slope:

7899
1.000
-0.011
0.886

Bijvoet Pairs:
Coverage:
DiffCalcMax:
Outlier Crit:

7909
98
42.51
85.03

Scatter Plot
Sigma Crit:
Select Pairs:
Number Plus:
Number
Minus:
Slope:

0.25
17
5
12
-0.288

Bayesian Statistics
Student_T Nu:
Select Pairs:
Theta_Min:
Theta_Max:
P2(true)
P3(true):
P3(rac-twin):
P3(false):
G:
G (su):
Hooft y:

99
7909
3.03
66.59
1.000
1.000
0.2E-05
0.6E-23
0.9806
0.1915
0.01(10)

A-3.4 List of references
1. Bruker (2016) SAINT V8.35A. Data Reduction Software.
2. Sheldrick, G. M. 1996, SADABS. Program for Empirical Absorption
Correction. University of Gottingen, Germany.
2. Bruker (2016). APEX3 (Version 2015.9). Bruker AXS Inc., Madison, Wisconsin, USA.
4. Sheldrick, G. M. "SHELXT - Integrated space-group and crystal structure determination" Acta
Cryst. 2015, A71, 3-8
5. Sheldrick, G.M. Acta Cryst. 1990, A46, 467-473
6. Sheldrick, G. M. Acta Cryst. 2008, A64, 112-122.
7. G.M. Sheldrick "Crystal structure refinement with SHELXL", Acta Cryst. 2015, C71, 3-8
8. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H., OLEX2: A
complete structure solution, refinement and analysis program. J. Appl. Cryst. 2009, 42,
339-341.
9. A.L.Spek, Acta Cryst. 2009, D65, 148-155.
10. R. W. W. Hooft, L. H. Straver , A. L. Spek J. Appl. Cryst. 2008, 41, 96-103
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Chapter 4 Transdermal Patch Production and Assay Procedures

A-4.1 Transdermal patch production:
A drug-in adhesive formulation containing cannabidiol (CBD) is applied to transdermal patch
release liner and laminated onto a desired backing.
All formulations (see table below for TPF5 formulation) consist of various permeation enhancers
and should be treated appropriately.
*This procedure considers a 4 g batch size for research scale.
In a 20 mL scintillation vial with a small stir bar were placed all solids for a formulation. Ethyl
acetate (1 mL) was added to dissolve the solids while stirring at room temperature. If propylene
glycol (PG) was used, it was added with the solids to aid in dissolution. Once the solids were
mostly dissolved (5 min) the remaining permeation enhancers/additives were added and continued
stirring at room temperature for 5 minutes. At this point most of the solids were dissolved and the
adhesive were added. The mixture continued to stir at room temperature for 30-60 minutes or until
all large bubbles were released. It was important to keep the cap on and secure to prevent
evaporation which could change the desired concentration. The desired release liner (ScotchPak
1022) was prepared by rolling it out (inside roll up) on a smooth, level surface and clamping the
free end. The roll should be pulled tight, so it lies evenly. The film applicator should be inspected

353

and made sure it is clean (ethyl acetate or acetone can be used for cleaning). The applicator should
be set between 35-40 mils depending on the formulation. The applicator was placed on the release
liner and the drug-in adhesive formulation was poured, or applied by positive displacement
syringe, onto to the release liner. The applicator was pulled down the release liner at a steady rate
(such that the draw down is usually 10-12 inches). The release liner was labeled and cut to the
appropriate size and placed inside a forced-air convection oven set at 40 °C. The drug-in adhesive
dried in the oven for 30 minutes. *Longer than 30 minutes doesn’t appear to change the weight or
drug load. Once dry, the drug-in adhesive was laminated onto the desired backing using a cold roll
laminator. The patch was cut into 1.66-inch-wide strips and 0.5 inches are cut off each side. *This
allows use of the most uniformly coated patch. The 1.66-inch-wide strips were cut into 1.66 x 1.66inch squares and labeled. Each patch was weighed and recorded in order to determine drug load.
Drug load was determined by known weight of a 1.66 ix 1.66-inch patch backing and release liner.
Using the percent of drug in the formulation, drug load can be determined.
Table A-4.1: Composition of lead transdermal patch formulation.

Ingredient
Cannabidiol
Transcutol [2-(2-ethoxyethoxy)ethanol]
Labrasol (PEG-8 caprylic/capric glycerides)
Peppermint Oil
Adhesive (DuroTak 87-900A)
Backing used: CoTran 9700 (nonwoven polyurethane)
Coating thickness: 35 mils (0.889 mm)
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Concentration (in wt. %)
14
5
5
1
75

A-4.2 Skin PAMPA procedures for transdermal patches:
Materials
The skin PAMPA materials were purchased directly from PION and include the following: 96-well
modified skin PAMPA plate, PION skin membrane hydration solution and a modified Gut-Box
(PAMPA incubator element for heating and stirring). Patches were either made in-house using the
above procedures or purchased from retail suppliers (Prototypes 1 and 2). Ethanol and propylene
glycol were purchased from Fischer Scientific and used without further purification. DI water was
used directly from a DI water tap in-house.
Procedures
A skin PAMPA plate was hydrated overnight using the PION hydrating solution before the start of
the assay. Stir disks were added to all the wells a patch would cover. A fresh solution of ethanol,
water and propylene glycol (4:5:4) was used to fill all wells (0.25 mL) of the skin PAMPA plate.
Two patches were applied to the hydrated artificial skin membrane of the 96-well plate and placed
in an incubator set at 37 °C on top of a Gut-Box for stirring. Sampling was performed by taking
aliquots (0.15 mL) at given time-points (0.5, 1, 3, 6, 12 h) and directly analyzed by LC-MS.
Concentration of CBD was determined using the AUC and a previously generated standard curve.
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